The multiple roles of interferon regulatory factor family in health and disease.

Tamura, T., Yanai, H., Savitsky, D. & Taniguchi, T. The IRF family transcription factors in immunity and oncogenesis. Annu. Rev. Immunol. 26, 535–584 (2008).

pubmed: 18303999 doi: 10.1146/annurev.immunol.26.021607.090400

Santana-de Anda, K., Gómez-Martín, D., Díaz-Zamudio, M. & Alcocer-Varela, J. Interferon regulatory factors: beyond the antiviral response and their link to the development of autoimmune pathology. Autoimmun. Rev. 11, 98–103 (2011).

pubmed: 21872684 doi: 10.1016/j.autrev.2011.08.006

Lohoff, M. & Mak, T. W. Roles of interferon-regulatory factors in T-helper-cell differentiation. Nat. Rev. Immunol. 5, 125–135 (2005).

pubmed: 15688040 doi: 10.1038/nri1552

Stoy, N. Involvement of Interleukin-1 Receptor-Associated Kinase 4 and Interferon Regulatory Factor 5 in the Immunopathogenesis of SARS-CoV-2 Infection: Implications for the Treatment of COVID-19. Front. Immunol. 12, 638446 (2021).

pubmed: 33936053 pmcid: 8085890 doi: 10.3389/fimmu.2021.638446

Jensen, M. A. & Niewold, T. B. Interferon regulatory factors: Critical mediators of human lupus. Transl. Res. 165, 283–295 (2015).

pubmed: 25445206 doi: 10.1016/j.trsl.2014.10.002

Salem, S., Salem, D. & Gros, P. Role of IRF8 in immune cells functions, protection against infections, and susceptibility to inflammatory diseases. Hum. Genet. 139, 707–721 (2020).

pubmed: 32232558 doi: 10.1007/s00439-020-02154-2

Zhang, Y. & Li, H. Reprogramming interferon regulatory factor signaling in cardiometabolic diseases. Physiol. (Bethesda) 32, 210–223 (2017).

Lukhele, S. et al. The transcription factor IRF2 drives interferon-mediated CD8(+) T cell exhaustion to restrict anti-tumor immunity. Immunity 55, 2369–2385.e2310 (2022).

pubmed: 36370712 pmcid: 9809269 doi: 10.1016/j.immuni.2022.10.020

Alfarano, G., Audano, M. & Di Chiaro, P. Interferon regulatory factor 1 (IRF1) controls the metabolic programmes of low-grade pancreatic cancer cells. Gut 72, 109–128 (2023).

pubmed: 35568393 doi: 10.1136/gutjnl-2021-325811

Nguyen, H., Hiscott, J. & Pitha, P. M. The growing family of interferon regulatory factors. Cytokine Growth Factor. Rev. 8, 293–312 (1997).

pubmed: 9620643 doi: 10.1016/S1359-6101(97)00019-1

Nehyba, J., Hrdlicková, R., Burnside, J. & Bose, H. R. Jr A novel interferon regulatory factor (IRF), IRF-10, has a unique role in immune defense and is induced by the v-Rel oncoprotein. Mol. Cell. Biol. 22, 3942–3957 (2002).

pubmed: 11997525 pmcid: 133824 doi: 10.1128/MCB.22.11.3942-3957.2002

Zhao, X. et al. Characterization of DNA binding and nuclear retention identifies zebrafish IRF11 as a positive regulator of IFN antiviral response. J. Immunol. 205, 237–250 (2020).

pubmed: 32471880 doi: 10.4049/jimmunol.2000245

Fujita, T. et al. Evidence for a nuclear factor(s), IRF-1, mediating induction and silencing properties to human IFN-beta gene regulatory elements. EMBO. J. 7, 3397–3405 (1988).

pubmed: 2850164 pmcid: 454838 doi: 10.1002/j.1460-2075.1988.tb03213.x

Miyamoto, M. et al. Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements. Cell 54, 903–913 (1988).

pubmed: 3409321 doi: 10.1016/S0092-8674(88)91307-4

Harada, H. et al. Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell 58, 729–739 (1989).

pubmed: 2475256 doi: 10.1016/0092-8674(89)90107-4

Driggers, P. H. et al. An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes. Proc. Natl. Acad. Sci. USA 87, 3743–3747 (1990).

pubmed: 2111015 pmcid: 53979 doi: 10.1073/pnas.87.10.3743

Nelson, N., Marks, M. S., Driggers, P. H. & Ozato, K. Interferon consensus sequence-binding protein, a member of the interferon regulatory factor family, suppresses interferon-induced gene transcription. Mol. Cell. Biol. 13, 588–599 (1993).

pubmed: 7678054 pmcid: 358938

Fu, X. Y. et al. ISGF3, the transcriptional activator induced by interferon alpha, consists of multiple interacting polypeptide chains. Proc. Natl. Acad. Sci. USA 87, 8555–8559 (1990).

pubmed: 2236065 pmcid: 54995 doi: 10.1073/pnas.87.21.8555

Kessler, D. S., Veals, S. A., Fu, X. Y. & Levy, D. E. Interferon-alpha regulates nuclear translocation and DNA-binding affinity of ISGF3, a multimeric transcriptional activator. Genes. Dev. 4, 1753–1765 (1990).

pubmed: 2249773 doi: 10.1101/gad.4.10.1753

Fu, X. Y. et al. The proteins of ISGF-3, the interferon alpha-induced transcriptional activator, define a gene family involved in signal transduction. Proc. Natl. Acad. Sci. USA 89, 7840–7843 (1992).

pubmed: 1502204 pmcid: 49807 doi: 10.1073/pnas.89.16.7840

Au, W. C. et al. Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes. Proc. Natl Acad. Sci. USA 92, 11657–11661 (1995).

pubmed: 8524823 pmcid: 40461 doi: 10.1073/pnas.92.25.11657

Matsuyama, T. et al. Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE). Nucleic Acids Res. 23, 2127–2136 (1995).

pubmed: 7541907 pmcid: 306999 doi: 10.1093/nar/23.12.2127

Mittrücker, H. W. et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 275, 540–543 (1997).

pubmed: 8999800 doi: 10.1126/science.275.5299.540

Eisenbeis, C. F., Singh, H. & Storb, U. Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator. Genes. Dev. 9, 1377–1387 (1995).

pubmed: 7797077 doi: 10.1101/gad.9.11.1377

Yamagata, T. et al. A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes. Mol. Cell. Biol. 16, 1283–1294 (1996).

pubmed: 8657101 pmcid: 231112 doi: 10.1128/MCB.16.4.1283

Marecki, S. & Fenton, M. J. The role of IRF-4 in transcriptional regulation. J. Interferon Cytokine Res. 22, 121–133 (2002).

pubmed: 11846983 doi: 10.1089/107999002753452737

Taniguchi, T., Ogasawara, K., Takaoka, A. & Tanaka, N. IRF family of transcription factors as regulators of host defense. Annu. Rev. Immunol. 19, 623–655 (2001).

pubmed: 11244049 doi: 10.1146/annurev.immunol.19.1.623

Barnes, B. J., Moore, P. A. & Pitha, P. M. Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J. Biol. Chem. 276, 23382–23390 (2001).

pubmed: 11303025 doi: 10.1074/jbc.M101216200

Schutte, B. C. et al. Microdeletions at chromosome bands 1q32-q41 as a cause of Van der Woude syndrome. Am. J. Med. Genet. 84, 145–150 (1999).

pubmed: 10323740 doi: 10.1002/(SICI)1096-8628(19990521)84:2<145::AID-AJMG11>3.0.CO;2-L

Kumaran, S., Dogra, S. & Kanwar, A. J. Van der Woude syndrome. Clin. Exp. Dermatol. 29, 434 (2004).

pubmed: 15245554 doi: 10.1111/j.1365-2230.2004.01556.x

Zhang, L. & Pagano, J. S. IRF-7, a new interferon regulatory factor associated with Epstein-Barr virus latency. Mol. Cell. Biol. 17, 5748–5757 (1997).

pubmed: 9315633 pmcid: 232423 doi: 10.1128/MCB.17.10.5748

Zhou, H., Tang, Y. D. & Zheng, C. Revisiting IRF1-mediated antiviral innate immunity. Cytokine Growth Factor. Rev. 64, 1–6 (2022).

pubmed: 35090813 doi: 10.1016/j.cytogfr.2022.01.004

Trujillo-Ochoa, J. L., Kazemian, M. & Afzali, B. The role of transcription factors in shaping regulatory T cell identity. Nat. Rev. Immunol. 23, 842–856 (2023).

pubmed: 37336954 pmcid: 10893967 doi: 10.1038/s41577-023-00893-7

Roberts, B. K., Collado, G. & Barnes, B. J. Role of interferon regulatory factor 5 (IRF5) in tumor progression: Prognostic and therapeutic potential. Biochim. Biophys. Acta Rev. Cancer 1879, 189061 (2024).

pubmed: 38141865 doi: 10.1016/j.bbcan.2023.189061

Fujita, T. et al. Induction of the transcription factor IRF-1 and interferon-beta mRNAs by cytokines and activators of second-messenger pathways. Proc. Natl Acad. Sci. Usa. 86, 9936–9940 (1989).

pubmed: 2557635 pmcid: 298617 doi: 10.1073/pnas.86.24.9936

Au, W. C. et al. Characterization of the interferon regulatory factor-7 and its potential role in the transcription activation of interferon A genes. J. Biol. Chem. 273, 29210–29217 (1998).

pubmed: 9786932 doi: 10.1074/jbc.273.44.29210

Hiscott, J. Triggering the innate antiviral response through IRF-3 activation. J. Biol. Chem. 282, 15325–15329 (2007).

pubmed: 17395583 doi: 10.1074/jbc.R700002200

Lin, R., Mamane, Y. & Hiscott, J. Multiple regulatory domains control IRF-7 activity in response to virus infection. J. Biol. Chem. 275, 34320–34327 (2000).

pubmed: 10893229 doi: 10.1074/jbc.M002814200

Zhang, L., Wu, L., Hong, K. & Pagano, J. S. Intracellular signaling molecules activated by Epstein-Barr virus for induction of interferon regulatory factor 7. J. Virol. 75, 12393–12401 (2001).

pubmed: 11711629 pmcid: 116135 doi: 10.1128/JVI.75.24.12393-12401.2001

Zhang, L. & Pagano, J. S. Interferon regulatory factor 7 is induced by Epstein-Barr virus latent membrane protein 1. J. Virol. 74, 1061–1068 (2000).

pubmed: 10627515 pmcid: 111439 doi: 10.1128/JVI.74.3.1061-1068.2000

Kim, T. K. et al. Chemotherapeutic DNA-damaging drugs activate interferon regulatory factor-7 by the mitogen-activated protein kinase kinase-4-cJun NH2-terminal kinase pathway. Cancer Res. 60, 1153–1156 (2000).

pubmed: 10728664

Zhang, L. & Pagano, J. S. Interferon regulatory factor 7 mediates activation of Tap-2 by Epstein-Barr virus latent membrane protein 1. J. Virol. 75, 341–350 (2001).

pubmed: 11119603 pmcid: 113927 doi: 10.1128/JVI.75.1.341-350.2001

Shindo, H. et al. Interferon regulatory factor-4 activates IL-2 and IL-4 promoters in cooperation with c-Rel. Cytokine 56, 564–572 (2011).

pubmed: 21890374 doi: 10.1016/j.cyto.2011.08.014

De Silva, N. S., Simonetti, G., Heise, N. & Klein, U. The diverse roles of IRF4 in late germinal center B-cell differentiation. Immunol. Rev. 247, 73–92 (2012).

pubmed: 22500833 doi: 10.1111/j.1600-065X.2012.01113.x

Xu, W. D., Pan, H. F., Ye, D. Q. & Xu, Y. Targeting IRF4 in autoimmune diseases. Autoimmun. Rev. 11, 918–924 (2012).

pubmed: 23010632 doi: 10.1016/j.autrev.2012.08.011

Kesper, C. et al. Impact of the transcription factor IRF8 on limbal epithelial progenitor cells in a mouse model. Exp. Eye. Res. 218, 108985 (2022).

pubmed: 35227665 doi: 10.1016/j.exer.2022.108985

Li, W. et al. Interferon consensus sequence-binding protein is constitutively expressed and differentially regulated in the ocular lens. J. Biol. Chem. 274, 9686–9691 (1999).

pubmed: 10092656 doi: 10.1074/jbc.274.14.9686

Jiang, D. S. et al. IRF8 suppresses pathological cardiac remodelling by inhibiting calcineurin signalling. Nat. Commun. 5, 3303 (2014).

pubmed: 24526256 doi: 10.1038/ncomms4303

Mancl, M. E. et al. Two discrete promoters regulate the alternatively spliced human interferon regulatory factor-5 isoforms. Multiple isoforms with distinct cell type-specific expression, localization, regulation, and function. J. Biol. Chem. 280, 21078–21090 (2005).

pubmed: 15805103 doi: 10.1074/jbc.M500543200

Gothe, F. et al. Aberrant inflammatory responses to type I interferon in STAT2 or IRF9 deficiency. J. Allergy Clin. Immunol. 150, 955–964.e916 (2022).

pubmed: 35182547 doi: 10.1016/j.jaci.2022.01.026

Deribe, Y. L., Pawson, T. & Dikic, I. Post-translational modifications in signal integration. Nat. Struct. Mol. Biol. 17, 666–672 (2010).

pubmed: 20495563 doi: 10.1038/nsmb.1842

Garvin, A. J. et al. GSK3β-SCFFBXW7α mediated phosphorylation and ubiquitination of IRF1 are required for its transcription-dependent turnover. Nucleic Acids Res 47, 4476–4494 (2019).

pubmed: 30854564 pmcid: 6511875 doi: 10.1093/nar/gkz163

Remoli, A. L. et al. IκB kinase-ε-mediated phosphorylation triggers IRF-1 degradation in breast cancer cells. Neoplasia 22, 459–469 (2020).

pubmed: 32784074 pmcid: 7419274 doi: 10.1016/j.neo.2020.07.004

Kautz, B., Kakar, R., David, E. & Eklund, E. A. SHP1 protein-tyrosine phosphatase inhibits gp91PHOX and p67PHOX expression by inhibiting interaction of PU.1, IRF1, interferon consensus sequence-binding protein, and CREB-binding protein with homologous Cis elements in the CYBB and NCF2 genes. J. Biol. Chem. 276, 37868–37878 (2001).

pubmed: 11483597 doi: 10.1074/jbc.M103381200

Lin, R. & Hiscott, J. A role for casein kinase II phosphorylation in the regulation of IRF-1 transcriptional activity. Mol. Cell. Biochem. 191, 169–180 (1999).

pubmed: 10094406 doi: 10.1023/A:1006850009017

Lin, R., Heylbroeck, C., Pitha, P. M. & Hiscott, J. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. Mol. Cell. Biol. 18, 2986–2996 (1998).

pubmed: 9566918 pmcid: 110678 doi: 10.1128/MCB.18.5.2986

Sharma, S. et al. Triggering the interferon antiviral response through an IKK-related pathway. Science 300, 1148–1151 (2003).

pubmed: 12702806 doi: 10.1126/science.1081315

Hemmi, H. et al. The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J. Exp. Med. 199, 1641–1650 (2004).

pubmed: 15210742 pmcid: 2212809 doi: 10.1084/jem.20040520

Fitzgerald, K. A. et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4, 491–496 (2003).

pubmed: 12692549 doi: 10.1038/ni921

Lin, R., Mamane, Y. & Hiscott, J. Structural and functional analysis of interferon regulatory factor 3: localization of the transactivation and autoinhibitory domains. Mol. Cell. Biol. 19, 2465–2474 (1999).

pubmed: 10082512 pmcid: 84039 doi: 10.1128/MCB.19.4.2465

Xiao, J. et al. Targeting 7-dehydrocholesterol reductase integrates cholesterol metabolism and IRF3 activation to eliminate infection. Immunity 52, 109–122.e106 (2020).

pubmed: 31882361 doi: 10.1016/j.immuni.2019.11.015

Zhang, B. et al. The TAK1-JNK cascade is required for IRF3 function in the innate immune response. Cell. Res. 19, 412–428 (2009).

pubmed: 19153595 doi: 10.1038/cr.2009.8

Xu, J. et al. IRF3-binding lncRNA-ISIR strengthens interferon production in viral infection and autoinflammation. Cell. Rep. 37, 109926 (2021).

pubmed: 34731629 doi: 10.1016/j.celrep.2021.109926

Wang, S. et al. LPA maintains innate antiviral immunity in a pro-active state via STK38L-mediated IRF3 Ser303 phosphorylation. Cell. Rep. 41, 111661 (2022).

pubmed: 36417850 doi: 10.1016/j.celrep.2022.111661

Meng, F. et al. Mst1 shuts off cytosolic antiviral defense through IRF3 phosphorylation. Genes. Dev. 30, 1086–1100 (2016).

pubmed: 27125670 pmcid: 4863739 doi: 10.1101/gad.277533.116

Wang, L. et al. LMP1 signaling pathway activates IRF4 in latent EBV infection and a positive circuit between PI3K and Src is required. Oncogene 36, 2265–2274 (2017).

pubmed: 27819673 doi: 10.1038/onc.2016.380

Biswas, P. S. et al. Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J. Clin. Invest. 120, 3280–3295 (2010).

pubmed: 20697158 pmcid: 2929726 doi: 10.1172/JCI42856

Ngwa, C. et al. Phosphorylation of microglial IRF5 and IRF4 by IRAK4 regulates inflammatory responses to ischemia. Cells 10, 276 (2021).

Ren, J., Chen, X. & Chen, Z. J. IKKβ is an IRF5 kinase that instigates inflammation. Proc. Natl. Acad. Sci. USA 111, 17438–17443 (2014).

pubmed: 25326420 pmcid: 4267374 doi: 10.1073/pnas.1418516111

Chang Foreman, H. C., Van Scoy, S., Cheng, T. F. & Reich, N. C. Activation of interferon regulatory factor 5 by site specific phosphorylation. PLoS. One 7, e33098 (2012).

pubmed: 22412986 pmcid: 3297630 doi: 10.1371/journal.pone.0033098

Lopez-Pelaez, M. et al. Protein kinase IKKβ-catalyzed phosphorylation of IRF5 at Ser462 induces its dimerization and nuclear translocation in myeloid cells. Proc. Natl Acad. Sci. Usa. 111, 17432–17437 (2014).

pubmed: 25326418 pmcid: 4267347 doi: 10.1073/pnas.1418399111

Balkhi, M. Y., Fitzgerald, K. A. & Pitha, P. M. IKKalpha negatively regulates IRF-5 function in a MyD88-TRAF6 pathway. Cell. Signal. 22, 117–127 (2010).

pubmed: 19786094 doi: 10.1016/j.cellsig.2009.09.021

Oberbeck, N. et al. The RIPK4-IRF6 signalling axis safeguards epidermal differentiation and barrier function. Nature 574, 249–253 (2019).

pubmed: 31578523 doi: 10.1038/s41586-019-1615-3

Kwa, M. Q. et al. Receptor-interacting protein kinase 4 and interferon regulatory factor 6 function as a signaling axis to regulate keratinocyte differentiation. J. Biol. Chem. 289, 31077–31087 (2014).

pubmed: 25246526 pmcid: 4223312 doi: 10.1074/jbc.M114.589382

Uematsu, S. et al. Interleukin-1 receptor-associated kinase-1 plays an essential role for toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} induction. J. Exp. Med. 201, 915–923 (2005).

pubmed: 15767370 pmcid: 2213113 doi: 10.1084/jem.20042372

Hoshino, K. et al. IkappaB kinase-alpha is critical for interferon-alpha production induced by toll-like receptors 7 and 9. Nature 440, 949–953 (2006).

pubmed: 16612387 doi: 10.1038/nature04641

Pfaller, C. K. & Conzelmann, K. K. Measles virus V protein is a decoy substrate for IkappaB kinase alpha and prevents Toll-like receptor 7/9-mediated interferon induction. J. Virol. 82, 12365–12373 (2008).

pubmed: 18922877 pmcid: 2593327 doi: 10.1128/JVI.01321-08

Wang, L. et al. Protein phosphatase 1 abrogates IRF7-mediated type I IFN response in antiviral immunity. Eur. J. Immunol. 46, 2409–2419 (2016).

pubmed: 27469204 pmcid: 5175453 doi: 10.1002/eji.201646491

Smith, E. J. et al. IRF3 and IRF7 phosphorylation in virus-infected cells does not require double-stranded RNA-dependent protein kinase R or Ikappa B kinase but is blocked by Vaccinia virus E3L protein. J. Biol. Chem. 276, 8951–8957 (2001).

pubmed: 11124948 doi: 10.1074/jbc.M008717200

Lee, K. J., Lee, H. & Joo, C. H. Negative Regulation of IKKε-Mediated IRF7 Phosphorylation by HSP70. J. Immunol. 204, 2562–2574 (2020).

pubmed: 32169844 doi: 10.4049/jimmunol.1900297

Liang, Q. et al. ORF45 of Kaposi’s sarcoma-associated herpesvirus inhibits phosphorylation of interferon regulatory factor 7 by IKKε and TBK1 as an alternative substrate. J. Virol. 86, 10162–10172 (2012).

pubmed: 22787218 pmcid: 3446610 doi: 10.1128/JVI.05224-11

Liu, B. Q., Jin, J. & Li, Y. Y. Ubiquitination modification: critical regulation of IRF family stability and activity. Sci. China Life. Sci. 64, 957–965 (2021).

pubmed: 33141302 doi: 10.1007/s11427-020-1796-0

Popovic, D., Vucic, D. & Dikic, I. Ubiquitination in disease pathogenesis and treatment. Nat. Med. 20, 1242–1253 (2014).

pubmed: 25375928 doi: 10.1038/nm.3739

Pion, E., Narayan, V., Eckert, M. & Ball, K. L. Role of the IRF-1 enhancer domain in signalling polyubiquitination and degradation. Cell. Signal. 21, 1479–1487 (2009).

pubmed: 19450680 doi: 10.1016/j.cellsig.2009.05.004

Nakagawa, K. & Yokosawa, H. Degradation of transcription factor IRF-1 by the ubiquitin-proteasome pathway. The C-terminal region governs the protein stability. Eur. J. Biochem. 267, 1680–1686 (2000).

pubmed: 10712599 doi: 10.1046/j.1432-1327.2000.01163.x

Remoli, A. L. et al. HIV-1 tat recruits HDM2 E3 ligase to target IRF-1 for ubiquitination and proteasomal degradation. mBio 7, e01528-16 (2016).

Tulli, L. et al. Src family kinases regulate interferon regulatory factor 1 K63 ubiquitination following activation by TLR7/8 vaccine adjuvant in human monocytes and B cells. Front. Immunol. 9, 330 (2018).

pubmed: 29545793 pmcid: 5837968 doi: 10.3389/fimmu.2018.00330

Harikumar, K. B. et al. K63-linked polyubiquitination of transcription factor IRF1 is essential for IL-1-induced production of chemokines CXCL10 and CCL5. Nat. Immunol. 15, 231–238 (2014).

pubmed: 24464131 pmcid: 3976678 doi: 10.1038/ni.2810

Wang, Y. et al. African swine fever virus MGF360-14L negatively regulates type I interferon signaling by targeting IRF3. Front. Cell. Infect. Microbiol. 11, 818969 (2021).

pubmed: 35096660 doi: 10.3389/fcimb.2021.818969

Zhang, M. et al. Negative feedback regulation of cellular antiviral signaling by RBCK1-mediated degradation of IRF3. Cell. Res. 18, 1096–1104 (2008).

pubmed: 18711448 doi: 10.1038/cr.2008.277

Chen, X. et al. Ubiquitin E3 ligase MID1 inhibits the innate immune response by ubiquitinating IRF3. Immunology 163, 278–292 (2021).

pubmed: 33513265 pmcid: 8207362 doi: 10.1111/imm.13315

Zhang, W. et al. JMJD6 negatively regulates cytosolic RNA induced antiviral signaling by recruiting RNF5 to promote activated IRF3 K48 ubiquitination. PLoS. Pathog. 17, e1009366 (2021).

pubmed: 33684176 pmcid: 7971890 doi: 10.1371/journal.ppat.1009366

Ran, Y. et al. SENP2 negatively regulates cellular antiviral response by deSUMOylating IRF3 and conditioning it for ubiquitination and degradation. J. Mol. Cell. Biol. 3, 283–292 (2011).

pubmed: 22028379 doi: 10.1093/jmcb/mjr020

Chattopadhyay, S. et al. Ubiquitination of the transcription factor IRF-3 activates RIPA, the apoptotic pathway that protects mice from viral pathogenesis. Immunity 44, 1151–1161 (2016).

pubmed: 27178468 pmcid: 4991351 doi: 10.1016/j.immuni.2016.04.009

Raja, R. & Sen, G. C. The antiviral action of the RIG-I induced pathway of apoptosis (RIPA) is enhanced by its ability to degrade Otulin, which deubiquitinates IRF3. Cell. Death. Differ. 29, 504–513 (2022).

pubmed: 34545182 doi: 10.1038/s41418-021-00870-4

Wang, J. et al. RNF2 promotes the progression of colon cancer by regulating ubiquitination and degradation of IRF4. Biochim. Biophys. Acta Mol. Cell. Res. 1869, 119162 (2022).

pubmed: 34670117 doi: 10.1016/j.bbamcr.2021.119162

Sun, X. et al. microRNA-155-5p initiates childhood acute lymphoblastic leukemia by regulating the IRF4/CDK6/CBL axis. Lab. Invest. 102, 411–421 (2022).

pubmed: 34775495 doi: 10.1038/s41374-021-00638-x

Li, X. et al. Cbl ubiquitin ligases control B cell exit from the germinal-center reaction. Immunity 48, 530–541.e536 (2018).

pubmed: 29562201 doi: 10.1016/j.immuni.2018.03.006

Guo, Z. et al. Ubiquitin specific peptidase 4 stabilizes interferon regulatory factor protein and promotes its function to facilitate interleukin-4 expression in T helper type 2 cells. Int. J. Mol. Med. 40, 979–986 (2017).

pubmed: 28791349 pmcid: 5593473 doi: 10.3892/ijmm.2017.3087

Balkhi, M. Y., Fitzgerald, K. A. & Pitha, P. M. Functional regulation of MyD88-activated interferon regulatory factor 5 by K63-linked polyubiquitination. Mol. Cell. Biol. 28, 7296–7308 (2008).

pubmed: 18824541 pmcid: 2593423 doi: 10.1128/MCB.00662-08

Kim, D. et al. Cytosolic pellino-1-mediated K63-linked ubiquitination of IRF5 in M1 macrophages regulates glucose intolerance in obesity. Cell. Rep. 20, 832–845 (2017).

pubmed: 28746869 doi: 10.1016/j.celrep.2017.06.088

Chen, H. et al. Peli1 deletion in macrophages attenuates myocardial ischemia/reperfusion injury by suppressing M1 polarization. J. Leukoc. Biol. 113, 95–108 (2023).

pubmed: 36822176 doi: 10.1093/jleuko/qiac012

Yu, Y., Wang, S. E. & Hayward, G. S. The KSHV immediate-early transcription factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteosome-mediated degradation. Immunity 22, 59–70 (2005).

pubmed: 15664159 doi: 10.1016/j.immuni.2004.11.011

Yu, Y. & Hayward, G. S. The ubiquitin E3 ligase RAUL negatively regulates type i interferon through ubiquitination of the transcription factors IRF7 and IRF3. Immunity 33, 863–877 (2010).

pubmed: 21167755 pmcid: 3012379 doi: 10.1016/j.immuni.2010.11.027

Ning, S. & Pagano, J. S. The A20 deubiquitinase activity negatively regulates LMP1 activation of IRF7. J. Virol. 84, 6130–6138 (2010).

pubmed: 20392859 pmcid: 2876664 doi: 10.1128/JVI.00364-10

Wang, J. et al. Negative regulation of Nmi on virus-triggered type I IFN production by targeting IRF7. J. Immunol. 191, 3393–3399 (2013).

pubmed: 23956435 doi: 10.4049/jimmunol.1300740

Young, J. A. et al. Fas-associated death domain (FADD) and the E3 ubiquitin-protein ligase TRIM21 interact to negatively regulate virus-induced interferon production. J. Biol. Chem. 286, 6521–6531 (2011).

pubmed: 21183682 doi: 10.1074/jbc.M110.172288

Huye, L. E., Ning, S., Kelliher, M. & Pagano, J. S. Interferon regulatory factor 7 is activated by a viral oncoprotein through RIP-dependent ubiquitination. Mol. Cell. Biol. 27, 2910–2918 (2007).

pubmed: 17296724 pmcid: 1899925 doi: 10.1128/MCB.02256-06

Ning, S. et al. TRAF6 and the three C-terminal lysine sites on IRF7 are required for its ubiquitination-mediated activation by the tumor necrosis factor receptor family member latent membrane protein 1. Mol. Cell. Biol. 28, 6536–6546 (2008).

pubmed: 18710948 pmcid: 2577435 doi: 10.1128/MCB.00785-08

Ling, T. et al. TARBP2 inhibits IRF7 activation by suppressing TRAF6-mediated K63-linked ubiquitination of IRF7. Mol. Immunol. 109, 116–125 (2019).

pubmed: 30927622 doi: 10.1016/j.molimm.2019.02.019

Xiong, H. et al. Ubiquitin-dependent degradation of interferon regulatory factor-8 mediated by Cbl down-regulates interleukin-12 expression. J. Biol. Chem. 280, 23531–23539 (2005).

pubmed: 15837792 doi: 10.1074/jbc.M414296200

Kong, H. J. et al. Cutting edge: autoantigen Ro52 is an interferon inducible E3 ligase that ubiquitinates IRF-8 and enhances cytokine expression in macrophages. J. Immunol. 179, 26–30 (2007).

pubmed: 17579016 doi: 10.4049/jimmunol.179.1.26

Lin, R. et al. USP4 interacts and positively regulates IRF8 function via K48-linked deubiquitination in regulatory T cells. FEBS Lett. 591, 1677–1686 (2017).

pubmed: 28477415 doi: 10.1002/1873-3468.12668

Zhang, M. et al. Herpes simplex virus type 2 inhibits type I IFN signaling mediated by the novel E3 ubiquitin protein ligase activity of viral protein ICP22. J. Immunol. 205, 1281–1292 (2020).

pubmed: 32699158 doi: 10.4049/jimmunol.2000418

Vertegaal, A. C. O. Signalling mechanisms and cellular functions of SUMO. Nat. Rev. Mol. Cell. Biol. 23, 715–731 (2022).

pubmed: 35750927 doi: 10.1038/s41580-022-00500-y

Liang, Y. C. et al. SUMO5, a novel poly-SUMO isoform, regulates PML nuclear bodies. Sci. Rep. 6, 26509 (2016).

pubmed: 27211601 pmcid: 4876461 doi: 10.1038/srep26509

Bergink, S. & Jentsch, S. Principles of ubiquitin and SUMO modifications in DNA repair. Nature 458, 461–467 (2009).

pubmed: 19325626 doi: 10.1038/nature07963

Meulmeester, E. & Melchior, F. Cell biology: SUMO. Nature 452, 709–711 (2008).

pubmed: 18401402 doi: 10.1038/452709a

Kunz, K., Piller, T. & Müller, S. SUMO-specific proteases and isopeptidases of the SENP family at a glance. J. Cell. Sci. 131, jcs211904 (2018).

Nakagawa, K. & Yokosawa, H. PIAS3 induces SUMO-1 modification and transcriptional repression of IRF-1. FEBS Lett. 530, 204–208 (2002).

pubmed: 12387893 doi: 10.1016/S0014-5793(02)03486-5

Kim, E. J., Park, J. S. & Um, S. J. Ubc9-mediated sumoylation leads to transcriptional repression of IRF-1. Biochem. Biophys. Res. Commun. 377, 952–956 (2008).

pubmed: 18955028 doi: 10.1016/j.bbrc.2008.10.092

Park, S. M. et al. SUMOylated IRF-1 shows oncogenic potential by mimicking IRF-2. Biochem. Biophys. Res. Commun. 391, 926–930 (2010).

pubmed: 19962964 doi: 10.1016/j.bbrc.2009.11.166

Park, J. et al. Elevated level of SUMOylated IRF-1 in tumor cells interferes with IRF-1-mediated apoptosis. Proc. Natl. Acad. Sci. USA 104, 17028–17033 (2007).

pubmed: 17942705 pmcid: 2040422 doi: 10.1073/pnas.0609852104

Sun, T. et al. α-Lipoic acid (α-LA) inhibits the transcriptional activity of interferon regulatory factor 1 (IRF-1) via SUMOylation. Toxicol. Vitr. 28, 1242–1248 (2014).

doi: 10.1016/j.tiv.2014.06.003

Jeong, H. Y. et al. 5-Azacytidine modulates interferon regulatory factor 1 in macrophages to exert a cardioprotective effect. Sci. Rep. 5, 15768 (2015).

pubmed: 26510961 pmcid: 4625165 doi: 10.1038/srep15768

Han, K. J., Jiang, L. & Shu, H. B. Regulation of IRF2 transcriptional activity by its sumoylation. Biochem. Biophys. Res. Commun. 372, 772–778 (2008).

pubmed: 18514056 doi: 10.1016/j.bbrc.2008.05.103

Kubota, T. et al. Virus infection triggers SUMOylation of IRF3 and IRF7, leading to the negative regulation of type I interferon gene expression. J. Biol. Chem. 283, 25660–25670 (2008).

pubmed: 18635538 pmcid: 2533075 doi: 10.1074/jbc.M804479200

Maarifi, G. et al. MxA mediates SUMO-induced resistance to vesicular stomatitis virus. J. Virol. 90, 6598–6610 (2016).

pubmed: 27170750 pmcid: 4936121 doi: 10.1128/JVI.00722-16

Chang, T. H. et al. Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS. Pathog. 5, e1000493 (2009).

pubmed: 19557165 pmcid: 2696038 doi: 10.1371/journal.ppat.1000493

Bentz, G. L., Shackelford, J. & Pagano, J. S. Epstein-Barr virus latent membrane protein 1 regulates the function of interferon regulatory factor 7 by inducing its sumoylation. J. Virol. 86, 12251–12261 (2012).

pubmed: 22951831 pmcid: 3486478 doi: 10.1128/JVI.01407-12

Liang, Q. et al. Tripartite motif-containing protein 28 is a small ubiquitin-related modifier E3 ligase and negative regulator of IFN regulatory factor 7. J. Immunol. 187, 4754–4763 (2011).

pubmed: 21940674 doi: 10.4049/jimmunol.1101704

Wang, F. et al. Loss of ubiquitin-conjugating enzyme E2 (Ubc9) in macrophages exacerbates multiple low-dose streptozotocin-induced diabetes by attenuating M2 macrophage polarization. Cell. Death. Dis. 10, 892 (2019).

pubmed: 31767832 pmcid: 6877645 doi: 10.1038/s41419-019-2130-z

Liu, J. et al. TRIM28 is a distinct prognostic biomarker that worsens the tumor immune microenvironment in lung adenocarcinoma. Aging (Albany NY) 12, 20308–20331 (2020).

pubmed: 33091876 doi: 10.18632/aging.103804

Zhang, Y. et al. SENP3 suppresses osteoclastogenesis by de-conjugating SUMO2/3 from IRF8 in bone marrow-derived monocytes. Cell. Rep. 30, 1951–1963.e1954 (2020).

pubmed: 32049023 doi: 10.1016/j.celrep.2020.01.036

Chang, T. H. et al. The small ubiquitin-like modifier-deconjugating enzyme sentrin-specific peptidase 1 switches IFN regulatory factor 8 from a repressor to an activator during macrophage activation. J. Immunol. 189, 3548–3556 (2012).

pubmed: 22942423 doi: 10.4049/jimmunol.1201104

Masumi, A. & Ozato, K. Coactivator p300 acetylates the interferon regulatory factor-2 in U937 cells following phorbol ester treatment. J. Biol. Chem. 276, 20973–20980 (2001).

pubmed: 11304541 doi: 10.1074/jbc.M101707200

Qiu, W. et al. Sublytic C5b-9 triggers glomerular mesangial cell apoptosis via XAF1 gene activation mediated by p300-dependent IRF-1 acetylation. Cell. Death. Dis. 5, e1176 (2014).

pubmed: 24743731 pmcid: 4001307 doi: 10.1038/cddis.2014.153

Wu, Y. et al. Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity. Nat. Cancer 4, 382–400 (2023).

pubmed: 36894639 pmcid: 10042735 doi: 10.1038/s43018-023-00522-1

Masumi, A. et al. Interferon regulatory factor-2 regulates cell growth through its acetylation. J. Biol. Chem. 278, 25401–25407 (2003).

pubmed: 12738767 doi: 10.1074/jbc.M213037200

Masumi, A. et al. Nucleolin is involved in interferon regulatory factor-2-dependent transcriptional activation. Oncogene 25, 5113–5124 (2006).

pubmed: 16582966 doi: 10.1038/sj.onc.1209522

Wang, C. et al. The methyltransferase NSD3 promotes antiviral innate immunity via direct lysine methylation of IRF3. J. Exp. Med. 214, 3597–3610 (2017).

pubmed: 29101251 pmcid: 5716042 doi: 10.1084/jem.20170856

Mino, T. & Takeuchi, O. NSD3 keeps IRF3 active. J. Exp. Med. 214, 3475–3476 (2017).

pubmed: 29158375 pmcid: 5716047 doi: 10.1084/jem.20171980

Wang, J. et al. Arginine methylation by PRMT2 promotes IFN-β production through TLR4/IRF3 signaling pathway. Mol. Immunol. 139, 202–210 (2021).

pubmed: 34583098 doi: 10.1016/j.molimm.2021.08.014

Huai, W. et al. KAT8 selectively inhibits antiviral immunity by acetylating IRF3. J. Exp. Med. 216, 772–785 (2019).

pubmed: 30842237 pmcid: 6446880 doi: 10.1084/jem.20181773

Caillaud, A. et al. Acetylation of interferon regulatory factor-7 by p300/CREB-binding protein (CBP)-associated factor (PCAF) impairs its DNA binding. J. Biol. Chem. 277, 49417–49421 (2002).

pubmed: 12374802 doi: 10.1074/jbc.M207484200

Qin, Z. et al. Deactylation by SIRT1 enables liquid-liquid phase separation of IRF3/IRF7 in innate antiviral immunity. Nat. Immunol. 23, 1193–1207 (2022).

pubmed: 35879450 doi: 10.1038/s41590-022-01269-0

Acidereli, H., Turut, F. A. & Cevik, O. Acetylation of interferon regulatory factor-5 suppresses androgen receptor and downregulates expression of Sox2. Cell. Biochem. Funct. 39, 667–678 (2021).

pubmed: 33780016 doi: 10.1002/cbf.3633

Tang, X. et al. Acetylation-dependent signal transduction for type I interferon receptor. Cell 131, 93–105 (2007).

pubmed: 17923090 doi: 10.1016/j.cell.2007.07.034

Worbs, T., Hammerschmidt, S. I. & Förster, R. Dendritic cell migration in health and disease. Nat. Rev. Immunol. 17, 30–48 (2017).

pubmed: 27890914 doi: 10.1038/nri.2016.116

Collin, M. & Bigley, V. Human dendritic cell subsets: an update. Immunology 154, 3–20 (2018).

pubmed: 29313948 pmcid: 5904714 doi: 10.1111/imm.12888

Tailor, P., Tamura, T. & Ozato, K. IRF family proteins and type I interferon induction in dendritic cells. Cell. Res. 16, 134–140 (2006).

pubmed: 16474425 doi: 10.1038/sj.cr.7310018

Suzuki, S. et al. Critical roles of interferon regulatory factor 4 in CD11bhighCD8alpha- dendritic cell development. Proc. Natl Acad. Sci. USA 101, 8981–8986 (2004).

pubmed: 15184678 pmcid: 428458 doi: 10.1073/pnas.0402139101

Tsujimura, H., Tamura, T. & Ozato, K. Cutting edge: IFN consensus sequence binding protein/IFN regulatory factor 8 drives the development of type I IFN-producing plasmacytoid dendritic cells. J. Immunol. 170, 1131–1135 (2003).

pubmed: 12538667 doi: 10.4049/jimmunol.170.3.1131

Tamura, T. et al. IFN regulatory factor-4 and -8 govern dendritic cell subset development and their functional diversity. J. Immunol. 174, 2573–2581 (2005).

pubmed: 15728463 doi: 10.4049/jimmunol.174.5.2573

Schiavoni, G. et al. ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8alpha(+) dendritic cells. J. Exp. Med. 196, 1415–1425 (2002).

pubmed: 12461077 pmcid: 2194263 doi: 10.1084/jem.20021263

Aliberti, J. et al. Essential role for ICSBP in the in vivo development of murine CD8alpha + dendritic cells. Blood 101, 305–310 (2003).

pubmed: 12393690 doi: 10.1182/blood-2002-04-1088

Lança, T. et al. IRF8 deficiency induces the transcriptional, functional, and epigenetic reprogramming of cDC1 into the cDC2 lineage. Immunity 55, 1431–1447.e1411 (2022).

pubmed: 35830859 doi: 10.1016/j.immuni.2022.06.006

Gabriele, L. et al. IRF-1 deficiency skews the differentiation of dendritic cells toward plasmacytoid and tolerogenic features. J. Leukoc. Biol. 80, 1500–1511 (2006).

pubmed: 16966383 doi: 10.1189/jlb.0406246

Ichikawa, E. et al. Defective development of splenic and epidermal CD4+ dendritic cells in mice deficient for IFN regulatory factor-2. Proc. Natl Acad. Sci. USA 101, 3909–3914 (2004).

pubmed: 15004277 pmcid: 374343 doi: 10.1073/pnas.0400610101

Negishi, H., Taniguchi, T. & Yanai, H. The interferon (IFN) class of cytokines and the IFN regulatory factor (IRF) transcription factor family. Cold. Spring. Harb. Perspect. Biol. 10, a028423 (2018).

Petro, T. M. IFN regulatory factor 3 in health and disease. J. Immunol. 205, 1981–1989 (2020).

pubmed: 33020188 doi: 10.4049/jimmunol.2000462

Negishi, H. et al. Cross-interference of RLR and TLR signaling pathways modulates antibacterial T cell responses. Nat. Immunol. 13, 659–666 (2012).

pubmed: 22610141 doi: 10.1038/ni.2307

Matta, B., Song, S., Li, D. & Barnes, B. J. Interferon regulatory factor signaling in autoimmune disease. Cytokine 98, 15–26 (2017).

pubmed: 28283223 pmcid: 8033540 doi: 10.1016/j.cyto.2017.02.006

Qing, F. & Liu, Z. Interferon regulatory factor 7 in inflammation, cancer and infection. Front. Immunol. 14, 1190841 (2023).

pubmed: 37251373 pmcid: 10213216 doi: 10.3389/fimmu.2023.1190841

Al Hamrashdi, M. & Brady, G. Regulation of IRF3 activation in human antiviral signaling pathways. Biochem. Pharmacol. 200, 115026 (2022).

pubmed: 35367198 doi: 10.1016/j.bcp.2022.115026

Almuttaqi, H. & Udalova, I. A. Advances and challenges in targeting IRF5, a key regulator of inflammation. FEBS J. 286, 1624–1637 (2019).

pubmed: 30199605 doi: 10.1111/febs.14654

Lazear, H. M. et al. IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling. PLoS. Pathog. 9, e1003118 (2013).

pubmed: 23300459 pmcid: 3536698 doi: 10.1371/journal.ppat.1003118

Panda, D. et al. IRF1 maintains optimal constitutive expression of antiviral genes and regulates the early antiviral response. Front. Immunol. 10, 1019 (2019).

pubmed: 31156620 pmcid: 6529937 doi: 10.3389/fimmu.2019.01019

Xia, X., Wang, W., Yin, K. & Wang, S. Interferon regulatory factor 8 governs myeloid cell development. Cytokine Growth Factor. Rev. 55, 48–57 (2020).

pubmed: 32327344 doi: 10.1016/j.cytogfr.2020.03.003

Tait Wojno, E. D., Hunter, C. A. & Stumhofer, J. S. The Immunobiology of the Interleukin-12 Family: Room for Discovery. Immunity 50, 851–870 (2019).

pubmed: 30995503 doi: 10.1016/j.immuni.2019.03.011

Verstockt, B. et al. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 20, 433–446 (2023).

pubmed: 37069321 pmcid: 10958371 doi: 10.1038/s41575-023-00768-1

Kröger, A. et al. Activities of IRF-1. J. Interferon Cytokine Res. 22, 5–14 (2002).

pubmed: 11846971 doi: 10.1089/107999002753452610

Ng, L. G., Liu, Z., Kwok, I. & Ginhoux, F. Origin and heterogeneity of tissue myeloid cells: A focus on GMP-derived monocytes and neutrophils. Annu. Rev. Immunol. 41, 375–404 (2023).

pubmed: 37126421 doi: 10.1146/annurev-immunol-081022-113627

Holtschke, T. et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87, 307–317 (1996).

pubmed: 8861914 doi: 10.1016/S0092-8674(00)81348-3

Scheller, M. et al. Altered development and cytokine responses of myeloid progenitors in the absence of transcription factor, interferon consensus sequence binding protein. Blood 94, 3764–3771 (1999).

pubmed: 10572090 doi: 10.1182/blood.V94.11.3764

Schmidt, M. et al. The interferon regulatory factor ICSBP/IRF-8 in combination with PU.1 up-regulates expression of tumor suppressor p15(Ink4b) in murine myeloid cells. Blood 103, 4142–4149 (2004).

pubmed: 14976051 doi: 10.1182/blood-2003-01-0285

Diaz-Blanco, E. et al. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia 21, 494–504 (2007).

pubmed: 17252012 doi: 10.1038/sj.leu.2404549

Zhao, Y. et al. mTOR masters monocyte development in bone marrow by decreasing the inhibition of STAT5 on IRF8. Blood 131, 1587–1599 (2018).

pubmed: 29463562 doi: 10.1182/blood-2017-04-777128

Li, P. et al. IRF8 and IRF3 cooperatively regulate rapid interferon-β induction in human blood monocytes. Blood 117, 2847–2854 (2011).

pubmed: 21228327 doi: 10.1182/blood-2010-07-294272

Rosenbauer, F. et al. Disabled-2 is transcriptionally regulated by ICSBP and augments macrophage spreading and adhesion. EMBO J. 21, 211–220 (2002).

pubmed: 11823414 pmcid: 125345 doi: 10.1093/emboj/21.3.211

Tamura, T. et al. Identification of target genes and a unique cis element regulated by IRF-8 in developing macrophages. Blood 106, 1938–1947 (2005).

pubmed: 15947094 pmcid: 1895144 doi: 10.1182/blood-2005-01-0080

Dror, N. et al. Identification of IRF-8 and IRF-1 target genes in activated macrophages. Mol. Immunol. 44, 338–346 (2007).

pubmed: 16597464 doi: 10.1016/j.molimm.2006.02.026

Tamura, T. et al. ICSBP directs bipotential myeloid progenitor cells to differentiate into mature macrophages. Immunity 13, 155–165 (2000).

pubmed: 10981959 doi: 10.1016/S1074-7613(00)00016-9

Karki, R. et al. IRF8 regulates transcription of naips for NLRC4 inflammasome activation. Cell 173, 920–933.e913 (2018).

pubmed: 29576451 pmcid: 5935577 doi: 10.1016/j.cell.2018.02.055

Gupta, M. et al. IRF8 directs stress-induced autophagy in macrophages and promotes clearance of Listeria monocytogenes. Nat. Commun. 6, 6379 (2015).

pubmed: 25775030 doi: 10.1038/ncomms7379

Sjöstrand, M. et al. Expression of the immune regulator tripartite-motif 21 is controlled by IFN regulatory factors. J. Immunol. 191, 3753–3763 (2013).

pubmed: 23975864 doi: 10.4049/jimmunol.1202341

Blanco, J. C. et al. Interferon regulatory factor (IRF)-1 and IRF-2 regulate interferon gamma-dependent cyclooxygenase 2 expression. J. Exp. Med. 191, 2131–2144 (2000).

pubmed: 10859338 pmcid: 2193204 doi: 10.1084/jem.191.12.2131

Hobart, M. et al. IFN regulatory factor-1 plays a central role in the regulation of the expression of class I and II MHC genes in vivo. J. Immunol. 158, 4260–4269 (1997).

pubmed: 9126988 doi: 10.4049/jimmunol.158.9.4260

Kimura, T. et al. Involvement of the IRF-1 transcription factor in antiviral responses to interferons. Science 264, 1921–1924 (1994).

pubmed: 8009222 doi: 10.1126/science.8009222

Blériot, C., Chakarov, S. & Ginhoux, F. Determinants of resident tissue macrophage identity and function. Immunity 52, 957–970 (2020).

pubmed: 32553181 doi: 10.1016/j.immuni.2020.05.014

Park, M. D., Silvin, A., Ginhoux, F. & Merad, M. Macrophages in health and disease. Cell 185, 4259–4279 (2022).

pubmed: 36368305 pmcid: 9908006 doi: 10.1016/j.cell.2022.10.007

Colonna, M. & Butovsky, O. Microglia function in the central nervous system during health and neurodegeneration. Annu. Rev. Immunol. 35, 441–468 (2017).

pubmed: 28226226 pmcid: 8167938 doi: 10.1146/annurev-immunol-051116-052358

Borst, K., Dumas, A. A. & Prinz, M. Microglia: Immune and non-immune functions. Immunity 54, 2194–2208 (2021).

pubmed: 34644556 doi: 10.1016/j.immuni.2021.09.014

Zhou, N. et al. Transcriptional mechanism of IRF8 and PU.1 governs microglial activation in neurodegenerative condition. Protein Cell. 10, 87–103 (2019).

pubmed: 30484118 doi: 10.1007/s13238-018-0599-3

Masuda, T. et al. IRF8 is a critical transcription factor for transforming microglia into a reactive phenotype. Cell. Rep. 1, 334–340 (2012).

pubmed: 22832225 pmcid: 4158926 doi: 10.1016/j.celrep.2012.02.014

Zhou, Y. et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease. Nat. Med. 26, 131–142 (2020).

pubmed: 31932797 pmcid: 6980793 doi: 10.1038/s41591-019-0695-9

Masuda, T. et al. Transcription factor IRF1 is responsible for IRF8-mediated IL-1β expression in reactive microglia. J. Pharmacol. Sci. 128, 216–220 (2015).

pubmed: 26318672 doi: 10.1016/j.jphs.2015.08.002

Feinberg, P. A. et al. Elevated TNF-α leads to neural circuit instability in the absence of interferon regulatory factor 8. J. Neurosci. 42, 6171–6185 (2022).

pubmed: 35790400 pmcid: 9374154 doi: 10.1523/JNEUROSCI.0601-22.2022

Ivashkiv, L. B. Metabolic-epigenetic coupling in osteoclast differentiation. Nat. Med. 21, 212–213 (2015).

pubmed: 25742453 pmcid: 4795459 doi: 10.1038/nm.3815

Zhao, B. et al. Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nat. Med. 15, 1066–1071 (2009).

pubmed: 19718038 pmcid: 2755267 doi: 10.1038/nm.2007

Izawa, N. et al. Cooperation of PU.1 with IRF8 and NFATc1 defines chromatin landscapes during RANKL-induced osteoclastogenesis. J. Bone Miner. Res. 34, 1143–1154 (2019).

pubmed: 30721543 doi: 10.1002/jbmr.3689

Saito, E. et al. Down-regulation of Irf8 by Lyz2-cre/loxP accelerates osteoclast differentiation in vitro. Cytotechnology 69, 443–450 (2017).

pubmed: 27502007 doi: 10.1007/s10616-016-0013-z

Thumbigere-Math, V. et al. Inactivating mutation in IRF8 promotes osteoclast transcriptional programs and increases susceptibility to tooth root resorption. J. Bone Miner. Res. 34, 1155–1168 (2019).

pubmed: 30840779 doi: 10.1002/jbmr.3690

Xia, Y. et al. TGFβ reprograms TNF stimulation of macrophages towards a non-canonical pathway driving inflammatory osteoclastogenesis. Nat. Commun. 13, 3920 (2022).

pubmed: 35798734 pmcid: 9263175 doi: 10.1038/s41467-022-31475-1

Gabrilovich, D. I. Myeloid-derived suppressor cells. Cancer Immunol. Res. 5, 3–8 (2017).

pubmed: 28052991 pmcid: 5426480 doi: 10.1158/2326-6066.CIR-16-0297

Li, K. et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal. Transduct. Target. Ther. 6, 362 (2021).

pubmed: 34620838 pmcid: 8497485 doi: 10.1038/s41392-021-00670-9

Wu, Y. et al. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol. Cancer 21, 184 (2022).

pubmed: 36163047 pmcid: 9513992 doi: 10.1186/s12943-022-01657-y

Waight, J. D. et al. Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J. Clin. Invest. 123, 4464–4478 (2013).

pubmed: 24091328 pmcid: 3784535 doi: 10.1172/JCI68189

Paschall, A. V. et al. IFN regulatory factor 8 represses GM-CSF expression in T cells to affect myeloid cell lineage differentiation. J. Immunol. 194, 2369–2379 (2015).

pubmed: 25646302 doi: 10.4049/jimmunol.1402412

Yang, J. et al. Cutting edge: IRF8 regulates Bax transcription in vivo in primary myeloid cells. J. Immunol. 187, 4426–4430 (2011).

pubmed: 21949018 doi: 10.4049/jimmunol.1101034

Cumbo, C. et al. IRF4 expression is low in Philadelphia negative myeloproliferative neoplasms and is associated with a worse prognosis. Exp. Hematol. Oncol. 10, 58 (2021).

pubmed: 34952638 pmcid: 8705160 doi: 10.1186/s40164-021-00253-y

Lu, J., Liang, T., Li, P. & Yin, Q. Regulatory effects of IRF4 on immune cells in the tumor microenvironment. Front. Immunol. 14, 1086803 (2023).

pubmed: 36814912 pmcid: 9939821 doi: 10.3389/fimmu.2023.1086803

Nam, S. et al. Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function. J. Leukoc. Biol. 100, 1273–1284 (2016).

pubmed: 27601624 doi: 10.1189/jlb.1A0215-068RR

Yang, Q. et al. IRF7 regulates the development of granulocytic myeloid-derived suppressor cells through S100A9 transrepression in cancer. Oncogene 36, 2969–2980 (2017).

pubmed: 28092673 doi: 10.1038/onc.2016.448

Lian, R. H. & Kumar, V. Murine natural killer cell progenitors and their requirements for development. Semin. Immunol. 14, 453–460 (2002).

pubmed: 12457618 doi: 10.1016/S1044532302000805

Taki, S. et al. IFN regulatory factor-2 deficiency revealed a novel checkpoint critical for the generation of peripheral NK cells. J. Immunol. 174, 6005–6012 (2005).

pubmed: 15879093 doi: 10.4049/jimmunol.174.10.6005

Maffei, R. et al. The dynamic functions of IRF4 in B cell malignancies. Clin. Exp. Med. 23, 1171–1180 (2023).

pubmed: 36495369 doi: 10.1007/s10238-022-00968-0

Cook, S. L., Franke, M. C., Sievert, E. P. & Sciammas, R. A Synchronous IRF4-Dependent Gene Regulatory Network in B and Helper T Cells Orchestrating the Antibody Response. Trends Immunol. 41, 614–628 (2020).

pubmed: 32467029 pmcid: 8722497 doi: 10.1016/j.it.2020.05.001

Lu, R., Medina, K. L., Lancki, D. W. & Singh, H. IRF-4,8 orchestrate the pre-B-to-B transition in lymphocyte development. Genes. Dev. 17, 1703–1708 (2003).

pubmed: 12832394 pmcid: 196178 doi: 10.1101/gad.1104803

Cattoretti, G. et al. Stages of germinal center transit are defined by B cell transcription factor coexpression and relative abundance. J. Immunol. 177, 6930–6939 (2006).

pubmed: 17082608 doi: 10.4049/jimmunol.177.10.6930

Falini, B. et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 95, 2084–2092 (2000).

pubmed: 10706878 doi: 10.1182/blood.V95.6.2084

Sciammas, R. et al. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity 25, 225–236 (2006).

pubmed: 16919487 doi: 10.1016/j.immuni.2006.07.009

Zhan, F. et al. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood 101, 1128–1140 (2003).

pubmed: 12393520 doi: 10.1182/blood-2002-06-1737

Lee, C. H. et al. Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequence-binding protein. J. Exp. Med. 203, 63–72 (2006).

pubmed: 16380510 pmcid: 2118063 doi: 10.1084/jem.20051450

Ashby, K. M. & Hogquist, K. A. A guide to thymic selection of T cells. Nat. Rev. Immunol. 24, 103–117 (2024).

pubmed: 37464188 doi: 10.1038/s41577-023-00911-8

Shrikant, P. A. et al. Regulating functional cell fates in CD8 T cells. Immunol. Res. 46, 12–22 (2010).

pubmed: 19859830 pmcid: 5049497 doi: 10.1007/s12026-009-8130-9

Visekruna, A. et al. Tc9 cells, a new subset of CD8(+) T cells, support Th2-mediated airway inflammation. Eur. J. Immunol. 43, 606–618 (2013).

pubmed: 23254356 doi: 10.1002/eji.201242825

Yen, H. R. et al. Tc17 CD8 T cells: functional plasticity and subset diversity. J. Immunol. 183, 7161–7168 (2009).

pubmed: 19917680 doi: 10.4049/jimmunol.0900368

Huber, M. et al. IL-17A secretion by CD8+ T cells supports Th17-mediated autoimmune encephalomyelitis. J. Clin. Invest. 123, 247–260 (2013).

pubmed: 23221338 doi: 10.1172/JCI63681

Matsuyama, T. et al. Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell 75, 83–97 (1993).

pubmed: 8402903 doi: 10.1016/S0092-8674(05)80086-8

Hida, S. et al. CD8(+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling. Immunity 13, 643–655 (2000).

pubmed: 11114377 doi: 10.1016/S1074-7613(00)00064-9

Taki, S. et al. Multistage regulation of Th1-type immune responses by the transcription factor IRF-1. Immunity 6, 673–679 (1997).

pubmed: 9208840 doi: 10.1016/S1074-7613(00)80443-4

Hida, S., Tadachi, M., Saito, T. & Taki, S. Negative control of basophil expansion by IRF-2 critical for the regulation of Th1/Th2 balance. Blood 106, 2011–2017 (2005).

pubmed: 15914553 doi: 10.1182/blood-2005-04-1344

Theofilopoulos, A. N., Koundouris, S., Kono, D. H. & Lawson, B. R. The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity. Arthritis Res. 3, 136–141 (2001).

pubmed: 11299053 pmcid: 128889 doi: 10.1186/ar290

Feng, D. et al. Irf5-deficient mice are protected from pristane-induced lupus via increased Th2 cytokines and altered IgG class switching. Eur. J. Immunol. 42, 1477–1487 (2012).

pubmed: 22678902 pmcid: 3684952 doi: 10.1002/eji.201141642

Brune, Z., Rice, M. R. & Barnes, B. J. Potential T cell-intrinsic regulatory roles for IRF5 via cytokine modulation in T helper subset differentiation and function. Front. Immunol. 11, 1143 (2020).

pubmed: 32582209 pmcid: 7283537 doi: 10.3389/fimmu.2020.01143

Walker, J. A. & McKenzie, A. N. J. T(H)2 cell development and function. Nat. Rev. Immunol. 18, 121–133 (2018).

pubmed: 29082915 doi: 10.1038/nri.2017.118

Biswas, P. S., Bhagat, G. & Pernis, A. B. IRF4 and its regulators: evolving insights into the pathogenesis of inflammatory arthritis? Immunol. Rev. 233, 79–96 (2010).

pubmed: 20192994 pmcid: 2920730 doi: 10.1111/j.0105-2896.2009.00864.x

Honma, K. et al. Interferon regulatory factor 4 differentially regulates the production of Th2 cytokines in naive vs. effector/memory CD4+ T cells. Proc. Natl Acad. Sci. USA 105, 15890–15895 (2008).

pubmed: 18836070 pmcid: 2572975 doi: 10.1073/pnas.0803171105

Jefferies, C. A. Regulating IRFs in IFN driven disease. Front. Immunol. 10, 325 (2019).

pubmed: 30984161 pmcid: 6449421 doi: 10.3389/fimmu.2019.00325

Yagi, R., Zhu, J. & Paul, W. E. An updated view on transcription factor GATA3-mediated regulation of Th1 and Th2 cell differentiation. Int. Immunol. 23, 415–420 (2011).

pubmed: 21632975 pmcid: 3123974 doi: 10.1093/intimm/dxr029

Zhu, J. et al. Conditional deletion of Gata3 shows its essential function in T(H)1-T(H)2 responses. Nat. Immunol. 5, 1157–1165 (2004).

pubmed: 15475959 doi: 10.1038/ni1128

Fang, C. M. et al. Unique contribution of IRF-5-Ikaros axis to the B-cell IgG2a response. Genes. Immun. 13, 421–430 (2012).

pubmed: 22535200 pmcid: 3628768 doi: 10.1038/gene.2012.10

Huber, M. & Lohoff, M. IRF4 at the crossroads of effector T-cell fate decision. Eur. J. Immunol. 44, 1886–1895 (2014).

pubmed: 24782159 doi: 10.1002/eji.201344279

Jabeen, R. et al. Th9 cell development requires a BATF-regulated transcriptional network. J. Clin. Invest. 123, 4641–4653 (2013).

pubmed: 24216482 pmcid: 3809790 doi: 10.1172/JCI69489

Chang, H. C. et al. The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation. Nat. Immunol. 11, 527–534 (2010).

pubmed: 20431622 pmcid: 3136246 doi: 10.1038/ni.1867

Brüstle, A. et al. The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat. Immunol. 8, 958–966 (2007).

pubmed: 17676043 doi: 10.1038/ni1500

Wang, J., Zhao, X. & Wan, Y. Y. Intricacies of TGF-β signaling in Treg and Th17 cell biology. Cell. Mol. Immunol. 20, 1002–1022 (2023).

pubmed: 37217798 pmcid: 10468540 doi: 10.1038/s41423-023-01036-7

Mudter, J. et al. The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. J. Clin. Invest. 118, 2415–2426 (2008).

pubmed: 18535667 pmcid: 2413182

Mudter, J. et al. IRF4 regulates IL-17A promoter activity and controls RORγt-dependent Th17 colitis in vivo. Inflamm. Bowel. Dis. 17, 1343–1358 (2011).

pubmed: 21305677 doi: 10.1002/ibd.21476

Huber, M. et al. IRF4 is essential for IL-21-mediated induction, amplification, and stabilization of the Th17 phenotype. Proc. Natl. Acad. Sci. USA 105, 20846–20851 (2008).

pubmed: 19088203 pmcid: 2634912 doi: 10.1073/pnas.0809077106

Gutiérrez-Melo, N. & Baumjohann, D. T follicular helper cells in cancer. Trends Cancer 9, 309–325 (2023).

pubmed: 36642575 doi: 10.1016/j.trecan.2022.12.007

Liu, X., Nurieva, R. I. & Dong, C. Transcriptional regulation of follicular T-helper (Tfh) cells. Immunol. Rev. 252, 139–145 (2013).

pubmed: 23405901 pmcid: 3579502 doi: 10.1111/imr.12040

Kwon, H. et al. Analysis of interleukin-21-induced Prdm1 gene regulation reveals functional cooperation of STAT3 and IRF4 transcription factors. Immunity 31, 941–952 (2009).

pubmed: 20064451 pmcid: 3272079 doi: 10.1016/j.immuni.2009.10.008

Ise, W. et al. The transcription factor BATF controls the global regulators of class-switch recombination in both B cells and T cells. Nat. Immunol. 12, 536–543 (2011).

pubmed: 21572431 pmcid: 3117275 doi: 10.1038/ni.2037

Betz, B. C. et al. Batf coordinates multiple aspects of B and T cell function required for normal antibody responses. J. Exp. Med. 207, 933–942 (2010).

pubmed: 20421391 pmcid: 2867277 doi: 10.1084/jem.20091548

Ponnusamy, K. et al. The innate sensor ZBP1-IRF3 axis regulates cell proliferation in multiple myeloma. Haematologica 107, 721–732 (2022).

pubmed: 33596642 doi: 10.3324/haematol.2020.274480

Hu, G. & Barnes, B. J. IRF-5 is a mediator of the death receptor-induced apoptotic signaling pathway. J. Biol. Chem. 284, 2767–2777 (2009).

pubmed: 19028697 doi: 10.1074/jbc.M804744200

Massimino, M. et al. IRF5 promotes the proliferation of human thyroid cancer cells. Mol. Cancer 11, 21 (2012).

pubmed: 22507190 pmcid: 3444366 doi: 10.1186/1476-4598-11-21

Botti, E. et al. Developmental factor IRF6 exhibits tumor suppressor activity in squamous cell carcinomas. Proc. Natl Acad. Sci. USA 108, 13710–13715 (2011).

pubmed: 21807998 pmcid: 3158164 doi: 10.1073/pnas.1110931108

Xu, L. et al. The developmental transcription factor IRF6 attenuates ABCG2 gene expression and distinctively reverses stemness phenotype in nasopharyngeal carcinoma. Cancer Lett. 431, 230–243 (2018).

pubmed: 29111349 doi: 10.1016/j.canlet.2017.10.016

Ma, X. et al. Inhibition of KIF20A by transcription factor IRF6 affects the progression of renal clear cell carcinoma. Cancer Cell. Int. 21, 246 (2021).

pubmed: 33941190 pmcid: 8091794 doi: 10.1186/s12935-021-01879-y

Lu, J. et al. Lin28A promotes IRF6-regulated aerobic glycolysis in glioma cells by stabilizing SNHG14. Cell. Death. Dis. 11, 447 (2020).

pubmed: 32527996 pmcid: 7289837 doi: 10.1038/s41419-020-2650-6

Chattopadhyay, S. & Sen, G. C. RIG-I-like receptor-induced IRF3 mediated pathway of apoptosis (RIPA): a new antiviral pathway. Protein Cell. 8, 165–168 (2017).

pubmed: 27815826 doi: 10.1007/s13238-016-0334-x

Chattopadhyay, S., Yamashita, M., Zhang, Y. & Sen, G. C. The IRF-3/Bax-mediated apoptotic pathway, activated by viral cytoplasmic RNA and DNA, inhibits virus replication. J. Virol. 85, 3708–3716 (2011).

pubmed: 21307205 pmcid: 3126131 doi: 10.1128/JVI.02133-10

White, C. L., Chattopadhyay, S. & Sen, G. C. Phosphatidylinositol 3-kinase signaling delays sendai virus-induced apoptosis by preventing XIAP degradation. J. Virol. 85, 5224–5227 (2011).

pubmed: 21367892 pmcid: 3126159 doi: 10.1128/JVI.00053-11

Sanz-Garcia, C. et al. The non-transcriptional activity of IRF3 modulates hepatic immune cell populations in acute-on-chronic ethanol administration in mice. J. Hepatol. 70, 974–984 (2019).

pubmed: 30710579 pmcid: 6462245 doi: 10.1016/j.jhep.2019.01.021

Wang, L. et al. Mechanisms of PANoptosis and relevant small-molecule compounds for fighting diseases. Cell. Death. Dis. 14, 851 (2023).

pubmed: 38129399 pmcid: 10739961 doi: 10.1038/s41419-023-06370-2

Malireddi, R. K. S., Kesavardhana, S. & Kanneganti, T. D. ZBP1 and TAK1: Master Regulators of NLRP3 Inflammasome/Pyroptosis, Apoptosis, and Necroptosis (PAN-optosis). Front. Cell. Infect. Microbiol. 9, 406 (2019).

pubmed: 31850239 pmcid: 6902032 doi: 10.3389/fcimb.2019.00406

Sharma, B. R., Karki, R., Rajesh, Y. & Kanneganti, T. D. Immune regulator IRF1 contributes to ZBP1-, AIM2-, RIPK1-, and NLRP12-PANoptosome activation and inflammatory cell death (PANoptosis). J. Biol. Chem. 299, 105141 (2023).

pubmed: 37557956 pmcid: 10494469 doi: 10.1016/j.jbc.2023.105141

Kuriakose, T., Zheng, M., Neale, G. & Kanneganti, T. D. IRF1 Is a Transcriptional Regulator of ZBP1 Promoting NLRP3 Inflammasome Activation and Cell Death during Influenza Virus Infection. J. Immunol. 200, 1489–1495 (2018).

pubmed: 29321274 doi: 10.4049/jimmunol.1701538

Man, S. M. et al. The transcription factor IRF1 and guanylate-binding proteins target activation of the AIM2 inflammasome by Francisella infection. Nat. Immunol. 16, 467–475 (2015).

pubmed: 25774715 pmcid: 4406811 doi: 10.1038/ni.3118

Karki, R. et al. Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes. Cell 184, 149–168.e117 (2021).

pubmed: 33278357 doi: 10.1016/j.cell.2020.11.025

Sundaram, B. et al. NLRP12-PANoptosome activates PANoptosis and pathology in response to heme and PAMPs. Cell 186, 2783–2801.e2720 (2023).

pubmed: 37267949 pmcid: 10330523 doi: 10.1016/j.cell.2023.05.005

Karki, R. et al. Interferon regulatory factor 1 regulates PANoptosis to prevent colorectal cancer. JCI. Insight. 5, e136720 (2020).

Zhuang, Y. et al. Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses, and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1. Hepatology 79, 752–767 (2024).

pubmed: 37725754

Kondo, S. et al. Mutations in IRF6 cause Van der Woude and popliteal pterygium syndromes. Nat. Genet. 32, 285–289 (2002).

pubmed: 12219090 pmcid: 3169431 doi: 10.1038/ng985

Ingraham, C. R. et al. Abnormal skin, limb and craniofacial morphogenesis in mice deficient for interferon regulatory factor 6 (Irf6). Nat. Genet. 38, 1335–1340 (2006).

pubmed: 17041601 pmcid: 2082114 doi: 10.1038/ng1903

Richardson, R. J. et al. Irf6 is a key determinant of the keratinocyte proliferation-differentiation switch. Nat. Genet. 38, 1329–1334 (2006).

pubmed: 17041603 doi: 10.1038/ng1894

Restivo, G. et al. IRF6 is a mediator of Notch pro-differentiation and tumour suppressive function in keratinocytes. EMBO J. 30, 4571–4585 (2011).

pubmed: 21909072 pmcid: 3243593 doi: 10.1038/emboj.2011.325

Fitzgerald, K. A. & Kagan, J. C. Toll-like receptors and the control of immunity. Cell 180, 1044–1066 (2020).

pubmed: 32164908 pmcid: 9358771 doi: 10.1016/j.cell.2020.02.041

Kawai, T. & Akira, S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat. Immunol. 11, 373–384 (2010).

pubmed: 20404851 doi: 10.1038/ni.1863

Li, D. & Wu, M. Pattern recognition receptors in health and diseases. Signal. Transduct. Target. Ther. 6, 291 (2021).

pubmed: 34344870 pmcid: 8333067 doi: 10.1038/s41392-021-00687-0

Honda, K. et al. Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling. Proc. Natl Acad. Sci. Usa. 101, 15416–15421 (2004).

pubmed: 15492225 pmcid: 523464 doi: 10.1073/pnas.0406933101

Kawai, T. et al. Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat. Immunol. 5, 1061–1068 (2004).

pubmed: 15361868 doi: 10.1038/ni1118

del Fresno, C. et al. Interferon-β production via Dectin-1-Syk-IRF5 signaling in dendritic cells is crucial for immunity to C. albicans. Immunity 38, 1176–1186 (2013).

pubmed: 23770228 doi: 10.1016/j.immuni.2013.05.010

Takaoka, A. et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434, 243–249 (2005).

pubmed: 15665823 doi: 10.1038/nature03308

Barnes, B. J., Kellum, M. J., Field, A. E. & Pitha, P. M. Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes. Mol. Cell. Biol. 22, 5721–5740 (2002).

pubmed: 12138184 pmcid: 133975 doi: 10.1128/MCB.22.16.5721-5740.2002

Feng, D. et al. Differential requirement of histone acetylase and deacetylase activities for IRF5-mediated proinflammatory cytokine expression. J. Immunol. 185, 6003–6012 (2010).

pubmed: 20935208 doi: 10.4049/jimmunol.1000482

Yang, C. et al. CXCL4 synergizes with TLR8 for TBK1-IRF5 activation, epigenomic remodeling and inflammatory response in human monocytes. Nat. Commun. 13, 3426 (2022).

pubmed: 35701499 pmcid: 9195402 doi: 10.1038/s41467-022-31132-7

Pradhan, P. et al. TRAF6-IRF5 kinetics, TRIF, and biophysical factors drive synergistic innate responses to particle-mediated MPLA-CpG co-presentation. Sci. Adv. 7, eabd4235 (2021).

Heinz, L. X. et al. TASL is the SLC15A4-associated adaptor for IRF5 activation by TLR7-9. Nature 581, 316–322 (2020).

pubmed: 32433612 pmcid: 7610944 doi: 10.1038/s41586-020-2282-0

Zhang, H. et al. SLC15A4 controls endolysosomal TLR7-9 responses by recruiting the innate immune adaptor TASL. Cell. Rep. 42, 112916 (2023).

pubmed: 37527038 doi: 10.1016/j.celrep.2023.112916

Briard, B. et al. Fungal ligands released by innate immune effectors promote inflammasome activation during Aspergillus fumigatus infection. Nat. Microbiol. 4, 316–327 (2019).

pubmed: 30510167 doi: 10.1038/s41564-018-0298-0

Tailor, P. et al. The feedback phase of type I interferon induction in dendritic cells requires interferon regulatory factor 8. Immunity 27, 228–239 (2007).

pubmed: 17702615 pmcid: 2768351 doi: 10.1016/j.immuni.2007.06.009

Zhao, J. et al. IRF-8/interferon (IFN) consensus sequence-binding protein is involved in Toll-like receptor (TLR) signaling and contributes to the cross-talk between TLR and IFN-gamma signaling pathways. J. Biol. Chem. 281, 10073–10080 (2006).

pubmed: 16484229 doi: 10.1074/jbc.M507788200

Shi, G. et al. IRF-8/miR-451a regulates M-MDSC differentiation via the AMPK/mTOR signal pathway during lupus development. Cell. Death. Discov. 7, 179 (2021).

pubmed: 34282122 pmcid: 8289825 doi: 10.1038/s41420-021-00568-z

Li, D. et al. IRF8 Impacts Self-Renewal of Hematopoietic Stem Cells by Regulating TLR9 Signaling Pathway of Innate Immune Cells. Adv. Sci. (Weinh.). 8, e2101031 (2021).

pubmed: 34365741

Goubau, D., Deddouche, S. & Reis e Sousa, C. Cytosolic sensing of viruses. Immunity 38, 855–869 (2013).

pubmed: 23706667 pmcid: 7111113 doi: 10.1016/j.immuni.2013.05.007

Rehwinkel, J. & Gack, M. U. RIG-I-like receptors: Their regulation and roles in RNA sensing. Nat. Rev. Immunol. 20, 537–551 (2020).

pubmed: 32203325 pmcid: 7094958 doi: 10.1038/s41577-020-0288-3

Yoneyama, M. et al. Viral RNA detection by RIG-I-like receptors. Curr. Opin. Immunol. 32, 48–53 (2015).

pubmed: 25594890 doi: 10.1016/j.coi.2014.12.012

Sakaguchi, S. et al. Essential role of IRF-3 in lipopolysaccharide-induced interferon-beta gene expression and endotoxin shock. Biochem. Biophys. Res. Commun. 306, 860–866 (2003).

pubmed: 12821121 doi: 10.1016/S0006-291X(03)01049-0

Panne, D., McWhirter, S. M., Maniatis, T. & Harrison, S. C. Interferon regulatory factor 3 is regulated by a dual phosphorylation-dependent switch. J. Biol. Chem. 282, 22816–22822 (2007).

pubmed: 17526488 doi: 10.1074/jbc.M703019200

Liu, S. et al. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science 347, aaa2630 (2015).

pubmed: 25636800 doi: 10.1126/science.aaa2630

Yin, X. et al. MDA5 Governs the Innate Immune Response to SARS-CoV-2 in Lung Epithelial Cells. Cell. Rep. 34, 108628 (2021).

pubmed: 33440148 doi: 10.1016/j.celrep.2020.108628

Ruffner, H., Reis, L. F., Näf, D. & Weissmann, C. Induction of type I interferon genes and interferon-inducible genes in embryonal stem cells devoid of interferon regulatory factor 1. Proc. Natl Acad. Sci. Usa. 90, 11503–11507 (1993).

pubmed: 8265581 doi: 10.1073/pnas.90.24.11503

Rosain, J. et al. Human IRF1 governs macrophagic IFN-γ immunity to mycobacteria. Cell 186, 621–645.e633 (2023).

pubmed: 36736301 doi: 10.1016/j.cell.2022.12.038

Ishii, K. J. et al. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat. Immunol. 7, 40–48 (2006).

pubmed: 16286919 doi: 10.1038/ni1282

Takaoka, A. et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 448, 501–505 (2007).

pubmed: 17618271 doi: 10.1038/nature06013

Lei, Y. et al. Cooperative sensing of mitochondrial DNA by ZBP1 and cGAS promotes cardiotoxicity. Cell 186, 3013–3032.e3022 (2023).

pubmed: 37352855 pmcid: 10330843 doi: 10.1016/j.cell.2023.05.039

Di Paolo, N. C. et al. The transcription factor IRF3 triggers “defensive suicide” necrosis in response to viral and bacterial pathogens. Cell. Rep. 3, 1840–1846 (2013).

pubmed: 23770239 pmcid: 3718285 doi: 10.1016/j.celrep.2013.05.025

Cevik, O. et al. Interferon regulatory factor 5 (IRF5) suppresses hepatitis C virus (HCV) replication and HCV-associated hepatocellular carcinoma. J. Biol. Chem. 292, 21676–21689 (2017).

pubmed: 29079574 pmcid: 5766933 doi: 10.1074/jbc.M117.792721

Nie, S. et al. The protective effect of interfering TLR9-IRF5 signaling pathway on the development of CVB3-induced myocarditis. Clin. Immunol. 207, 24–35 (2019).

pubmed: 31279856 doi: 10.1016/j.clim.2019.07.002

Carmona-Pérez, L. et al. The TLR7/IRF-5 axis sensitizes memory CD4+ T cells to Fas-mediated apoptosis during HIV-1 infection. JCI. Insight. 8, e167329 (2023).

Liu, Y. et al. Airway acidification impaired host defense against Pseudomonas aeruginosa infection by promoting type 1 interferon β response. Emerg. Microbes Infect. 11, 2132–2146 (2022).

pubmed: 35930458 pmcid: 9487950 doi: 10.1080/22221751.2022.2110524

Puthia, M. et al. IRF7 inhibition prevents destructive innate immunity-A target for nonantibiotic therapy of bacterial infections. Sci. Transl. Med. 8, 336ra359 (2016).

doi: 10.1126/scitranslmed.aaf1156

Schoggins, J. W. et al. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature 505, 691–695 (2014).

pubmed: 24284630 doi: 10.1038/nature12862

Mboko, W. P. et al. Interferon Regulatory Factor 1 and Type I Interferon Cooperate To Control Acute Gammaherpesvirus Infection. J. Virol. 91, e01444-16 (2017).

Feng, H., Zhang, Y. B. & Gui, J. F. Interferon regulatory factor 1 (IRF1) and anti-pathogen innate immune responses. PLoS. Pathog. 17, e1009220 (2021).

pubmed: 33476326 pmcid: 7819612 doi: 10.1371/journal.ppat.1009220

Loevenich, S. et al. Human Metapneumovirus Induces IRF1 via TANK-Binding Kinase 1 and Type I IFN. Front. Immunol. 12, 563336 (2021).

pubmed: 34248923 pmcid: 8264192 doi: 10.3389/fimmu.2021.563336

Yamane, D. et al. Basal expression of interferon regulatory factor 1 drives intrinsic hepatocyte resistance to multiple RNA viruses. Nat. Microbiol. 4, 1096–1104 (2019).

pubmed: 30988429 pmcid: 6588457 doi: 10.1038/s41564-019-0425-6

Wang, J. et al. IRF1 Promotes the Innate Immune Response to Viral Infection by Enhancing the Activation of IRF3. J. Virol. 94, e01231-20 (2020).

Ren, K. et al. IRF2 inhibits ZIKV replication by promoting FAM111A expression to enhance the host restriction effect of RFC3. Virol. J. 18, 256 (2021).

pubmed: 34930359 pmcid: 8691090 doi: 10.1186/s12985-021-01724-8

Panda, D. et al. Triad of human cellular proteins, IRF2, FAM111A, and RFC3, restrict replication of orthopoxvirus SPI-1 host-range mutants. Proc. Natl Acad. Sci. USA 114, 3720–3725 (2017).

pubmed: 28320935 pmcid: 5389286 doi: 10.1073/pnas.1700678114

Persyn, E. et al. IRF2 is required for development and functional maturation of human NK cells. Front. Immunol. 13, 1038821 (2022).

pubmed: 36544762 pmcid: 9762550 doi: 10.3389/fimmu.2022.1038821

Glanz, A. et al. Transcriptional and Non-Transcriptional Activation, Posttranslational Modifications, and Antiviral Functions of Interferon Regulatory Factor 3 and Viral Antagonism by the SARS-Coronavirus. Viruses 13, 575 (2021).

pubmed: 33805458 pmcid: 8066409 doi: 10.3390/v13040575

Popli, S., Chakravarty, S., Fan, S. & Glanz, A. IRF3 inhibits nuclear translocation of NF-κB to prevent viral inflammation. Proc. Natl Acad. Sci. Usa. 119, e2121385119 (2022).

pubmed: 36067309 pmcid: 9478676 doi: 10.1073/pnas.2121385119

Canivet, C. et al. Both IRF3 and especially IRF7 play a key role to orchestrate an effective cerebral inflammatory response in a mouse model of herpes simplex virus encephalitis. J. Neurovirol. 24, 761–768 (2018).

pubmed: 30094631 doi: 10.1007/s13365-018-0666-9

Andersen, L. L. et al. Functional IRF3 deficiency in a patient with herpes simplex encephalitis. J. Exp. Med. 212, 1371–1379 (2015).

pubmed: 26216125 pmcid: 4548062 doi: 10.1084/jem.20142274

Campbell, T. M. & Liu, Z. Respiratory viral infections in otherwise healthy humans with inherited IRF7 deficiency. J. Exp. Med. 219, e20220202 (2022).

Tucker, M. H. et al. IRF7 and UNC93B1 variants in an infant with recurrent herpes simplex virus infection. J. Clin. Invest. 133, e154016 (2023).

Clohisey, S. & Baillie, J. K. Host susceptibility to severe influenza A virus infection. Crit. Care. 23, 303 (2019).

pubmed: 31488196 pmcid: 6729070 doi: 10.1186/s13054-019-2566-7

Hernandez, N. & Melki, I. Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency. J. Exp. Med. 215, 2567–2585 (2018).

pubmed: 30143481 pmcid: 6170168 doi: 10.1084/jem.20180628

Ji, W. et al. TBK1 and IRF3 are potential therapeutic targets in Enterovirus A71-associated diseases. PLoS. Negl. Trop. Dis. 17, e0011001 (2023).

pubmed: 36626364 pmcid: 9831319 doi: 10.1371/journal.pntd.0011001

Man, K. et al. Transcription Factor IRF4 Promotes CD8(+) T Cell Exhaustion and Limits the Development of Memory-like T Cells during Chronic Infection. Immunity 47, 1129–1141.e1125 (2017).

pubmed: 29246443 doi: 10.1016/j.immuni.2017.11.021

Grusdat, M. et al. IRF4 and BATF are critical for CD8

pubmed: 24531538 pmcid: 4207473 doi: 10.1038/cdd.2014.19

Yanai, H. et al. Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression. Proc. Natl Acad. Sci. USA 104, 3402–3407 (2007).

pubmed: 17360658 pmcid: 1805533 doi: 10.1073/pnas.0611559104

Thackray, L. B. et al. Interferon regulatory factor 5-dependent immune responses in the draining lymph node protect against West Nile virus infection. J. Virol. 88, 11007–11021 (2014).

pubmed: 25031348 pmcid: 4178807 doi: 10.1128/JVI.01545-14

Song, J. et al. Human cytomegalovirus induces and exploits Roquin to counteract the IRF1-mediated antiviral state. Proc. Natl Acad. Sci. USA 116, 18619–18628 (2019).

pubmed: 31451648 pmcid: 6744924 doi: 10.1073/pnas.1909314116

Ueki, I. F. et al. Respiratory virus-induced EGFR activation suppresses IRF1-dependent interferon λ and antiviral defense in airway epithelium. J. Exp. Med. 210, 1929–1936 (2013).

pubmed: 23999497 pmcid: 3782052 doi: 10.1084/jem.20121401

Cheng, X. & Ratner, L. HIV-2 Vpx protein interacts with interferon regulatory factor 5 (IRF5) and inhibits its function. J. Biol. Chem. 289, 9146–9157 (2014).

pubmed: 24532789 pmcid: 3979364 doi: 10.1074/jbc.M113.534321

Su, S. et al. Modulation of innate immune response to viruses including SARS-CoV-2 by progesterone. Signal. Transduct. Target. Ther. 7, 137 (2022).

pubmed: 35468896 pmcid: 9035769 doi: 10.1038/s41392-022-00981-5

Yoo, J. S. & Sasaki, M. SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis. Nat. Commun. 12, 6602 (2021).

pubmed: 34782627 pmcid: 8594428 doi: 10.1038/s41467-021-26910-8

Hall, R. et al. SARS-CoV-2 ORF6 disrupts innate immune signalling by inhibiting cellular mRNA export. PLoS. Pathog. 18, e1010349 (2022).

pubmed: 36007063 pmcid: 9451085 doi: 10.1371/journal.ppat.1010349

Rashid, F. et al. Roles and functions of SARS-CoV-2 proteins in host immune evasion. Front. Immunol. 13, 940756 (2022).

pubmed: 36003396 pmcid: 9394213 doi: 10.3389/fimmu.2022.940756

Moustaqil, M. & Ollivier, E. SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species. Emerg. Microbes Infect. 10, 178–195 (2021).

pubmed: 33372854 pmcid: 7850364 doi: 10.1080/22221751.2020.1870414

Shin, D. & Mukherjee, R. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 587, 657–662 (2020).

pubmed: 32726803 pmcid: 7116779 doi: 10.1038/s41586-020-2601-5

Wang, W. et al. SARS-CoV-2 nsp12 attenuates type I interferon production by inhibiting IRF3 nuclear translocation. Cell. Mol. Immunol. 18, 945–953 (2021).

pubmed: 33637958 doi: 10.1038/s41423-020-00619-y

Zheng, Y. et al. SARS-CoV-2 NSP5 and N protein counteract the RIG-I signaling pathway by suppressing the formation of stress granules. Signal. Transduct. Target. Ther. 7, 22 (2022).

pubmed: 35075101 pmcid: 8785035 doi: 10.1038/s41392-022-00878-3

Feng, K. et al. SARS-CoV-2 NSP13 interacts with host IRF3, blocking antiviral immune responses. J. Med. Virol. 95, e28881 (2023).

pubmed: 37314155 doi: 10.1002/jmv.28881

Fung, S. Y. et al. SARS-CoV-2 main protease suppresses type I interferon production by preventing nuclear translocation of phosphorylated IRF3. Int. J. Biol. Sci. 17, 1547–1554 (2021).

pubmed: 33907518 pmcid: 8071772 doi: 10.7150/ijbs.59943

Shin, J. et al. SARS-CoV-2 infection impairs the insulin/IGF signaling pathway in the lung, liver, adipose tissue, and pancreatic cells via IRF1. Metabolism 133, 155236 (2022).

pubmed: 35688210 pmcid: 9173833 doi: 10.1016/j.metabol.2022.155236

Huang, H. C. et al. Upregulation of PD-L1 by SARS-CoV-2 promotes immune evasion. J. Med. Virol. 95, e28478 (2023).

pubmed: 36609964 pmcid: 10107526 doi: 10.1002/jmv.28478

Zhang, Q. & Bastard, P. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370, eabd4570 (2020).

Lévy, R. & Zhang, P. Monoclonal antibody-mediated neutralization of SARS-CoV-2 in an IRF9-deficient child. Proc. Natl. Acad. Sci. USA. 118, e2114390118 (2021).

Mishra, R. & Banerjea, A. C. SARS-CoV-2 Spike Targets USP33-IRF9 Axis via Exosomal miR-148a to Activate Human Microglia. Front. Immunol. 12, 656700 (2021).

pubmed: 33936086 pmcid: 8079643 doi: 10.3389/fimmu.2021.656700

Gidon, A. et al. The Tumor Necrosis Factor Alpha and Interleukin 6 Auto-paracrine Signaling Loop Controls Mycobacterium avium Infection via Induction of IRF1/IRG1 in Human Primary Macrophages. mBio 12, e0212121 (2021).

pubmed: 34607464 doi: 10.1128/mBio.02121-21

Zhou, X. et al. Interferon regulatory factor 1 eliminates mycobacteria by suppressing p70 S6 kinase via mechanistic target of rapamycin signaling. J. Infect. 79, 262–276 (2019).

pubmed: 31226272 doi: 10.1016/j.jinf.2019.06.007

Schmalzl, A., Leupold, T. & Kreiss, L. Interferon regulatory factor 1 (IRF-1) promotes intestinal group 3 innate lymphoid responses during Citrobacter rodentium infection. Nat. Commun. 13, 5730 (2022).

pubmed: 36175404 pmcid: 9522774 doi: 10.1038/s41467-022-33326-5

Yoon, G. S. et al. Interferon regulatory factor-1 in flagellin-induced reprogramming: potential protective role of CXCL10 in cornea innate defense against Pseudomonas aeruginosa infection. Invest. Ophthalmol. Vis. Sci. 54, 7510–7521 (2013).

pubmed: 24130180 pmcid: 3832217 doi: 10.1167/iovs.13-12453

Li, Q., Liu, C., Yue, R. & El-Ashram, S. cGAS/STING/TBK1/IRF3 Signaling Pathway Activates BMDCs Maturation Following Mycobacterium bovis Infection. Int. J. Mol. Sci. 20, 895 (2019).

Cui, Y. et al. Mycobacterium bovis Induces Endoplasmic Reticulum Stress Mediated-Apoptosis by Activating IRF3 in a Murine Macrophage Cell Line. Front. Cell. Infect. Microbiol. 6, 182 (2016).

pubmed: 28018864 pmcid: 5149527 doi: 10.3389/fcimb.2016.00182

Cheng, Y. & Schorey, J. S. Mycobacterium tuberculosis-induced IFN-β production requires cytosolic DNA and RNA sensing pathways. J. Exp. Med. 215, 2919–2935 (2018).

pubmed: 30337468 pmcid: 6219742 doi: 10.1084/jem.20180508

Pandey, A. K. et al. NOD2, RIP2 and IRF5 play a critical role in the type I interferon response to Mycobacterium tuberculosis. PLoS. Pathog. 5, e1000500 (2009).

pubmed: 19578435 pmcid: 2698121 doi: 10.1371/journal.ppat.1000500

Zhang, Z. et al. MicroRNA-31 mediated by interferon regulatory factor 7 signaling facilitates control of Mycobacterium tuberculosis infection. Int. J. Med. Microbiol. 312, 151569 (2022).

pubmed: 36274382 doi: 10.1016/j.ijmm.2022.151569

Skjesol, A. & Yurchenko, M. The TLR4 adaptor TRAM controls the phagocytosis of Gram-negative bacteria by interacting with the Rab11-family interacting protein 2. PLoS. Pathog. 15, e1007684 (2019).

pubmed: 30883606 pmcid: 6438586 doi: 10.1371/journal.ppat.1007684

Dooyema, S. D. R. et al. Helicobacter pylori actively suppresses innate immune nucleic acid receptors. Gut. Microbes 14, 2105102 (2022).

pubmed: 35905376 pmcid: 9341374 doi: 10.1080/19490976.2022.2105102

Yu, X. et al. Cross-Regulation of Two Type I Interferon Signaling Pathways in Plasmacytoid Dendritic Cells Controls Anti-malaria Immunity and Host Mortality. Immunity 45, 1093–1107 (2016).

pubmed: 27793594 pmcid: 7128466 doi: 10.1016/j.immuni.2016.10.001

Yu, X. et al. Inflammasome activation negatively regulates MyD88-IRF7 type I IFN signaling and anti-malaria immunity. Nat. Commun. 9, 4964 (2018).

pubmed: 30470758 pmcid: 6251914 doi: 10.1038/s41467-018-07384-7

Swanson, R. V. et al. Antigen-specific B cells direct T follicular-like helper cells into lymphoid follicles to mediate Mycobacterium tuberculosis control. Nat. Immunol. 24, 855–868 (2023).

pubmed: 37012543 pmcid: 11133959 doi: 10.1038/s41590-023-01476-3

Harberts, A. & Schmidt, C. Interferon regulatory factor 4 controls effector functions of CD8(+) memory T cells. Proc. Natl. Acad. Sci. USA 118, e2014553118 (2021).

Pandey, S. P., Yan, J., Turner, J. R. & Abraham, C. Reducing IRF5 expression attenuates colitis in mice, but impairs the clearance of intestinal pathogens. Mucosal. Immunol. 12, 874–887 (2019).

pubmed: 31053739 pmcid: 6688861 doi: 10.1038/s41385-019-0165-1

Hedl, M., Yan, J. & Witt, H. IRF5 Is Required for Bacterial Clearance in Human M1-Polarized Macrophages, and IRF5 Immune-Mediated Disease Risk Variants Modulate This Outcome. J. Immunol. 202, 920–930 (2019).

pubmed: 30593537 doi: 10.4049/jimmunol.1800226

Corbin, A. L., Gomez-Vazquez, M. & Berthold, D. L. IRF5 guides monocytes toward an inflammatory CD11c(+) macrophage phenotype and promotes intestinal inflammation. Sci. Immunol. 5, eaax6085 (2020).

Mathy, N. W. et al. The Long Non-Coding RNA Nostrill Regulates Transcription of Irf7 Through Interaction With NF-κB p65 to Enhance Intestinal Epithelial Defense Against Cryptosporidium parvum. Front. Immunol. 13, 863957 (2022).

pubmed: 35464447 pmcid: 9021721 doi: 10.3389/fimmu.2022.863957

Karki, R., Lee, E. & Sharma, B. R. IRF8 Regulates Gram-Negative Bacteria-Mediated NLRP3 Inflammasome Activation and Cell Death. J. Immunol. 204, 2514–2522 (2020).

pubmed: 32205422 doi: 10.4049/jimmunol.1901508

Biondo, C. et al. Recognition of fungal RNA by TLR7 has a nonredundant role in host defense against experimental candidiasis. Eur. J. Immunol. 42, 2632–2643 (2012).

pubmed: 22777843 doi: 10.1002/eji.201242532

Yang, L. et al. InsP(3)R-SEC5 interaction on phagosomes modulates innate immunity to Candida albicans by promoting cytosolic Ca(2+) elevation and TBK1 activity. Bmc. Biol. 16, 46 (2018).

pubmed: 29703257 pmcid: 5921305 doi: 10.1186/s12915-018-0507-6

Brown Harding, H. et al. Candida albicans extracellular vesicles trigger type I IFN signalling via cGAS and STING. Nat. Microbiol. 9, 95–107 (2024).

pubmed: 38168615 doi: 10.1038/s41564-023-01546-0

Li, F. et al. C-type lectin receptor 2d forms homodimers and heterodimers with TLR2 to negatively regulate IRF5-mediated antifungal immunity. Nat. Commun. 14, 6718 (2023).

pubmed: 37872182 pmcid: 10593818 doi: 10.1038/s41467-023-42216-3

Qing, F. et al. IRF7 Exacerbates Candida albicans Infection by Compromising CD209-Mediated Phagocytosis and Autophagy-Mediated Killing in Macrophages. J. Immunol. 212, 1932–1944 (2024).

pubmed: 38709167 doi: 10.4049/jimmunol.2300826

Wevers, B. A. et al. Fungal engagement of the C-type lectin mincle suppresses dectin-1-induced antifungal immunity. Cell. Host. Microbe 15, 494–505 (2014).

pubmed: 24721577 doi: 10.1016/j.chom.2014.03.008

Wiesner, D. L. et al. Regulatory T Cell Induction and Retention in the Lungs Drives Suppression of Detrimental Type 2 Th Cells During Pulmonary Cryptococcal Infection. J. Immunol. 196, 365–374 (2016).

pubmed: 26590316 doi: 10.4049/jimmunol.1501871

Valdez, P. A. et al. Prostaglandin E2 suppresses antifungal immunity by inhibiting interferon regulatory factor 4 function and interleukin-17 expression in T cells. Immunity 36, 668–679 (2012).

pubmed: 22464170 pmcid: 3334441 doi: 10.1016/j.immuni.2012.02.013

Harada, H. et al. Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science 259, 971–974 (1993).

pubmed: 8438157 doi: 10.1126/science.8438157

van der Weyden, L. et al. Genome-wide in vivo screen identifies novel host regulators of metastatic colonization. Nature 541, 233–236 (2017).

pubmed: 28052056 pmcid: 5603286 doi: 10.1038/nature20792

Jeong, S. I. et al. XAF1 forms a positive feedback loop with IRF-1 to drive apoptotic stress response and suppress tumorigenesis. Cell. Death. Dis. 9, 806 (2018).

pubmed: 30042418 pmcid: 6057933 doi: 10.1038/s41419-018-0867-4

Yanai, H., Negishi, H. & Taniguchi, T. The IRF family of transcription factors: Inception, impact and implications in oncogenesis. Oncoimmunology 1, 1376–1386 (2012).

pubmed: 23243601 pmcid: 3518510 doi: 10.4161/onci.22475

Shao, L., Hou, W. & Scharping, N. E. IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell. Cancer Immunol. Res. 7, 1258–1266 (2019).

pubmed: 31239318 doi: 10.1158/2326-6066.CIR-18-0711

Kriegsman, B. A. & Vangala, P. Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression. J. Immunol. 203, 1999–2010 (2019).

pubmed: 31471524 doi: 10.4049/jimmunol.1900475

Arnold, M. et al. Global Burden of 5 Major Types of Gastrointestinal Cancer. Gastroenterology 159, 335–349.e315 (2020).

pubmed: 32247694 doi: 10.1053/j.gastro.2020.02.068

Wang, Y. et al. Involvement of IFN regulatory factor (IRF)-1 and IRF-2 in the formation and progression of human esophageal cancers. Cancer Res. 67, 2535–2543 (2007).

pubmed: 17363571 doi: 10.1158/0008-5472.CAN-06-3530

Wang, Y. et al. Negative feedback regulation of IFN-gamma pathway by IFN regulatory factor 2 in esophageal cancers. Cancer Res. 68, 1136–1143 (2008).

pubmed: 18281489 doi: 10.1158/0008-5472.CAN-07-5021

Huang, J. et al. Interferon-inducible lncRNA IRF1-AS represses esophageal squamous cell carcinoma by promoting interferon response. Cancer Lett. 459, 86–99 (2019).

pubmed: 31173852 doi: 10.1016/j.canlet.2019.05.038

Watson, G. A. et al. Ad-IRF-1 induces apoptosis in esophageal adenocarcinoma. Neoplasia 8, 31–37 (2006).

pubmed: 16533423 pmcid: 1584287 doi: 10.1593/neo.05559

Zhou, Y. et al. FOXM1c promotes oesophageal cancer metastasis by transcriptionally regulating IRF1 expression. Cell. Prolif. 52, e12553 (2019).

pubmed: 30485581 doi: 10.1111/cpr.12553

Wierstra, I. FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy. Adv. Cancer Res. 119, 191–419 (2013).

pubmed: 23870513 doi: 10.1016/B978-0-12-407190-2.00016-2

Zhang, C. F. et al. Relationship between polymorphism of IRF-3 gene codon 427 and esophageal cancer in Anyang population of China. Beijing. Da. Xue. Xue. Bao. Yi. Xue. Ban. 36, 345–347 (2004).

pubmed: 15303122

Dai, W. et al. Whole-exome sequencing reveals critical genes underlying metastasis in oesophageal squamous cell carcinoma. J. Pathol. 242, 500–510 (2017).

pubmed: 28608921 doi: 10.1002/path.4925

Chen, J. et al. Genomic profiling of 766 cancer-related genes in archived esophageal normal and carcinoma tissues. Int. J. Cancer 122, 2249–2254 (2008).

pubmed: 18241037 doi: 10.1002/ijc.23397

Sun, R. et al. Prognostic significance of interferon regulating factor 4 in esophageal squamous cell carcinoma. Biochem. Biophys. Res. Commun. 506, 685–691 (2018).

pubmed: 30376993 doi: 10.1016/j.bbrc.2018.10.142

Nozawa, H. et al. Functionally inactivating point mutation in the tumor-suppressor IRF-1 gene identified in human gastric cancer. Int. J. Cancer 77, 522–527 (1998).

pubmed: 9679752 doi: 10.1002/(SICI)1097-0215(19980812)77:4<522::AID-IJC8>3.0.CO;2-W

Gao, J. et al. IRF-1 transcriptionally upregulates PUMA, which mediates the mitochondrial apoptotic pathway in IRF-1-induced apoptosis in cancer cells. Cell. Death. Differ. 17, 699–709 (2010).

pubmed: 19851330 doi: 10.1038/cdd.2009.156

Gao, J., Tian, Y. & Zhang, J. Overexpression of interferon regulatory factor 1 enhances chemosensitivity to 5-fluorouracil in gastric cancer cells. J. Cancer Res. Ther. 8, 57–61 (2012).

pubmed: 22531515 doi: 10.4103/0973-1482.95175

Yuan, J. et al. Interferon regulatory factor-1 reverses chemoresistance by downregulating the expression of P-glycoprotein in gastric cancer. Cancer Lett. 457, 28–39 (2019).

pubmed: 31078735 doi: 10.1016/j.canlet.2019.05.006

Tan, L. et al. Interferon regulatory factor-1 suppresses DNA damage response and reverses chemotherapy resistance by downregulating the expression of RAD51 in gastric cancer. Am. J. Cancer Res. 10, 1255–1270 (2020).

pubmed: 32368400 pmcid: 7191096

Yuan, J. et al. MIR17HG-miR-18a/19a axis, regulated by interferon regulatory factor-1, promotes gastric cancer metastasis via Wnt/β-catenin signalling. Cell. Death. Dis. 10, 454 (2019).

pubmed: 31186404 pmcid: 6560107 doi: 10.1038/s41419-019-1685-z

Chen, Y. J. et al. MicroRNA-18a modulates P53 expression by targeting IRF2 in gastric cancer patients. J. Gastroenterol. Hepatol. 31, 155–163 (2016).

pubmed: 26173586 doi: 10.1111/jgh.13041

Chen, Y. J. et al. IRF-2 Inhibits Gastric Cancer Invasion and Migration by Down-Regulating MMP-1. Dig. Dis. Sci. 65, 168–177 (2020).

pubmed: 31350707 doi: 10.1007/s10620-019-05739-8

Chen, Y. J. et al. IRF-2 inhibits cancer proliferation by promoting AMER-1 transcription in human gastric cancer. J. Transl. Med. 20, 68 (2022).

pubmed: 35115027 pmcid: 8812234 doi: 10.1186/s12967-022-03275-0

Jiao, S. et al. Targeting IRF3 as a YAP agonist therapy against gastric cancer. J. Exp. Med. 215, 699–718 (2018).

pubmed: 29339449 pmcid: 5789414 doi: 10.1084/jem.20171116

Qiao, Y., Li, T., Zheng, S. & Wang, H. The Hippo pathway as a drug target in gastric cancer. Cancer Lett. 420, 14–25 (2018).

pubmed: 29408652 doi: 10.1016/j.canlet.2018.01.062

Zhang, T. et al. microRNA-365 inhibits YAP through TLR4-mediated IRF3 phosphorylation and thereby alleviates gastric precancerous lesions. Cancer Cell. Int. 20, 549 (2020).

pubmed: 33292210 pmcid: 7664090 doi: 10.1186/s12935-020-01578-0

Yamashita, M. et al. DNA methylation of interferon regulatory factors in gastric cancer and noncancerous gastric mucosae. Cancer Sci. 101, 1708–1716 (2010).

pubmed: 20507321 pmcid: 11158968 doi: 10.1111/j.1349-7006.2010.01581.x

Jee, C. D. et al. Identification of genes epigenetically silenced by CpG methylation in human gastric carcinoma. Eur. J. Cancer 45, 1282–1293 (2009).

pubmed: 19195878 doi: 10.1016/j.ejca.2008.12.027

Li, D. et al. IRF6 Is Directly Regulated by ZEB1 and ELF3, and Predicts a Favorable Prognosis in Gastric Cancer. Front. Oncol. 9, 220 (2019).

pubmed: 31019894 pmcid: 6458252 doi: 10.3389/fonc.2019.00220

Du, J. et al. Cytoplasmic localization of IRF5 induces Wnt5a/E-cadherin degradation and promotes gastric cancer cells metastasis. Cancer Gene. Ther. 30, 866–877 (2023).

pubmed: 36782048 doi: 10.1038/s41417-023-00596-0

Xing, Y., Chen, H., Guo, Z. & Zhou, X. Circular RNA circ0007360 Attenuates Gastric Cancer Progression by Altering the miR-762/IRF7 Axis. Front. Cell. Dev. Biol. 10, 789073 (2022).

pubmed: 35252169 pmcid: 8891931 doi: 10.3389/fcell.2022.789073

Fu, K. et al. Single-cell RNA sequencing of immune cells in gastric cancer patients. Aging (Albany NY) 12, 2747–2763 (2020).

pubmed: 32039830 doi: 10.18632/aging.102774

Yan, Y. et al. Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells. Cancer Immunol. Immunother. 69, 1891–1903 (2020).

pubmed: 32377817 pmcid: 10112362 doi: 10.1007/s00262-020-02586-9

Lin, Y. H. et al. Repression of microRNA-130b by thyroid hormone enhances cell motility. J. Hepatol. 62, 1328–1340 (2015).

pubmed: 25617495 doi: 10.1016/j.jhep.2014.12.035

Wang, R. et al. Interferon Gamma-Induced Interferon Regulatory Factor 1 Activates Transcription of HHLA2 and Induces Immune Escape of Hepatocellular Carcinoma Cells. Inflammation 45, 308–330 (2022).

pubmed: 34536158 doi: 10.1007/s10753-021-01547-3

Wang, Z. & Pan, B. SUMOylated IL-33 in the nucleus stabilizes the transcription factor IRF1 in hepatocellular carcinoma cells to promote immune escape. Sci. Signal. 16, eabq3362 (2023).

pubmed: 36917642 doi: 10.1126/scisignal.abq3362

Yu, M. et al. miR-345 inhibits tumor metastasis and EMT by targeting IRF1-mediated mTOR/STAT3/AKT pathway in hepatocellular carcinoma. Int. J. Oncol. 50, 975–983 (2017).

pubmed: 28098858 doi: 10.3892/ijo.2017.3852

Li, P. et al. Interferon-γ induces autophagy with growth inhibition and cell death in human hepatocellular carcinoma (HCC) cells through interferon-regulatory factor-1 (IRF-1). Cancer Lett. 314, 213–222 (2012).

pubmed: 22056812 doi: 10.1016/j.canlet.2011.09.031

Kröger, A. et al. Growth suppression of the hepatocellular carcinoma cell line Hepa1-6 by an activatable interferon regulatory factor-1 in mice. Cancer Res. 61, 2609–2617 (2001).

pubmed: 11289138

Zekri, A. R. et al. Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with repression of interferon regulatory factor-1. Eur. J. Gastroenterol. Hepatol. 22, 450–456 (2010).

pubmed: 19858727 doi: 10.1097/MEG.0b013e3283329d00

Yi, Y. et al. Interferon regulatory factor (IRF)-1 and IRF-2 are associated with prognosis and tumor invasion in HCC. Ann. Surg. Oncol. 20, 267–276 (2013).

pubmed: 22805863 doi: 10.1245/s10434-012-2487-z

Moriyama, Y. et al. Tumor-suppressor effect of interferon regulatory factor-1 in human hepatocellular carcinoma. Clin. Cancer Res. 7, 1293–1298 (2001).

pubmed: 11350897

Yan, Y. et al. Interferon regulatory factor 1 (IRF-1) downregulates Checkpoint kinase 1 (CHK1) through miR-195 to upregulate apoptosis and PD-L1 expression in Hepatocellular carcinoma (HCC) cells. Br. J. Cancer 125, 101–111 (2021).

pubmed: 33772151 pmcid: 8257880 doi: 10.1038/s41416-021-01337-6

Yan, Y. et al. Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10/CXCR3 axis in hepatocellular carcinoma (HCC). Cancer Lett. 506, 95–106 (2021).

pubmed: 33689775 pmcid: 8009854 doi: 10.1016/j.canlet.2021.03.002

Wan, P. Q. et al. Analysis of the relationship between microRNA-31 and interferon regulatory factor-1 in hepatocellular carcinoma cells. Eur. Rev. Med. Pharmacol. Sci. 24, 647–654 (2020).

pubmed: 32016965

Yan, Y. et al. MicroRNA-23a downregulates the expression of interferon regulatory factor-1 in hepatocellular carcinoma cells. Oncol. Rep. 36, 633–640 (2016).

pubmed: 27279136 pmcid: 4933546 doi: 10.3892/or.2016.4864

Dong, K. et al. MicroRNA-301a (miR-301a) is induced in hepatocellular carcinoma (HCC) and down- regulates the expression of interferon regulatory factor-1. Biochem. Biophys. Res. Commun. 524, 273–279 (2020).

pubmed: 31987500 pmcid: 7857543 doi: 10.1016/j.bbrc.2020.01.034

Yu, W. et al. NR4A1 mediates NK-cell dysfunction in hepatocellular carcinoma via the IFN-γ/p-STAT1/IRF1 pathway. Immunology 169, 69–82 (2023).

pubmed: 36420610 doi: 10.1111/imm.13611

Guichard, C. et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet. 44, 694–698 (2012).

pubmed: 22561517 pmcid: 3819251 doi: 10.1038/ng.2256

Guo, Y. et al. IRF2 regulates cellular survival and Lenvatinib-sensitivity of hepatocellular carcinoma (HCC) through regulating β-catenin. Transl. Oncol. 14, 101059 (2021).

pubmed: 33735820 pmcid: 7988337 doi: 10.1016/j.tranon.2021.101059

Yu, H. et al. Major Vault Protein Promotes Hepatocellular Carcinoma Through Targeting Interferon Regulatory Factor 2 and Decreasing p53 Activity. Hepatology 72, 518–534 (2020).

pubmed: 31758709 doi: 10.1002/hep.31045

Yuan, M. M. et al. TLR3 expression correlates with apoptosis, proliferation and angiogenesis in hepatocellular carcinoma and predicts prognosis. Bmc. Cancer 15, 245 (2015).

pubmed: 25884709 pmcid: 4435918 doi: 10.1186/s12885-015-1262-5

Qi, Z. et al. Identification of prognostic biomarkers and correlations with immune infiltrates among cGAS-STING in hepatocellular carcinoma. Biosci. Rep. 40, BSR20202603 (2020).

Kim, G. W. & Imam, H. HBV-Induced Increased N6 Methyladenosine Modification of PTEN RNA Affects Innate Immunity and Contributes to HCC. Hepatology 73, 533–547 (2021).

pubmed: 32394474 doi: 10.1002/hep.31313

Du, S. S. et al. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation. Int. J. Radiat. Oncol. Biol. Phys. 112, 1243–1255 (2022).

pubmed: 34986380 doi: 10.1016/j.ijrobp.2021.12.162

Ma, H., Kang, Z. & Foo, T. K. Disrupted BRCA1-PALB2 interaction induces tumor immunosuppression and T-lymphocyte infiltration in HCC through cGAS-STING pathway. Hepatology 77, 33–47 (2023).

pubmed: 35006619

Yuan, J. et al. Construction and validation of an IRF4 risk score to predict prognosis and response to immunotherapy in hepatocellular carcinoma. Int. Immunopharmacol. 113, 109411 (2022).

pubmed: 36461603 doi: 10.1016/j.intimp.2022.109411

Shin, S. H. et al. Identification of novel methylation markers in hepatocellular carcinoma using a methylation array. J. Korean Med. Sci. 25, 1152–1159 (2010).

pubmed: 20676325 pmcid: 2908783 doi: 10.3346/jkms.2010.25.8.1152

Yu, J. et al. Methylation profiling of twenty four genes and the concordant methylation behaviours of nineteen genes that may contribute to hepatocellular carcinogenesis. Cell. Res. 13, 319–333 (2003).

pubmed: 14672555 doi: 10.1038/sj.cr.7290177

Wu, H. et al. Hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti-programmed cell death protein-1 therapy. Hepatology 76, 1602–1616 (2022).

pubmed: 34989013 doi: 10.1002/hep.32316

Tamada, Y. et al. p48 Overexpression enhances interferon-mediated expression and activity of double-stranded RNA-dependent protein kinase in human hepatoma cells. J. Hepatol. 37, 493–499 (2002).

pubmed: 12217603 doi: 10.1016/S0168-8278(02)00232-5

Wu, W. Z. et al. Reduction in p48-ISGFgamma levels confers resistance to interferon-alpha2a in MHCC97 cells. Oncology 67, 428–440 (2004).

pubmed: 15714000 doi: 10.1159/000082928

Qian, Y. B. et al. P48 is a predictive marker for outcome of postoperative interferon-alpha treatment in patients with hepatitis B virus infection-related hepatocellular carcinoma. Cancer 107, 1562–1569 (2006).

pubmed: 16948122 doi: 10.1002/cncr.22206

Huang, X., Zhang, G. & Liang, T. Subtyping for pancreatic cancer precision therapy. Trends Pharmacol. Sci. 43, 482–494 (2022).

pubmed: 35400559 doi: 10.1016/j.tips.2022.03.005

Sakai, T. et al. The roles of interferon regulatory factors 1 and 2 in the progression of human pancreatic cancer. Pancreas 43, 909–916 (2014).

pubmed: 24632547 doi: 10.1097/MPA.0000000000000116

Hannes, S., Karlowitz, R. & van Wijk, S. J. L. The Smac mimetic BV6 cooperates with STING to induce necroptosis in apoptosis-resistant pancreatic carcinoma cells. Cell. Death. Dis. 12, 816 (2021).

pubmed: 34462421 pmcid: 8405653 doi: 10.1038/s41419-021-04014-x

Somerville, T. D. D., Xu, Y., Wu, X. S. & Maia-Silva, D. ZBED2 is an antagonist of interferon regulatory factor 1 and modifies cell identity in pancreatic cancer. Proc. Natl Acad. Sci. Usa. 117, 11471–11482 (2020).

pubmed: 32385160 pmcid: 7261015 doi: 10.1073/pnas.1921484117

Cui, L. et al. IRF-2 is over-expressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. Tumour Biol. 33, 247–255 (2012).

pubmed: 22119988 doi: 10.1007/s13277-011-0273-3

Zhang, K. et al. Comprehensive analysis of expression profile and prognostic significance of interferon regulatory factors in pancreatic cancer. Bmc. Genom. Data. 23, 5 (2022).

pubmed: 35012444 pmcid: 8751298 doi: 10.1186/s12863-021-01019-5

Kou, Y. Q. et al. Prognostic-Related Biomarkers in Pancreatic Ductal Adenocarcinoma Correlating with Immune Infiltrates Based on Proteomics. Med. Sci. Monit. 29, e938785 (2023).

pubmed: 36905103 pmcid: 10015732 doi: 10.12659/MSM.938785

Liu, W. et al. Identifying a novel IRF3/circUHRF1/miR-1306-5p/ARL4C axis in pancreatic ductal adenocarcinoma progression. Cell. Cycle 21, 392–405 (2022).

pubmed: 34983293 pmcid: 8855851 doi: 10.1080/15384101.2021.2020450

Xie, W. & Li, X. The Pyroptosis-Related Gene Prognostic Index Associated with Tumor Immune Infiltration for Pancreatic Cancer. Int. J. Mol. Sci. 23, 6178 (2022).

Metzger, P. & Kirchleitner, S. V. Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model. Cancer Immunol. Immunother. 69, 2101–2112 (2020).

pubmed: 32448983 pmcid: 7511276 doi: 10.1007/s00262-020-02605-9

Muthalagu, N. & Monteverde, T. Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma. Cancer Discov. 10, 872–887 (2020).

pubmed: 32200350 pmcid: 7611248 doi: 10.1158/2159-8290.CD-19-0620

Meyer, M. A. et al. Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. Nat. Commun. 9, 1250 (2018).

pubmed: 29593283 pmcid: 5871846 doi: 10.1038/s41467-018-03600-6

Hong, M. et al. IRF1 inhibits the proliferation and metastasis of colorectal cancer by suppressing the RAS-RAC1 pathway. Cancer Manag. Res. 11, 369–378 (2019).

pubmed: 30643462 doi: 10.2147/CMAR.S186236

Wu, Y., Zhang, S. & Yan, J. IRF1 association with tumor immune microenvironment and use as a diagnostic biomarker for colorectal cancer recurrence. Oncol. Lett. 19, 1759–1770 (2020).

pubmed: 32194669 pmcid: 7039159

Yuan, L. et al. IRF1 Inhibits Autophagy-Mediated Proliferation of Colorectal Cancer via Targeting ATG13. Cancer Invest. 40, 35–45 (2022).

pubmed: 34313498 doi: 10.1080/07357907.2021.1961265

Sun, B. et al. Colorectal cancer exosomes induce lymphatic network remodeling in lymph nodes. Int. J. Cancer 145, 1648–1659 (2019).

pubmed: 30734278 doi: 10.1002/ijc.32196

Liao, W. et al. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell. 35, 559–572.e557 (2019).

pubmed: 30905761 pmcid: 6467776 doi: 10.1016/j.ccell.2019.02.008

Chen, Y. J. et al. Interferon regulatory factor family influences tumor immunity and prognosis of patients with colorectal cancer. J. Transl. Med. 19, 379 (2021).

pubmed: 34488791 pmcid: 8422700 doi: 10.1186/s12967-021-03054-3

You, W., Di, A., Zhang, L. & Zhao, G. Effects of wogonin on the growth and metastasis of colon cancer through the Hippo signaling pathway. Bioengineered 13, 2586–2597 (2022).

pubmed: 35037825 pmcid: 8973922 doi: 10.1080/21655979.2021.2019173

Tian, M. et al. IRF3 prevents colorectal tumorigenesis via inhibiting the nuclear translocation of β-catenin. Nat. Commun. 11, 5762 (2020).

pubmed: 33188184 pmcid: 7666182 doi: 10.1038/s41467-020-19627-7

Ding, C. et al. β-catenin regulates IRF3-mediated innate immune signalling in colorectal cancer. Cell. Prolif. 51, e12464 (2018).

pubmed: 30004146 pmcid: 6528881 doi: 10.1111/cpr.12464

Corrigendum. Cell Prolif 54, e12655, (2021).

Kießler, M. et al. Tumor-infiltrating plasmacytoid dendritic cells are associated with survival in human colon cancer. J. Immunother. Cancer. 9, e001813 (2021).

Roulois, D. et al. DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. Cell 162, 961–973 (2015).

pubmed: 26317465 pmcid: 4843502 doi: 10.1016/j.cell.2015.07.056

Udden, S. M. N. et al. NOD2 Suppresses Colorectal Tumorigenesis via Downregulation of the TLR Pathways. Cell. Rep. 19, 2756–2770 (2017).

pubmed: 28658623 pmcid: 6032983 doi: 10.1016/j.celrep.2017.05.084

Zhou, Y. et al. Integrated multi-omics data analyses for exploring the co-occurring and mutually exclusive gene alteration events in colorectal cancer. Hum. Mutat. 41, 1588–1599 (2020).

pubmed: 32485022 doi: 10.1002/humu.24059

Hu, G. & Barnes, B. J. Interferon regulatory factor-5-regulated pathways as a target for colorectal cancer therapeutics. Expert. Rev. Anticancer. Ther. 6, 775–784 (2006).

pubmed: 16759167 doi: 10.1586/14737140.6.5.775

Arnold, I. C. et al. The GM-CSF-IRF5 signaling axis in eosinophils promotes antitumor immunity through activation of type 1 T cell responses. J. Exp. Med. 217, e20190706 (2020).

Tan, L. et al. The interferon regulatory factor 6 promotes cisplatin sensitivity in colorectal cancer. Bioengineered 13, 10504–10517 (2022).

pubmed: 35443865 pmcid: 9161955 doi: 10.1080/21655979.2022.2062103

Ibrahim, M. L. et al. Myeloid-Derived Suppressor Cells Produce IL-10 to Elicit DNMT3b-Dependent IRF8 Silencing to Promote Colitis-Associated Colon Tumorigenesis. Cell. Rep. 25, 3036–3046.e3036 (2018).

pubmed: 30540937 pmcid: 6319669 doi: 10.1016/j.celrep.2018.11.050

Klement, J. D. et al. An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion. J. Clin. Invest. 128, 5549–5560 (2018).

pubmed: 30395540 pmcid: 6264631 doi: 10.1172/JCI123360

Sharma, B. R. et al. The Transcription Factor IRF9 Promotes Colorectal Cancer via Modulating the IL-6/STAT3 Signaling Axis. Cancers (Basel) 14, 919 (2022).

Thai, A. A. et al. Lung cancer. Lancet 398, 535–554 (2021).

pubmed: 34273294 doi: 10.1016/S0140-6736(21)00312-3

Lahiri, A. et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol. Cancer 22, 40 (2023).

pubmed: 36810079 pmcid: 9942077 doi: 10.1186/s12943-023-01740-y

Huang, J. X. et al. IRF1 Negatively Regulates Oncogenic KPNA2 Expression Under Growth Stimulation and Hypoxia in Lung Cancer Cells. Onco. Targets Ther. 12, 11475–11486 (2019).

pubmed: 31920336 pmcid: 6939401 doi: 10.2147/OTT.S221832

Zhang, L. et al. Interferon regulatory factor-1 regulates cisplatin-induced apoptosis and autophagy in A549 lung cancer cells. Med. Oncol. 39, 38 (2022).

pubmed: 35092496 pmcid: 8800914 doi: 10.1007/s12032-021-01638-z

Chan, Y. C. & Chang, Y. C. Overexpression of PSAT1 promotes metastasis of lung adenocarcinoma by suppressing the IRF1-IFNγ axis. Oncogene 39, 2509–2522 (2020).

pubmed: 31988456 doi: 10.1038/s41388-020-1160-4

Qi, L. et al. An individualized gene expression signature for prediction of lung adenocarcinoma metastases. Mol. Oncol. 11, 1630–1645 (2017).

pubmed: 28922552 pmcid: 5663997 doi: 10.1002/1878-0261.12137

Liang, C. et al. MicroRNA-18a-5p functions as an oncogene by directly targeting IRF2 in lung cancer. Cell. Death. Dis. 8, e2764 (2017).

pubmed: 28471447 pmcid: 5520692 doi: 10.1038/cddis.2017.145

Jin, J. J. et al. Overexpression of miR-1290 contributes to cell proliferation and invasion of non small cell lung cancer by targeting interferon regulatory factor 2. Int. J. Biochem. Cell. Biol. 95, 113–120 (2018).

pubmed: 29275213 doi: 10.1016/j.biocel.2017.12.017

Ma, J. et al. LncRNA GAS5 modulates the progression of non-small cell lung cancer through repressing miR-221-3p and up-regulating IRF2. Diagn. Pathol. 16, 46 (2021).

pubmed: 34022918 pmcid: 8140465 doi: 10.1186/s13000-021-01108-0

Xiao, X. H. & He, S. Y. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway. Eur. Rev. Med. Pharmacol. Sci. 24, 3130–3142 (2020).

pubmed: 32271431

Liu, F. et al. Upregulation of microRNA-450 inhibits the progression of lung cancer in vitro and in vivo by targeting interferon regulatory factor 2. Int. J. Mol. Med. 38, 283–290 (2016).

pubmed: 27246609 doi: 10.3892/ijmm.2016.2612

Yi, L. et al. Interferon regulatory factor 3 mediates Poly(I:C)-induced innate immune response and apoptosis in non‑small cell lung cancer. Int. J. Oncol. 52, 1623–1632 (2018).

pubmed: 29512705

Gong, K. et al. EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer. Nat. Cancer 1, 394–409 (2020).

pubmed: 33269343 pmcid: 7706867 doi: 10.1038/s43018-020-0048-0

Zhang, N. et al. PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer. Clin. Transl. Oncol. 23, 1827–1837 (2021).

pubmed: 33774805 doi: 10.1007/s12094-021-02591-z

Taniguchi, H. et al. WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. Cell. Rep. 39, 110814 (2022).

pubmed: 35584676 pmcid: 9449677 doi: 10.1016/j.celrep.2022.110814

Zhou, L. et al. Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer. Cancer Lett. 500, 163–171 (2021).

pubmed: 33278498 doi: 10.1016/j.canlet.2020.11.049

Sen, T. et al. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. Cancer Discov. 9, 646–661 (2019).

pubmed: 30777870 pmcid: 6563834 doi: 10.1158/2159-8290.CD-18-1020

Long, Y. et al. GPR162 activates STING dependent DNA damage pathway as a novel tumor suppressor and radiation sensitizer. Signal. Transduct. Target. Ther. 8, 48 (2023).

pubmed: 36725837 doi: 10.1038/s41392-022-01224-3

Wu, Y. Y. et al. CPEB4 and IRF4 expression in peripheral mononuclear cells are potential prognostic factors for advanced lung cancer. J. Formos. Med. Assoc. 116, 114–122 (2017).

pubmed: 27113098 doi: 10.1016/j.jfma.2016.01.009

Li, X. et al. Interferon Regulatory Factor 4 Correlated With Immune Cells Infiltration Could Predict Prognosis for Patients With Lung Adenocarcinoma. Front. Oncol. 11, 698465 (2021).

pubmed: 34195096 pmcid: 8236722 doi: 10.3389/fonc.2021.698465

Chen, H. Y. et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N. Engl. J. Med. 356, 11–20 (2007).

pubmed: 17202451 doi: 10.1056/NEJMoa060096

Gao, J. et al. Exosomal circZNF451 restrains anti-PD1 treatment in lung adenocarcinoma via polarizing macrophages by complexing with TRIM56 and FXR1. J. Exp. Clin. Cancer Res. 41, 295 (2022).

pubmed: 36209117 pmcid: 9547453 doi: 10.1186/s13046-022-02505-z

Carbó, J. M. & León, T. E. Pharmacologic Activation of LXR Alters the Expression Profile of Tumor-Associated Macrophages and the Abundance of Regulatory T Cells in the Tumor Microenvironment. Cancer Res. 81, 968–985 (2021).

pubmed: 33361391 doi: 10.1158/0008-5472.CAN-19-3360

Alvisi, G. et al. IRF4 instructs effector Treg differentiation and immune suppression in human cancer. J. Clin. Invest. 130, 3137–3150 (2020).

pubmed: 32125291 pmcid: 7260038 doi: 10.1172/JCI130426

Feng, D. D. et al. Transcription factor E2F1 positively regulates interferon regulatory factor 5 expression in non-small cell lung cancer. Onco. Targets Ther. 12, 6907–6915 (2019).

pubmed: 31692554 pmcid: 6711570 doi: 10.2147/OTT.S215701

Guo, J. et al. A promising role of interferon regulatory factor 5 as an early warning biomarker for the development of human non-small cell lung cancer. Lung. Cancer 135, 47–55 (2019).

pubmed: 31447002 doi: 10.1016/j.lungcan.2019.07.008

Yamashina, T. et al. Cancer stem-like cells derived from chemoresistant tumors have a unique capacity to prime tumorigenic myeloid cells. Cancer Res. 74, 2698–2709 (2014).

pubmed: 24638980 doi: 10.1158/0008-5472.CAN-13-2169

Liu, Y. et al. Interferon regulatory factor 6 correlates with the progression of non-small cell lung cancer and can be regulated by miR-320. J. Pharm. Pharmacol. 73, 682–691 (2021).

pubmed: 33772297 doi: 10.1093/jpp/rgab009

Huang, L. et al. IRF7 and IFIT2 in mediating different hemorrhage outcomes for non-small cell lung cancer after bevacizumab treatment. J. Thorac. Dis. 15, 2022–2036 (2023).

pubmed: 37197507 doi: 10.21037/jtd-23-389

Lai, Q. et al. Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells. Oncogene 37, 2302–2312 (2018).

pubmed: 29422611 doi: 10.1038/s41388-018-0125-3

Suzuki, M. et al. Aberrant methylation and silencing of IRF8 expression in non-small cell lung cancer. Oncol. Lett. 8, 1025–1030 (2014).

pubmed: 25120651 doi: 10.3892/ol.2014.2234

Liang, J. et al. IRF8 induces senescence of lung cancer cells to exert its tumor suppressive function. Cell. Cycle 18, 3300–3312 (2019).

pubmed: 31594449 doi: 10.1080/15384101.2019.1674053

Li, L. et al. Integrated analysis of dysregulated long non-coding RNAs/microRNAs/mRNAs in metastasis of lung adenocarcinoma. J. Transl. Med. 16, 372 (2018).

pubmed: 30587197 doi: 10.1186/s12967-018-1732-z

Brunn, D. & Turkowski, K. Interferon Regulatory Factor 9 Promotes Lung Cancer Progression via Regulation of Versican. Cancers (Basel) 13, 208 (2021).

Cohen, S. et al. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma. Gynecol. Oncol. 134, 591–598 (2014).

pubmed: 24995581 doi: 10.1016/j.ygyno.2014.06.025

Padmanabhan, S. et al. IFNγ-induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling. Cell. Signal. 97, 110400 (2022).

pubmed: 35820543 doi: 10.1016/j.cellsig.2022.110400

Huang, S. L., Chang, T. C., Chao, C. C. K. & Sun, N. K. TLR4/IL-6/IRF1 signaling regulates androgen receptor expression: A potential therapeutic target to overcome taxol resistance in ovarian cancer. Biochem. Pharmacol. 186, 114456 (2021).

pubmed: 33556340 doi: 10.1016/j.bcp.2021.114456

Pavan, S., Olivero, M., Corà, D. & Di Renzo, M. F. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness. Eur. J. Cancer 49, 964–973 (2013).

pubmed: 23079474 doi: 10.1016/j.ejca.2012.09.024

Zhang, J. et al. Deubiquitinase USP35 restrains STING-mediated interferon signaling in ovarian cancer. Cell. Death. Differ. 28, 139–155 (2021).

pubmed: 32678307 doi: 10.1038/s41418-020-0588-y

Cornelison, R. et al. CX-5461 Treatment Leads to Cytosolic DNA-Mediated STING Activation in Ovarian Cancer. Cancers (Basel) 13, 5056 (2021).

Heimes, A. S. et al. A retrospective analysis of immunohistochemically determined IRF4 (interferon regulating factor 4) expression in a consecutive cohort of 114 ovarian cancer patients. Arch. Gynecol. Obstet. 299, 239–246 (2019).

pubmed: 30357498 doi: 10.1007/s00404-018-4941-z

Zhang, F. et al. Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers. Nat. Commun. 10, 3974 (2019).

pubmed: 31481662 doi: 10.1038/s41467-019-11911-5

Hoffmann, M., Rak, A. & Ptak, A. Bisphenol A and its derivatives decrease expression of chemerin, which reverses its stimulatory action in ovarian cancer cells. Toxicol. Lett. 291, 61–69 (2018).

pubmed: 29653259 doi: 10.1016/j.toxlet.2018.04.004

Schmitt, M. et al. Anti-Tumoral Effect of Chemerin on Ovarian Cancer Cell Lines Mediated by Activation of Interferon Alpha Response. Cancers (Basel) 14, 4108 (2022).

Tang, D. G. Understanding and targeting prostate cancer cell heterogeneity and plasticity. Semin. Cancer Biol. 82, 68–93 (2022).

pubmed: 34844845 doi: 10.1016/j.semcancer.2021.11.001

Cheng, Y., Wang, D., Jiang, J. & Huang, W. Integrative analysis of AR-mediated transcriptional regulatory network reveals IRF1 as an inhibitor of prostate cancer progression. Prostate 80, 640–652 (2020).

pubmed: 32282098 doi: 10.1002/pros.23976

Sonkusre, P. & Cameotra, S. S. Biogenic selenium nanoparticles induce ROS-mediated necroptosis in PC-3 cancer cells through TNF activation. J. Nanobiotechnology. 15, 43 (2017).

pubmed: 28592284 doi: 10.1186/s12951-017-0276-3

Bachmann, S. B. et al. DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells. Mol. Cancer 13, 125 (2014).

pubmed: 24886089 pmcid: 4070648 doi: 10.1186/1476-4598-13-125

Wu, H. et al. Loss of a Negative Feedback Loop between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance. Cancer Res. 80, 2927–2939 (2020).

pubmed: 32341037 pmcid: 9601976 doi: 10.1158/0008-5472.CAN-19-2549

Kneitz, B. et al. Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. Cancer Res. 74, 2591–2603 (2014).

pubmed: 24607843 doi: 10.1158/0008-5472.CAN-13-1606

Deveci Ozkan, A. & Kaleli, S. Anti-inflammatory effects of nobiletin on TLR4/TRIF/IRF3 and TLR9/IRF7 signaling pathways in prostate cancer cells. Immunopharmacol. Immunotoxicol. 42, 93–100 (2020).

pubmed: 32048561 doi: 10.1080/08923973.2020.1725040

Zhao, Y. et al. Overexpression of Interferon Regulatory Factor 7 (IRF7) Reduces Bone Metastasis of Prostate Cancer Cells in Mice. Oncol. Res. 25, 511–522 (2017).

pubmed: 27733217 pmcid: 7841009 doi: 10.3727/096504016X14756226781802

Yu, S. J., Kim, H. S., Cho, S. W. & Sohn, J. IL-4 inhibits proliferation of renal carcinoma cells by increasing the expression of p21WAF1 and IRF-1. Exp. Mol. Med. 36, 372–379 (2004).

pubmed: 15365257 doi: 10.1038/emm.2004.49

Tomita, Y. et al. Role of IRF-1 and caspase-7 in IFN-gamma enhancement of Fas-mediated apoptosis in ACHN renal cell carcinoma cells. Int. J. Cancer 104, 400–408 (2003).

pubmed: 12584735 doi: 10.1002/ijc.10956

Kong, S. K. et al. Dissection of PD-L1 promoter reveals differential transcriptional regulation of PD-L1 in VHL mutant clear cell renal cell carcinoma. Lab. Invest. 102, 352–362 (2022).

pubmed: 34789838 doi: 10.1038/s41374-021-00703-5

Wu, J. et al. Overexpression of IRF3 Predicts Poor Prognosis in Clear Cell Renal Cell Carcinoma. Int. J. Gen. Med. 14, 5675–5692 (2021).

pubmed: 34557022 pmcid: 8454526 doi: 10.2147/IJGM.S328225

Zeng, X., Li, L., Hu, Z. & Peng, D. Integrated Multi-Omics Analysis Identified PTPRG and CHL1 as Key Regulators of Immunophenotypes in Clear Cell Renal Cell Carcinoma(ccRCC). Front. Oncol. 12, 832027 (2022).

pubmed: 35433461 pmcid: 9005830 doi: 10.3389/fonc.2022.832027

Wang, H. et al. ZNF692 promote proliferation through transcriptional repression of essential genes in clear cell renal carcinoma. Biochem. Biophys. Res. Commun. 671, 255–262 (2023).

pubmed: 37307709 doi: 10.1016/j.bbrc.2023.06.014

Li, Z. et al. Decreased interferon regulatory factor 6 expression due to DNA hypermethylation predicts an unfavorable prognosis in clear cell renal cell carcinoma. J. Cancer 12, 6640–6655 (2021).

pubmed: 34659554 pmcid: 8518015 doi: 10.7150/jca.62394

Wang, Y. et al. Gene Expression Microarray Data Meta-Analysis Identifies Candidate Genes and Molecular Mechanism Associated with Clear Cell Renal Cell Carcinoma. Cell. J. 22, 386–393 (2020).

pubmed: 31863665

Lin, L. & Cai, J. Circular RNA circ-EGLN3 promotes renal cell carcinoma proliferation and aggressiveness via miR-1299-mediated IRF7 activation. J. Cell. Biochem. 121, 4377–4385 (2020).

pubmed: 31904147 doi: 10.1002/jcb.29620

Muhitch, J. B. et al. Tumor-associated macrophage expression of interferon regulatory Factor-8 (IRF8) is a predictor of progression and patient survival in renal cell carcinoma. J. Immunother. Cancer 7, 155 (2019).

pubmed: 31221219 pmcid: 6585080 doi: 10.1186/s40425-019-0630-0

Zhang, Q. et al. Interferon regulatory factor 8 functions as a tumor suppressor in renal cell carcinoma and its promoter methylation is associated with patient poor prognosis. Cancer Lett. 354, 227–234 (2014).

pubmed: 25109451 doi: 10.1016/j.canlet.2014.07.040

Nixon, B. G. et al. Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer. Immunity 55, 2044–2058.e2045 (2022).

pubmed: 36288724 doi: 10.1016/j.immuni.2022.10.002

Kamaraj, B., Al-Subaie, A. M., Ahmad, F. & Surapaneni, K. M. Effect of novel leukemia mutations (K75E & E222K) on interferon regulatory factor 1 and its interaction with DNA: insights from molecular dynamics simulations and docking studies. J. Biomol. Struct. Dyn. 39, 5235–5247 (2021).

pubmed: 32619131 doi: 10.1080/07391102.2020.1784790

Semmes, E. C. & Vijayakrishnan, J. Leveraging Genome and Phenome-Wide Association Studies to Investigate Genetic Risk of Acute Lymphoblastic Leukemia. Cancer Epidemiol. Biomark. Prev. 29, 1606–1614 (2020).

doi: 10.1158/1055-9965.EPI-20-0113

Manzella, L. et al. Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia. Curr. Cancer Drug. Targets 16, 594–605 (2016).

pubmed: 26728039 doi: 10.2174/1568009616666160105105857

Mathew, N. R. et al. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat. Med. 24, 282–291 (2018).

pubmed: 29431743 pmcid: 6029618 doi: 10.1038/nm.4484

Wang, H. et al. Loss of IRF7 accelerates acute myeloid leukemia progression and induces VCAM1-VLA-4 mediated intracerebral invasion. Oncogene 41, 2303–2314 (2022).

pubmed: 35256780 pmcid: 9010288 doi: 10.1038/s41388-022-02233-w

Yang, X. et al. Repolarizing heterogeneous leukemia-associated macrophages with more M1 characteristics eliminates their pro-leukemic effects. Oncoimmunology 7, e1412910 (2018).

pubmed: 29632729 doi: 10.1080/2162402X.2017.1412910

Tian, W. L. et al. The IRF9-SIRT1-P53 axis is involved in the growth of human acute myeloid leukemia. Exp. Cell. Res. 365, 185–193 (2018).

pubmed: 29501566 doi: 10.1016/j.yexcr.2018.02.036

Zhang, F. et al. IRF2-INPP4B axis participates in the development of acute myeloid leukemia by regulating cell growth and survival. Gene 627, 9–14 (2017).

pubmed: 28579269 doi: 10.1016/j.gene.2017.06.001

Zhang, F. et al. IRF2-INPP4B-mediated autophagy suppresses apoptosis in acute myeloid leukemia cells. Biol. Res. 52, 11 (2019).

pubmed: 30876449 pmcid: 6419480 doi: 10.1186/s40659-019-0218-7

Zhang, F. et al. IRF2-INPP4B axis inhibits apoptosis of acute myeloid leukaemia cells via regulating T helper 1/2 cell differentiation. Cell. Biochem. Funct. 38, 582–590 (2020).

pubmed: 32115737 doi: 10.1002/cbf.3511

Zhang, F. et al. Exosomes derived from human bone marrow mesenchymal stem cells transfer miR-222-3p to suppress acute myeloid leukemia cell proliferation by targeting IRF2/INPP4B. Mol. Cell. Probes. 51, 101513 (2020).

pubmed: 31968218 doi: 10.1016/j.mcp.2020.101513

Tian, W. L. et al. IRF3 is involved in human acute myeloid leukemia through regulating the expression of miR-155. Biochem. Biophys. Res. Commun. 478, 1130–1135 (2016).

pubmed: 27530922 doi: 10.1016/j.bbrc.2016.08.080

Di Bernardo, M. C. et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat. Genet. 40, 1204–1210 (2008).

pubmed: 18758461 doi: 10.1038/ng.219

Wang, J. et al. Genome-Wide Association Analyses Identify Variants in IRF4 Associated With Acute Myeloid Leukemia and Myelodysplastic Syndrome Susceptibility. Front. Genet. 12, 554948 (2021).

pubmed: 34220922 pmcid: 8248805 doi: 10.3389/fgene.2021.554948

Maffei, R., Fiorcari, S., Benatti, S. & Atene, C. G. IRF4 modulates the response to BCR activation in chronic lymphocytic leukemia regulating IKAROS and SYK. 35, 1330-1343, (2021).

Asslaber, D. et al. B-cell-specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion. Blood 134, 1717–1729 (2019).

pubmed: 31537531 pmcid: 6895374 doi: 10.1182/blood.2019000973

Zhang, Y. & Zeng, X. Correlation of the transcription factors IRF4 and BACH2 with the abnormal NFATC1 expression in T cells from chronic myeloid leukemia patients. Hematology 27, 523–529 (2022).

pubmed: 35544467 doi: 10.1080/16078454.2022.2066245

Tarantini, F. et al. IRF4 Gene Expression on the Trail of Molecular Response: Looking at Chronic Myeloid Leukemia from Another Perspective. Acta Haematol. 146, 37–43 (2023).

pubmed: 36195064 doi: 10.1159/000527173

Pang, S. H. et al. PU.1 cooperates with IRF4 and IRF8 to suppress pre-B-cell leukemia. Leukemia 30, 1375–1387 (2016).

pubmed: 26932576 pmcid: 5179358 doi: 10.1038/leu.2016.27

So, A. Y. et al. Dual mechanisms by which miR-125b represses IRF4 to induce myeloid and B-cell leukemias. Blood 124, 1502–1512 (2014).

pubmed: 25006123 pmcid: 4148772 doi: 10.1182/blood-2014-02-553842

Wong, R. W. J. et al. Feed-forward regulatory loop driven by IRF4 and NF-κB in adult T-cell leukemia/lymphoma. Blood 135, 934–947 (2020).

pubmed: 31972002 doi: 10.1182/blood.2019002639

Sakamoto, H. & Ando, K. Alvocidib inhibits IRF4 expression via super-enhancer suppression and adult T-cell leukemia/lymphoma cell growth. Cancer Sci. 113, 4092–4103 (2022).

pubmed: 36047964 pmcid: 9746047 doi: 10.1111/cas.15550

Watanabe, T. et al. The transcription factor IRF8 counteracts BCR-ABL to rescue dendritic cell development in chronic myelogenous leukemia. Cancer Res. 73, 6642–6653 (2013).

pubmed: 24242069 doi: 10.1158/0008-5472.CAN-13-0802

Hu, X. et al. IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemia. Cancer Res. 71, 2882–2891 (2011).

pubmed: 21487040 pmcid: 3078194 doi: 10.1158/0008-5472.CAN-10-2493

Scheller, M. et al. Cross talk between Wnt/β-catenin and Irf8 in leukemia progression and drug resistance. J. Exp. Med. 210, 2239–2256 (2013).

pubmed: 24101380 pmcid: 3804946 doi: 10.1084/jem.20130706

Gaillard, C. et al. Identification of IRF8 as a potent tumor suppressor in murine acute promyelocytic leukemia. Blood. Adv. 2, 2462–2466 (2018).

pubmed: 30266821 pmcid: 6177650 doi: 10.1182/bloodadvances.2018018929

Zhou, Y. et al. Silencing of IRF8 Mediated by m6A Modification Promotes the Progression of T-Cell Acute Lymphoblastic Leukemia. Adv. Sci. (Weinh.). 10, e2201724 (2023).

pubmed: 36478193

Liss, F. et al. IRF8 Is an AML-Specific Susceptibility Factor That Regulates Signaling Pathways and Proliferation of AML Cells. Cancers (Basel) 13, 764 (2021).

Zhuang, H. et al. Loss of IRF8 inhibits the growth of acute myeloid leukemia cells. Ann. Hematol. 102, 1063–1072 (2023).

pubmed: 36959484 doi: 10.1007/s00277-023-05156-y

Cao, Z. et al. ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency. Mol. Cell. 81, 3604–3622.e3610 (2021).

pubmed: 34358447 pmcid: 8932643 doi: 10.1016/j.molcel.2021.07.018

Pingul, B. Y. et al. Dissection of the MEF2D-IRF8 transcriptional circuit dependency in acute myeloid leukemia. iScience 25, 105139 (2022).

pubmed: 36193052 pmcid: 9526175 doi: 10.1016/j.isci.2022.105139

Wiseman, D. H. et al. Chronic myelomonocytic leukaemia stem cell transcriptomes anticipate disease morphology and outcome. EBioMedicine 58, 102904 (2020).

pubmed: 32763828 pmcid: 7403890 doi: 10.1016/j.ebiom.2020.102904

Wang, Q. & Lin, Z. RARγ activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway. Blood 139, 59–72 (2022).

pubmed: 34411225 doi: 10.1182/blood.2020009856

Xing, L., Wang, S. & Liu, J. BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression. Clin. Cancer Res. 27, 5376–5388 (2021).

pubmed: 34301753 pmcid: 8783926 doi: 10.1158/1078-0432.CCR-21-1621

Tsubaki, M. et al. Macrophage inflammatory protein-1α induces osteoclast formation by activation of the MEK/ERK/c-Fos pathway and inhibition of the p38MAPK/IRF-3/IFN-β pathway. J. Cell. Biochem. 111, 1661–1672 (2010).

pubmed: 21053363 doi: 10.1002/jcb.22907

Liu, H., He, J. & Bagheri-Yarmand, R. Osteocyte CIITA aggravates osteolytic bone lesions in myeloma. Nat. Commun. 13, 3684 (2022).

pubmed: 35760800 pmcid: 9237076 doi: 10.1038/s41467-022-31356-7

Fedele, P. L., Liao, Y., Gong, J. N. & Yao, Y. The transcription factor IRF4 represses proapoptotic BMF and BIM to licence multiple myeloma survival. Leukemia 35, 2114–2118 (2021).

pubmed: 33149265 doi: 10.1038/s41375-020-01078-0

Katsarou, A., Trasanidis, N., Ponnusamy, K. & Kostopoulos, I. V. MAF functions as a pioneer transcription factor that initiates and sustains myelomagenesis. Blood. Adv. 7, 6395–6410 (2023).

pubmed: 37224458 pmcid: 10598502 doi: 10.1182/bloodadvances.2023009772

Du, L., Liu, W., Pichiorri, F. & Rosen, S. T. SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide. Cancer Gene. Ther. 30, 567–574 (2023).

pubmed: 35338347 doi: 10.1038/s41417-022-00450-9

Mougiakakos, D., Bach, C. & Böttcher, M. The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages. Cancer Immunol. Res. 9, 265–278 (2021).

pubmed: 33563611 doi: 10.1158/2326-6066.CIR-20-0555

Mondala, P. K. et al. Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption. Cell. Stem. Cell. 28, 623–636.e629 (2021).

pubmed: 33476575 pmcid: 8026723 doi: 10.1016/j.stem.2020.12.017

Morelli, E. et al. Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. Leukemia 29, 2173–2183 (2015).

pubmed: 25987254 pmcid: 4635336 doi: 10.1038/leu.2015.124

Wang, Q. S. et al. Identification of Immune-Related Genes for Risk Stratification in Multiple Myeloma Based on Whole Bone Marrow Gene Expression Profiling. Front. Genet. 13, 897886 (2022).

pubmed: 35692836 pmcid: 9178200 doi: 10.3389/fgene.2022.897886

Waller, R. G. et al. Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes. Hum. Mol. Genet. 30, 1142–1153 (2021).

pubmed: 33751038 pmcid: 8188404 doi: 10.1093/hmg/ddab066

Liu, R. et al. m(6)A reader hnRNPA2B1 drives multiple myeloma osteolytic bone disease. Theranostics 12, 7760–7774 (2022).

pubmed: 36451863 pmcid: 9706590 doi: 10.7150/thno.76852

Giannouli, S. et al. Autoimmune manifestations in human myelodysplasia: a positive correlation with interferon regulatory factor-1 (IRF-1) expression. Ann. Rheum. Dis. 63, 578–582 (2004).

pubmed: 15082491 pmcid: 1754981 doi: 10.1136/ard.2003.012948

Pinheiro, R. F., Metze, K., Silva, M. R. & Chauffaille Mde, L. The ambiguous role of interferon regulatory factor-1 (IRF-1) immunoexpression in myelodysplastic syndrome. Leuk. Res. 33, 1308–1312 (2009).

pubmed: 19345417 doi: 10.1016/j.leukres.2009.03.008

de Sousa, J. C. et al. Dysregulation of interferon regulatory genes reinforces the concept of chronic immune response in myelodysplastic syndrome pathogenesis. Hematol. Oncol. 37, 523–526 (2019).

pubmed: 30920666 doi: 10.1002/hon.2608

de Oliveira, R. T. G. et al. ERVs-TLR3-IRF axis is linked to myelodysplastic syndrome pathogenesis. Med. Oncol. 38, 27 (2021).

pubmed: 33594613 doi: 10.1007/s12032-021-01466-1

Le, Y. Screening and identification of key candidate genes and pathways in myelodysplastic syndrome by bioinformatic analysis. PeerJ 7, e8162 (2019).

pubmed: 31803541 pmcid: 6886488 doi: 10.7717/peerj.8162

Wang, S. et al. CTLA-4 blockade induces tumor pyroptosis via CD8(+) T cells in head and neck squamous cell carcinoma. Mol. Ther. 31, 2154–2168 (2023).

pubmed: 36869589 pmcid: 10362385 doi: 10.1016/j.ymthe.2023.02.023

Li, X. & Yang, W. IRF2-induced Claudin-7 suppresses cell proliferation, invasion and migration of oral squamous cell carcinoma. Exp. Ther. Med. 23, 7 (2022).

pubmed: 34815759 doi: 10.3892/etm.2021.10929

Jin, S. et al. The m6A demethylase ALKBH5 promotes tumor progression by inhibiting RIG-I expression and interferon alpha production through the IKKε/TBK1/IRF3 pathway in head and neck squamous cell carcinoma. Mol. Cancer 21, 97 (2022).

pubmed: 35395767 pmcid: 8994291 doi: 10.1186/s12943-022-01572-2

Yan, Y., Gauthier, M. A. & Malik, A. The NOTCH-RIPK4-IRF6-ELOVL4 Axis Suppresses Squamous Cell Carcinoma. Cancers (Basel) 15, 737 (2023).

Ke, L. et al. Nasopharyngeal carcinoma super-enhancer-driven ETV6 correlates with prognosis. Proc. Natl Acad. Sci. Usa. 114, 9683–9688 (2017).

pubmed: 28831010 pmcid: 5594663 doi: 10.1073/pnas.1705236114

Qi, C. L. et al. The IRF2/CENP-N/AKT signaling axis promotes proliferation, cell cycling and apoptosis resistance in nasopharyngeal carcinoma cells by increasing aerobic glycolysis. J. Exp. Clin. Cancer Res. 40, 390 (2021).

pubmed: 34893086 pmcid: 8662847 doi: 10.1186/s13046-021-02191-3

Ge, J. et al. Epstein-Barr Virus-Encoded Circular RNA CircBART2.2 Promotes Immune Escape of Nasopharyngeal Carcinoma by Regulating PD-L1. Cancer Res. 81, 5074–5088 (2021).

pubmed: 34321242 pmcid: 8974435 doi: 10.1158/0008-5472.CAN-20-4321

Wan, P., Zhang, J., Du, Q. & Geller, D. A. The clinical significance and biological function of interferon regulatory factor 1 in cholangiocarcinoma. Biomed. Pharmacother. 97, 771–777 (2018).

pubmed: 29107934 doi: 10.1016/j.biopha.2017.10.096

Wan, P. et al. miR-383 promotes cholangiocarcinoma cell proliferation, migration, and invasion through targeting IRF1. J. Cell. Biochem. 119, 9720–9729 (2018).

pubmed: 30145803 doi: 10.1002/jcb.27286

Wei, C. X. et al. IRF4-induced upregulation of lncRNA SOX2-OT promotes cell proliferation and metastasis in cholangiocarcinoma by regulating SOX2 and PI3K/AKT signaling. Eur. Rev. Med. Pharmacol. Sci. 22, 8169–8178 (2018).

pubmed: 30556855

Meyer-Schaller, N. et al. A dual role of Irf1 in maintaining epithelial identity but also enabling EMT and metastasis formation of breast cancer cells. Oncogene 39, 4728–4740 (2020).

pubmed: 32404986 doi: 10.1038/s41388-020-1326-0

Wu, B. et al. UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced PDL1 transcription in triple negative breast cancer. Theranostics 12, 5086–5102 (2022).

pubmed: 35836797 pmcid: 9274738 doi: 10.7150/thno.74989

Schwartz-Roberts, J. L. et al. Interferon regulatory factor-1 signaling regulates the switch between autophagy and apoptosis to determine breast cancer cell fate. Cancer Res. 75, 1046–1055 (2015).

pubmed: 25576084 pmcid: 4359953 doi: 10.1158/0008-5472.CAN-14-1851

Armstrong, M. J. et al. IRF-1 inhibits NF-κB activity, suppresses TRAF2 and cIAP1 and induces breast cancer cell specific growth inhibition. Cancer Biol. Ther. 16, 1029–1041 (2015).

pubmed: 26011589 pmcid: 4622679 doi: 10.1080/15384047.2015.1046646

Luker, K. E., Pica, C. M., Schreiber, R. D. & Piwnica-Worms, D. Overexpression of IRF9 confers resistance to antimicrotubule agents in breast cancer cells. Cancer Res. 61, 6540–6547 (2001).

pubmed: 11522652

Brockwell, N. K. et al. Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC. Npj. Precis. Oncol. 3, 21 (2019).

pubmed: 31482136 pmcid: 6715634 doi: 10.1038/s41698-019-0093-2

Bernardo, A. R., Cosgaya, J. M., Aranda, A. & Jiménez-Lara, A. M. Pro-apoptotic signaling induced by Retinoic acid and dsRNA is under the control of Interferon Regulatory Factor-3 in breast cancer cells. Apoptosis 22, 920–932 (2017).

pubmed: 28409399 doi: 10.1007/s10495-017-1377-z

Lu, X. et al. Anti-triple-negative breast cancer metastasis efficacy and molecular mechanism of the STING agonist for innate immune pathway. Ann. Med. 55, 2210845 (2023).

pubmed: 37162544 pmcid: 10173802 doi: 10.1080/07853890.2023.2210845

Pantelidou, C. & Sonzogni, O. PARP Inhibitor Efficacy Depends on CD8(+) T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. Cancer Discov. 9, 722–737 (2019).

pubmed: 31015319 pmcid: 6548644 doi: 10.1158/2159-8290.CD-18-1218

Vernier, M. et al. Inhibition of DNMT1 and ERRα crosstalk suppresses breast cancer via derepression of IRF4. Oncogene 39, 6406–6420 (2020).

pubmed: 32855526 pmcid: 7544553 doi: 10.1038/s41388-020-01438-1

Heimes, A. S. et al. Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer. J. Cancer Res. Clin. Oncol. 143, 1123–1131 (2017).

pubmed: 28251349 doi: 10.1007/s00432-017-2377-7

Pimenta, E. M. & Barnes, B. J. A conserved region within interferon regulatory factor 5 controls breast cancer cell migration through a cytoplasmic and transcription-independent mechanism. Mol. Cancer 14, 32 (2015).

pubmed: 25649192 pmcid: 4326371 doi: 10.1186/s12943-015-0305-5

Bi, X. et al. Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis. Breast Cancer Res. 13, R111 (2011).

pubmed: 22053985 pmcid: 3326553 doi: 10.1186/bcr3053

Xu, H. F. et al. Candidate tumor suppressor gene IRF6 is involved in human breast cancer pathogenesis via modulating PI3K-regulatory subunit PIK3R2 expression. Cancer Manag. Res. 11, 5557–5572 (2019).

pubmed: 31417306 pmcid: 6594015 doi: 10.2147/CMAR.S203060

Liu, X. & Chipurupalli, S. ErbB2/Her2-dependent downregulation of a cell death-promoting protein BLNK in breast cancer cells is required for 3D breast tumor growth. Cell. Death. Dis. 13, 687 (2022).

pubmed: 35933456 pmcid: 9357009 doi: 10.1038/s41419-022-05117-9

Khan, I. A. et al. ErbB2-driven downregulation of the transcription factor Irf6 in breast epithelial cells is required for their 3D growth. Breast Cancer Res. 20, 151 (2018).

pubmed: 30545388 pmcid: 6293553 doi: 10.1186/s13058-018-1080-1

de Mingo Pulido, Á. et al. TIM-3 Regulates CD103(+) Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. Cancer Cell. 33, 60–74.e66 (2018).

pubmed: 29316433 pmcid: 5764109 doi: 10.1016/j.ccell.2017.11.019

Cohen, P. A., Jhingran, A., Oaknin, A. & Denny, L. Cervical cancer. Lancet 393, 169–182 (2019).

pubmed: 30638582 doi: 10.1016/S0140-6736(18)32470-X

Rho, S. B., Lee, S. H., Byun, H. J. & Kim, B. R. IRF-1 Inhibits Angiogenic Activity of HPV16 E6 Oncoprotein in Cervical Cancer. Int. J. Mol. Sci. 21, 7622 (2020).

Walch-Rückheim, B. et al. STAT3/IRF1 Pathway Activation Sensitizes Cervical Cancer Cells to Chemotherapeutic Drugs. Cancer Res. 76, 3872–3883 (2016).

pubmed: 27216197 doi: 10.1158/0008-5472.CAN-14-1306

Lee, S. H. et al. IFN-gamma/IRF-1-induced p27kip1 down-regulates telomerase activity and human telomerase reverse transcriptase expression in human cervical cancer. Febs. Lett. 579, 1027–1033 (2005).

pubmed: 15710386 doi: 10.1016/j.febslet.2005.01.005

Deng, Z. M., Dai, F. F., Zhou, Q. & Cheng, Y. X. Hsa_circ_0000301 facilitates the progression of cervical cancer by targeting miR-1228-3p/IRF4 Axis. Bmc. Cancer 21, 583 (2021).

pubmed: 34020619 pmcid: 8140416 doi: 10.1186/s12885-021-08331-4

Ren, Y., Dong, J. & He, P. miR-587 promotes cervical cancer by repressing interferon regulatory factor 6. J. Gene. Med. 22, e3257 (2020).

pubmed: 32749750 doi: 10.1002/jgm.3257

Kuroboshi, H. et al. Interferon regulatory factor-1 expression in human uterine endometrial carcinoma. Gynecol. Oncol. 91, 354–358 (2003).

pubmed: 14599866 doi: 10.1016/S0090-8258(03)00515-8

Gao, K. et al. SPOP mutations promote tumor immune escape in endometrial cancer via the IRF1-PD-L1 axis. Cell. Death. Differ. 30, 475–487 (2023).

pubmed: 36481790 doi: 10.1038/s41418-022-01097-7

Zeng, X. et al. IL6 Induces mtDNA Leakage to Affect the Immune Escape of Endometrial Carcinoma via cGAS-STING. J. Immunol. Res. 2022, 3815853 (2022).

pubmed: 35692503 pmcid: 9184159 doi: 10.1155/2022/3815853

Nakamura, K. et al. ADAR1 and AZIN1 RNA editing function as an oncogene and contributes to immortalization in endometrial cancer. Gynecol. Oncol. 166, 326–333 (2022).

pubmed: 35697535 doi: 10.1016/j.ygyno.2022.05.026

Ghislat, G. et al. NF-κB-dependent IRF1 activation programs cDC1 dendritic cells to drive antitumor immunity. Sci. Immunol. 6, eabg3570 (2021).

Zhou, S. et al. IRF1 expression might be a biomarker of CD8+ T cell infiltration in cutaneous melanoma. Expert. Rev. Clin. Immunol. 18, 1319–1327 (2022).

pubmed: 36300336 doi: 10.1080/1744666X.2022.2141228

Mirjačić Martinović, K. et al. Decreased expression of pSTAT, IRF-1 and DAP10 signalling molecules in peripheral blood lymphocytes of patients with metastatic melanoma. J. Clin. Pathol. 69, 300–306 (2016).

pubmed: 26442832 doi: 10.1136/jclinpath-2015-203107

Yokoyama, S. et al. SOX10 Regulates Melanoma Immunogenicity through an IRF4-IRF1 Axis. Cancer Res. 81, 6131–6141 (2021).

pubmed: 34728538 pmcid: 8678351 doi: 10.1158/0008-5472.CAN-21-2078

Wang, W. et al. Upregulation of PD-L1 via HMGB1-Activated IRF3 and NF-κB Contributes to UV Radiation-Induced Immune Suppression. Cancer Res. 79, 2909–2922 (2019).

pubmed: 30737234 pmcid: 6548650 doi: 10.1158/0008-5472.CAN-18-3134

Occhigrossi, L. & D’Eletto, M. Transglutaminase type 2-dependent crosslinking of IRF3 in dying melanoma cells. Cell. Death. Discov. 8, 498 (2022).

pubmed: 36572679 pmcid: 9792452 doi: 10.1038/s41420-022-01278-w

Musick, M. & Yu, X. Immunotherapeutic effects of intratumorally injected Zymosan-Adenovirus conjugates encoding constant active IRF3 in a melanoma mouse model. Immunol. Res. 71, 197–212 (2023).

pubmed: 36418765 doi: 10.1007/s12026-022-09336-2

Humblin, E. et al. IRF8-dependent molecular complexes control the Th9 transcriptional program. Nat. Commun. 8, 2085 (2017).

pubmed: 29233972 pmcid: 5727025 doi: 10.1038/s41467-017-01070-w

Wang, D. et al. Increased IRF9-STAT2 Signaling Leads to Adaptive Resistance toward Targeted Therapy in Melanoma by Restraining GSDME-Dependent Pyroptosis. J. Invest. Dermatol. 142, 2476–2487.e2479 (2022).

pubmed: 35148998 doi: 10.1016/j.jid.2022.01.024

Chu, Z., Gu, L., Hu, Y. & Zhang, X. STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming. Nat. Commun. 13, 1859 (2022).

pubmed: 35388001 pmcid: 8986786 doi: 10.1038/s41467-022-29541-9

Sancéau, J., Hiscott, J., Delattre, O. & Wietzerbin, J. IFN-beta induces serine phosphorylation of Stat-1 in Ewing’s sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7. Oncogene 19, 3372–3383 (2000).

pubmed: 10918594 doi: 10.1038/sj.onc.1203670

Ma, Z. et al. MiR-134, Mediated by IRF1, Suppresses Tumorigenesis and Progression by Targeting VEGFA and MYCN in Osteosarcoma. Anticancer. Agents Med. Chem. 20, 1197–1208 (2020).

pubmed: 32238141 doi: 10.2174/1871520620666200402074752

Zhang, X. et al. The CtBP1-HDAC1/2-IRF1 transcriptional complex represses the expression of the long noncoding RNA GAS5 in human osteosarcoma cells. Int. J. Biol. Sci. 15, 1460–1471 (2019).

pubmed: 31337976 pmcid: 6643137 doi: 10.7150/ijbs.33529

Cheng, J. P. et al. miR-4295 promotes cell proliferation, migration and invasion of osteosarcoma through targeting interferon regulatory factor 1. Oncol. Lett. 20, 260 (2020).

pubmed: 32989394 pmcid: 7517570 doi: 10.3892/ol.2020.12123

Lu, C. et al. miR-18a-5p promotes cell invasion and migration of osteosarcoma by directly targeting IRF2. Oncol. Lett. 16, 3150–3156 (2018).

pubmed: 30127908 pmcid: 6096157

Wu, W. et al. SGLT2 inhibitor activates the STING/IRF3/IFN-β pathway and induces immune infiltration in osteosarcoma. Cell. Death. Dis. 13, 523 (2022).

pubmed: 35662245 pmcid: 9166744 doi: 10.1038/s41419-022-04980-w

Li, Z. et al. IRF7 inhibits the Warburg effect via transcriptional suppression of PKM2 in osteosarcoma. Int. J. Biol. Sci. 18, 30–42 (2022).

pubmed: 34975316 pmcid: 8692136 doi: 10.7150/ijbs.65255

Li, Z. et al. Erratum: IRF7 inhibits the Warburg effect via transcriptional suppression of PKM2 in osteosarcoma: Erratum. Int. J. Biol. Sci. 18, 6229–6230 (2022).

pubmed: 36439882 pmcid: 9682534 doi: 10.7150/ijbs.79598

Ni, X. & Wu, W. Interrogating glioma-M2 macrophage interactions identifies Gal-9/Tim-3 as a viable target against PTEN-null glioblastoma. Sci. Adv. 8, eabl5165 (2022).

pubmed: 35857445 pmcid: 9269888 doi: 10.1126/sciadv.abl5165

Tong, S. et al. IRF2-ferroptosis related gene is associated with prognosis and EMT in gliomas. Transl. Oncol. 26, 101544 (2022).

pubmed: 36156371 pmcid: 9508157 doi: 10.1016/j.tranon.2022.101544

Tarassishin, L. & Lee, S. C. Interferon regulatory factor 3 alters glioma inflammatory and invasive properties. J. Neurooncol. 113, 185–194 (2013).

pubmed: 23512614 doi: 10.1007/s11060-013-1109-3

Pattwell, S. S. & Holland, E. C. Putting Glioblastoma in Its Place: IRF3 Inhibits Invasion. Trends Mol. Med. 23, 773–776 (2017).

pubmed: 28774478 pmcid: 5843370 doi: 10.1016/j.molmed.2017.07.008

Pencheva, N. et al. Identification of a Druggable Pathway Controlling Glioblastoma Invasiveness. Cell. Rep. 20, 48–60 (2017).

pubmed: 28683323 doi: 10.1016/j.celrep.2017.06.036

Yang, T. et al. A BRD4 PROTAC nanodrug for glioma therapy via the intervention of tumor cells proliferation, apoptosis and M2 macrophages polarization. Acta Pharm. Sin. B. 12, 2658–2671 (2022).

pubmed: 35755286 pmcid: 9214068 doi: 10.1016/j.apsb.2022.02.009

Li, C., Guan, N. & Liu, F. T7 peptide-decorated exosome-based nanocarrier system for delivery of Galectin-9 siRNA to stimulate macrophage repolarization in glioblastoma. J. Neurooncol. 162, 93–108 (2023).

pubmed: 36854924 doi: 10.1007/s11060-023-04257-y

Shah, D. & Comba, A. A novel miR1983-TLR7-IFNβ circuit licenses NK cells to kill glioma cells, and is under the control of galectin-1. Oncoimmunology 10, 1939601 (2021).

pubmed: 34249474 pmcid: 8244780 doi: 10.1080/2162402X.2021.1939601

Tang, R. et al. Opposite effects of interferon regulatory factor 1 and osteopontin on the apoptosis of epithelial cells induced by TNF-α in inflammatory bowel disease. Inflamm. Bowel. Dis. 20, 1950–1961 (2014).

pubmed: 25208103 doi: 10.1097/MIB.0000000000000192

Tan, G. et al. An IRF1-dependent Pathway of TNFα-induced Shedding in Intestinal Epithelial Cells. J. Crohns. Colitis 16, 133–142 (2022).

pubmed: 34309645 doi: 10.1093/ecco-jcc/jjab134

Xu, H. & Fu, J. TNF-α Enhances the Therapeutic Effects of MenSC-Derived Small Extracellular Vesicles on Inflammatory Bowel Disease through Macrophage Polarization by miR-24-3p. Stem. Cells Int. 2023, 2988907 (2023).

pubmed: 36895784 pmcid: 9991477 doi: 10.1155/2023/2988907

Wang, K. W. et al. Enhanced susceptibility to chemically induced colitis caused by excessive endosomal TLR signaling in LRBA-deficient mice. Proc. Natl Acad. Sci. USA 116, 11380–11389 (2019).

pubmed: 31097594 pmcid: 6561264 doi: 10.1073/pnas.1901407116

Chiriac, M. T. et al. Activation of Epithelial Signal Transducer and Activator of Transcription 1 by Interleukin 28 Controls Mucosal Healing in Mice With Colitis and Is Increased in Mucosa of Patients With Inflammatory Bowel Disease. Gastroenterology 153, 123–138.e128 (2017).

pubmed: 28342759 doi: 10.1053/j.gastro.2017.03.015

Buchele, V. et al. Th17 Cell-Mediated Colitis Is Positively Regulated by Interferon Regulatory Factor 4 in a T Cell-Extrinsic Manner. Front. Immunol. 11, 590893 (2020).

pubmed: 33584655 doi: 10.3389/fimmu.2020.590893

Zhu, X. et al. 1,25‑Dihydroxyvitamin D regulates macrophage polarization and ameliorates experimental inflammatory bowel disease by suppressing miR-125b. Int. Immunopharmacol. 67, 106–118 (2019).

pubmed: 30540970 doi: 10.1016/j.intimp.2018.12.015

Zhu, W. et al. Baicalin ameliorates experimental inflammatory bowel disease through polarization of macrophages to an M2 phenotype. Int. Immunopharmacol. 35, 119–126 (2016).

pubmed: 27039210 doi: 10.1016/j.intimp.2016.03.030

Yan, J. et al. T Cell-Intrinsic IRF5 Regulates T Cell Signaling, Migration, and Differentiation and Promotes Intestinal Inflammation. Cell. Rep. 31, 107820 (2020).

pubmed: 32610123 pmcid: 7409536 doi: 10.1016/j.celrep.2020.107820

Kayama, H. et al. Heme ameliorates dextran sodium sulfate-induced colitis through providing intestinal macrophages with noninflammatory profiles. Proc. Natl Acad. Sci. USA 115, 8418–8423 (2018).

pubmed: 30061415 pmcid: 6099887 doi: 10.1073/pnas.1808426115

Ryzhakov, G., Almuttaqi, H. & Corbin, A. L. Defactinib inhibits PYK2 phosphorylation of IRF5 and reduces intestinal inflammation. Nat. Commun. 12, 6702 (2021).

pubmed: 34795257 pmcid: 8602323 doi: 10.1038/s41467-021-27038-5

Lu, J. et al. Thalidomide Attenuates Colitis and Is Associated with the Suppression of M1 Macrophage Polarization by Targeting the Transcription Factor IRF5. Dig. Dis. Sci. 66, 3803–3812 (2021).

pubmed: 34085173 doi: 10.1007/s10620-021-07067-2

Lin, Z. et al. microRNA-144/451 decreases dendritic cell bioactivity via targeting interferon-regulatory factor 5 to limit DSS-induced colitis. Front. Immunol. 13, 928593 (2022).

pubmed: 35967345 pmcid: 9372465 doi: 10.3389/fimmu.2022.928593

Zhang, R. et al. T follicular helper cells restricted by IRF8 contribute to T cell-mediated inflammation. J. Autoimmun. 96, 113–122 (2019).

pubmed: 30241692 doi: 10.1016/j.jaut.2018.09.001

Veiga, N. et al. Leukocyte-specific siRNA delivery revealing IRF8 as a potential anti-inflammatory target. J. Control. Release 313, 33–41 (2019).

pubmed: 31634546 doi: 10.1016/j.jconrel.2019.10.001

Landgraf-Rauf, K. et al. IRF-1 SNPs influence the risk for childhood allergic asthma: A critical role for pro-inflammatory immune regulation. Pediatr. Allergy Immunol. 29, 34–41 (2018).

pubmed: 29047170 doi: 10.1111/pai.12821

Kumar, A. et al. Genetic association of key Th1/Th2 pathway candidate genes, IRF2, IL6, IFNGR2, STAT4 and IL4RA, with atopic asthma in the Indian population. J. Hum. Genet. 60, 443–448 (2015).

pubmed: 25994869 doi: 10.1038/jhg.2015.45

Ozasa, K. et al. Cyclic GMP-AMP Triggers Asthma in an IL-33-Dependent Manner That Is Blocked by Amlexanox, a TBK1 Inhibitor. Front. Immunol. 10, 2212 (2019).

pubmed: 31616416 pmcid: 6775192 doi: 10.3389/fimmu.2019.02212

Marichal, T. et al. Interferon response factor 3 is essential for house dust mite-induced airway allergy. J. Allergy Clin. Immunol. 126, 836–844.e813 (2010).

pubmed: 20673978 doi: 10.1016/j.jaci.2010.06.009

He, J. et al. IRF-7 Is a Critical Regulator of Type 2 Innate Lymphoid Cells in Allergic Airway Inflammation. Cell. Rep. 29, 2718–2730.e2716 (2019).

pubmed: 31775040 doi: 10.1016/j.celrep.2019.10.077

Park, S. J. et al. Tilianin attenuates HDM-induced allergic asthma by suppressing Th2-immune responses via downregulation of IRF4 in dendritic cells. Phytomedicine 80, 153392 (2021).

pubmed: 33113503 doi: 10.1016/j.phymed.2020.153392

Xia, L. et al. lnc-BAZ2B promotes M2 macrophage activation and inflammation in children with asthma through stabilizing BAZ2B pre-mRNA. J. Allergy Clin. Immunol. 147, 921–932.e929 (2021).

pubmed: 32712329 doi: 10.1016/j.jaci.2020.06.034

Corrigendum. J. Allergy. Clin. Immunol. 149, 1134-1135, (2022).

Hwang, S. S. et al. RHS6 coordinately regulates the Th2 cytokine genes by recruiting GATA3, SATB1, and IRF4. Allergy 72, 772–782 (2017).

pubmed: 27878828 doi: 10.1111/all.13078

Kim, S. B. et al. Anthriscus sylvestris root extract reduces allergic lung inflammation by regulating interferon regulatory factor 4-mediated Th2 cell activation. J. Ethnopharmacol. 232, 165–175 (2019).

pubmed: 30552991 doi: 10.1016/j.jep.2018.12.016

Staudt, V. et al. Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. Immunity 33, 192–202 (2010).

pubmed: 20674401 doi: 10.1016/j.immuni.2010.07.014

Oriss, T. B. et al. IRF5 distinguishes severe asthma in humans and drives Th1 phenotype and airway hyperreactivity in mice. JCI. Insight. 2, e91019 (2017).

Swindell, W. R. et al. Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites. Clin. Transl. Med. 4, 13 (2015).

pubmed: 25883770 pmcid: 4392043 doi: 10.1186/s40169-015-0054-5

Kuai, L. et al. Celastrol Attenuates Psoriasiform Inflammation by Targeting the IRF1/GSTM3 Axis. J. Invest. Dermatol. 142, 2281–2285.e2211 (2022).

pubmed: 35134440 doi: 10.1016/j.jid.2022.01.018

Lin, S. H. et al. Treatment with TNF-α inhibitor rectifies M1 macrophage polarization from blood CD14+ monocytes in patients with psoriasis independent of STAT1 and IRF-1 activation. J. Dermatol. Sci. 91, 276–284 (2018).

pubmed: 29914850 doi: 10.1016/j.jdermsci.2018.05.009

Parkinson, J. et al. Variation at the IRF2 gene and susceptibility to psoriasis in chromosome 4q-linked families. J. Invest. Dermatol. 122, 640–643 (2004).

pubmed: 15086546 doi: 10.1046/j.0022-202X.2004.22135.x

Foerster, J. et al. Evaluation of the IRF-2 gene as a candidate for PSORS3. J. Invest. Dermatol. 122, 61–64 (2004).

pubmed: 14962090 doi: 10.1046/j.0022-202X.2003.22104.x

van der Fits, L. et al. In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. J. Invest. Dermatol. 122, 51–60 (2004).

pubmed: 14962089 doi: 10.1046/j.0022-202X.2003.22113.x

Kawaguchi, M. et al. IRF-2 haploinsufficiency causes enhanced imiquimod-induced psoriasis-like skin inflammation. J. Dermatol. Sci. 90, 35–45 (2018).

pubmed: 29305258 doi: 10.1016/j.jdermsci.2017.12.014

Xiaohong, L. et al. Activation of the STING-IRF3 pathway involved in psoriasis with diabetes mellitus. J. Cell. Mol. Med. 26, 2139–2151 (2022).

pubmed: 35174638 pmcid: 8995451 doi: 10.1111/jcmm.17236

Ni, A. et al. Expression of IRF-4 and IBP in skin lesions of patients with psoriasis vulgaris. J. Huazhong. Univ. Sci. Technol. Med. Sci. 32, 287–290 (2012).

doi: 10.1007/s11596-012-0050-6

Cai, Y. et al. Differential Roles of the mTOR-STAT3 Signaling in Dermal γδ T Cell Effector Function in Skin Inflammation. Cell. Rep. 27, 3034–3048.e3035 (2019).

pubmed: 31167146 pmcid: 6617524 doi: 10.1016/j.celrep.2019.05.019

Nakao, M. & Miyagaki, T. Exacerbated Imiquimod-Induced Psoriasis-Like Skin Inflammation in IRF5-Deficient Mice. Int. J. Mol. Sci. 21, 3681 (2020).

Raposo, R. A. et al. Antiviral gene expression in psoriasis. J. Eur. Acad. Dermatol. Venereol. 29, 1951–1957 (2015).

pubmed: 25809693 pmcid: 4580491 doi: 10.1111/jdv.13091

Jin, L. et al. A BET inhibitor, NHWD-870, can downregulate dendritic cells maturation via the IRF7-mediated signaling pathway to ameliorate imiquimod-induced psoriasis-like murine skin inflammation. Eur. J. Pharmacol. 968, 176382 (2024).

pubmed: 38311277 doi: 10.1016/j.ejphar.2024.176382

Zhou, B. et al. Zdhhc2 Is Essential for Plasmacytoid Dendritic Cells Mediated Inflammatory Response in Psoriasis. Front. Immunol. 11, 607442 (2020).

pubmed: 33488612 doi: 10.3389/fimmu.2020.607442

Morell, M. et al. SIDT1 plays a key role in type I IFN responses to nucleic acids in plasmacytoid dendritic cells and mediates the pathogenesis of an imiquimod-induced psoriasis model. EBioMedicine 76, 103808 (2022).

pubmed: 35065421 pmcid: 8784643 doi: 10.1016/j.ebiom.2021.103808

Su, W. et al. Exploring the Pathogenesis of Psoriasis Complicated With Atherosclerosis via Microarray Data Analysis. Front. Immunol. 12, 667690 (2021).

pubmed: 34122426 pmcid: 8190392 doi: 10.3389/fimmu.2021.667690

Zolotarenko, A. et al. Integrated computational approach to the analysis of RNA-seq data reveals new transcriptional regulators of psoriasis. Exp. Mol. Med. 48, e268 (2016).

pubmed: 27811935 pmcid: 5133374 doi: 10.1038/emm.2016.97

Gao, P. S. et al. Genetic variants in interferon regulatory factor 2 (IRF2) are associated with atopic dermatitis and eczema herpeticum. J. Invest. Dermatol. 132, 650–657 (2012).

pubmed: 22113474 doi: 10.1038/jid.2011.374

Li, C., Lu, Y. & Han, X. Identification of Effective Diagnostic Biomarkers and Immune Cell Infiltration in Atopic Dermatitis by Comprehensive Bioinformatics Analysis. Front. Mol. Biosci. 9, 917077 (2022).

pubmed: 35911963 pmcid: 9330059 doi: 10.3389/fmolb.2022.917077

Leung, Y. T. et al. Interferon regulatory factor 1 and histone H4 acetylation in systemic lupus erythematosus. Epigenetics 10, 191–199 (2015).

pubmed: 25611806 pmcid: 4622916 doi: 10.1080/15592294.2015.1009764

Corrigendum. Epigenetics 10, 891, (2015).

Zhang, Z. et al. Interferon regulatory factor 1 marks activated genes and can induce target gene expression in systemic lupus erythematosus. Arthritis Rheumatol. 67, 785–796 (2015).

pubmed: 25418955 pmcid: 4342285 doi: 10.1002/art.38964

Misidentified Band in Figure in the Article by Zhang et al (Arthritis Rheumatol, March 2015). Arthritis. Rheumatol. 67, 2481, (2015).

Liu, J., Berthier, C. C. & Kahlenberg, J. M. Enhanced Inflammasome Activity in Systemic Lupus Erythematosus Is Mediated via Type I Interferon-Induced Up-Regulation of Interferon Regulatory Factor 1. Arthritis Rheumatol. 69, 1840–1849 (2017).

pubmed: 28564495 pmcid: 5575977 doi: 10.1002/art.40166

Chen, J. et al. HDAC1 potentiates CD4 + T cell activation by inhibiting miR-124 and promoting IRF1 in systemic lupus erythematosus. Cell. Immunol. 362, 104284 (2021).

pubmed: 33550188 doi: 10.1016/j.cellimm.2021.104284

Han, X. et al. MicroRNA-130b Ameliorates Murine Lupus Nephritis Through Targeting the Type I Interferon Pathway on Renal Mesangial Cells. Arthritis Rheumatol. 68, 2232–2243 (2016).

pubmed: 27111096 doi: 10.1002/art.39725

Zhang, F. et al. Independent Replication on Genome-Wide Association Study Signals Identifies IRF3 as a Novel Locus for Systemic Lupus Erythematosus. Front. Genet. 11, 600 (2020).

pubmed: 32719713 pmcid: 7348047 doi: 10.3389/fgene.2020.00600

Xu, Z. Q. et al. CircELK4 Contributes to Lupus Nephritis by Acting as a miR-27b-3p Sponge to Regulate STING/IRF3/IFN-I Signaling. 44, 2106-2119, (2021).

Yoo, E. J. et al. Macrophage transcription factor TonEBP promotes systemic lupus erythematosus and kidney injury via damage-induced signaling pathways. Kidney Int. 104, 163–180 (2023).

pubmed: 37088425 doi: 10.1016/j.kint.2023.03.030

Zheng, X. et al. AKT2 reduces IFNβ1 production to modulate antiviral responses and systemic lupus erythematosus. Embo. J. 41, e108016 (2022).

pubmed: 35191555 pmcid: 8922272 doi: 10.15252/embj.2021108016

Faridi, M. H. et al. CD11b activation suppresses TLR-dependent inflammation and autoimmunity in systemic lupus erythematosus. J. Clin. Invest. 127, 1271–1283 (2017).

pubmed: 28263189 pmcid: 5373862 doi: 10.1172/JCI88442

Yao, M. et al. Identification of Molecular Markers Associated With the Pathophysiology and Treatment of Lupus Nephritis Based on Integrated Transcriptome Analysis. Front. Genet. 11, 583629 (2020).

pubmed: 33384713 pmcid: 7770169 doi: 10.3389/fgene.2020.583629

Luque, A. et al. Noncanonical immunomodulatory activity of complement regulator C4BP(β-) limits the development of lupus nephritis. Kidney Int. 97, 551–566 (2020).

pubmed: 31982108 doi: 10.1016/j.kint.2019.10.016

Coit, P. et al. Hypomethylation of miR-17-92 cluster in lupus T cells and no significant role for genetic factors in the lupus-associated DNA methylation signature. Ann. Rheum. Dis. 81, 1428–1437 (2022).

pubmed: 35710306 doi: 10.1136/annrheumdis-2022-222656

Miyagawa, F. & Tagaya, Y. Essential Requirement for IFN Regulatory Factor 7 in Autoantibody Production but Not Development of Nephritis in Murine Lupus. J. Immunol. 197, 2167–2176 (2016).

pubmed: 27527596 doi: 10.4049/jimmunol.1502445

Chandrasekaran, U. et al. Regulation of Effector Treg Cells in Murine Lupus. Arthritis Rheumatol. 68, 1454–1466 (2016).

pubmed: 26816213 pmcid: 5825185 doi: 10.1002/art.39599

Lech, M. et al. IRF4 deficiency abrogates lupus nephritis despite enhancing systemic cytokine production. J. Am. Soc. Nephrol. 22, 1443–1452 (2011).

pubmed: 21742731 pmcid: 3148699 doi: 10.1681/ASN.2010121260

Graham, R. R. et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat. Genet. 38, 550–555 (2006).

pubmed: 16642019 doi: 10.1038/ng1782

Graham, R. R. et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc. Natl Acad. Sci. Usa. 104, 6758–6763 (2007).

pubmed: 17412832 pmcid: 1847749 doi: 10.1073/pnas.0701266104

Barnes, B. J. Genetic Versus Non-genetic Drivers of SLE: Implications of IRF5 Dysregulation in Both Roads Leading to SLE. Curr. Rheumatol. Rep. 21, 2 (2019).

pubmed: 30645688 doi: 10.1007/s11926-019-0803-3

Hou, G. et al. Integrative Functional Genomics Identifies Systemic Lupus Erythematosus Causal Genetic Variant in the IRF5 Risk Locus. Arthritis Rheumatol. 75, 574–585 (2023).

pubmed: 36245280 doi: 10.1002/art.42390

Li, D. et al. IRF5 genetic risk variants drive myeloid-specific IRF5 hyperactivation and presymptomatic SLE. JCI. Insight. 5, e124020 (2020).

De, S. et al. B Cell-Intrinsic Role for IRF5 in TLR9/BCR-Induced Human B Cell Activation, Proliferation, and Plasmablast Differentiation. Front. Immunol. 8, 1938 (2017).

pubmed: 29367853 doi: 10.3389/fimmu.2017.01938

Pellerin, A. et al. Monoallelic IRF5 deficiency in B cells prevents murine lupus. JCI. Insight. 6, (2021).

Ban, T. et al. Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease. Nat. Commun. 12, 4379 (2021).

pubmed: 34282144 doi: 10.1038/s41467-021-24609-4

Song, S. et al. Inhibition of IRF5 hyperactivation protects from lupus onset and severity. J. Clin. Invest. 130, 6700–6717 (2020).

pubmed: 32897883 doi: 10.1172/JCI120288

Zhou, T., Zhu, X., Ye, Z. & Wang, Y. F. Lupus enhancer risk variant causes dysregulation of IRF8 through cooperative lncRNA and DNA methylation machinery. Nat. Commun. 13, 1855 (2022).

pubmed: 35388006 doi: 10.1038/s41467-022-29514-y

Ji, J. et al. Myeloid-derived suppressor cells contribute to systemic lupus erythaematosus by regulating differentiation of Th17 cells and Tregs. Clin. Sci. (Lond.). 130, 1453–1467 (2016).

pubmed: 27231253 doi: 10.1042/CS20160311

Smith, S. et al. MicroRNA-302d targets IRF9 to regulate the IFN-induced gene expression in SLE. J. Autoimmun. 79, 105–111 (2017).

pubmed: 28318807 doi: 10.1016/j.jaut.2017.03.003

Deng, Y. et al. Expression characteristics of interferon-stimulated genes and possible regulatory mechanisms in lupus patients using transcriptomics analyses. EBioMedicine 70, 103477 (2021).

pubmed: 34284174 doi: 10.1016/j.ebiom.2021.103477

Annibali, V. et al. Analysis of coding and non-coding transcriptome of peripheral B cells reveals an altered interferon response factor (IRF)-1 pathway in multiple sclerosis patients. J. Neuroimmunol. 324, 165–171 (2018).

pubmed: 30270021 doi: 10.1016/j.jneuroim.2018.09.005

Kortam, M. A. et al. MAGI2-AS3 and miR-374b-5p as Putative Regulators of Multiple Sclerosis via Modulating the PTEN/AKT/IRF-3/IFN-β Axis: New Clinical Insights. Acs. Chem. Neurosci. 14, 1107–1118 (2023).

pubmed: 36878000 doi: 10.1021/acschemneuro.2c00653

Khaw, Y. M. & Anwar, S. Estrogen receptor alpha signaling in dendritic cells modulates autoimmune disease phenotype in mice. Embo. Rep. 24, e54228 (2023).

pubmed: 36633157 doi: 10.15252/embr.202154228

Sha, Y. & Markovic-Plese, S. Activated IL-1RI Signaling Pathway Induces Th17 Cell Differentiation via Interferon Regulatory Factor 4 Signaling in Patients with Relapsing-Remitting Multiple Sclerosis. Front. Immunol. 7, 543 (2016).

pubmed: 27965670 doi: 10.3389/fimmu.2016.00543

Zhao, M., Sun, D., Guan, Y. & Wang, Z. Disulfiram and Diphenhydramine Hydrochloride Upregulate miR-30a to Suppress IL-17-Associated Autoimmune Inflammation. J. Neurosci. 36, 9253–9266 (2016).

pubmed: 27581464 doi: 10.1523/JNEUROSCI.4587-15.2016

Kiselev, I. et al. Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability. Mult. Scler. Relat. Disord. 29, 130–136 (2019).

pubmed: 30711878 doi: 10.1016/j.msard.2019.01.033

Kowalec, K. & Wright, G. E. B. Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis. Nat. Genet. 50, 1081–1085 (2018).

pubmed: 30013178 doi: 10.1038/s41588-018-0168-y

Hoppmann, N. et al. New candidates for CD4 T cell pathogenicity in experimental neuroinflammation and multiple sclerosis. Brain 138, 902–917 (2015).

pubmed: 25665584 doi: 10.1093/brain/awu408

Kotelnikova, E. et al. MAPK pathway and B cells overactivation in multiple sclerosis revealed by phosphoproteomics and genomic analysis. Proc. Natl Acad. Sci. USA 116, 9671–9676 (2019).

pubmed: 31004050 pmcid: 6510997 doi: 10.1073/pnas.1818347116

Sellebjerg, F. et al. Prediction of response to interferon therapy in multiple sclerosis. Acta Neurol. Scand. 130, 268–275 (2014).

pubmed: 24943672 doi: 10.1111/ane.12269

Yoshida, Y. et al. The transcription factor IRF8 activates integrin-mediated TGF-β signaling and promotes neuroinflammation. Immunity 40, 187–198 (2014).

pubmed: 24485804 pmcid: 4105266 doi: 10.1016/j.immuni.2013.11.022

Wei, Y. et al. Aryl hydrocarbon receptor activation drives polymorphonuclear myeloid-derived suppressor cell response and efficiently attenuates experimental Sjögren’s syndrome. Cell. Mol. Immunol. 19, 1361–1372 (2022).

pubmed: 36369368 doi: 10.1038/s41423-022-00943-5

Xiao, F. et al. Artesunate suppresses Th17 response via inhibiting IRF4-mediated glycolysis and ameliorates Sjögren’s syndrome. Signal. Transduct. Target Ther. 7, 274 (2022).

pubmed: 36031634 pmcid: 9420730 doi: 10.1038/s41392-022-01103-x

Nordmark, G. et al. Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjögren’s syndrome. Genes. Immun. 10, 68–76 (2009).

pubmed: 19092842 doi: 10.1038/gene.2008.94

Ortíz-Fernández, L., Martín, J. & Alarcón-Riquelme, M. E. A Summary on the Genetics of Systemic Lupus Erythematosus, Rheumatoid Arthritis, Systemic Sclerosis, and Sjögren’s Syndrome. Clin. Rev. Allergy Immunol. 64, 392–411 (2023).

pubmed: 35749015 doi: 10.1007/s12016-022-08951-z

Bonelli, M. et al. IRF1 is critical for the TNF-driven interferon response in rheumatoid fibroblast-like synoviocytes: JAKinibs suppress the interferon response in RA-FLSs. Exp. Mol. Med. 51, 1–11 (2019).

pubmed: 31285419 doi: 10.1038/s12276-019-0267-6

Du, Y. et al. Regulation of type I interferon signature by VGLL3 in the fibroblast-like synoviocytes of rheumatoid arthritis patients via targeting the Hippo pathway. Arthritis Res. Ther. 24, 188 (2022).

pubmed: 35941675 doi: 10.1186/s13075-022-02880-0

van Hamburg, J. P. & Tas, S. W. Molecular mechanisms underpinning T helper 17 cell heterogeneity and functions in rheumatoid arthritis. J. Autoimmun. 87, 69–81 (2018).

pubmed: 29254845 doi: 10.1016/j.jaut.2017.12.006

López-Isac, E. et al. Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies. Arthritis Rheumatol. 68, 2338–2344 (2016).

pubmed: 27111665 doi: 10.1002/art.39730

Nakajima, S. et al. Synovial Tissue Heterogeneity in Japanese Patients with Rheumatoid Arthritis Elucidated Using a Cell-Type Deconvolution Approach. Arthritis Rheumatol. 75, 2130–2136 (2023).

pubmed: 37390361 doi: 10.1002/art.42642

Karami, J. et al. Genetic implications in the pathogenesis of rheumatoid arthritis; an updated review. Gene 702, 8–16 (2019).

pubmed: 30904715 doi: 10.1016/j.gene.2019.03.033

Dawidowicz, K. et al. The interferon regulatory factor 5 gene confers susceptibility to rheumatoid arthritis and influences its erosive phenotype. Ann. Rheum. Dis. 70, 117–121 (2011).

pubmed: 20980283 doi: 10.1136/ard.2010.129171

Duffau, P. et al. Promotion of Inflammatory Arthritis by Interferon Regulatory Factor 5 in a Mouse Model. Arthritis Rheumatol. 67, 3146–3157 (2015).

pubmed: 26315890 doi: 10.1002/art.39321

Cotter, T. G. & Rinella, M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology 158, 1851–1864 (2020).

pubmed: 32061595 doi: 10.1053/j.gastro.2020.01.052

Patel, S. J. & Liu, N. Hepatic IRF3 fuels dysglycemia in obesity through direct regulation of Ppp2r1b. Sci. Transl. Med. 14, eabh3831 (2022).

pubmed: 35320000 doi: 10.1126/scitranslmed.abh3831

Qiao, J. T. et al. Activation of the STING-IRF3 pathway promotes hepatocyte inflammation, apoptosis and induces metabolic disorders in nonalcoholic fatty liver disease. Metabolism 81, 13–24 (2018).

pubmed: 29106945 doi: 10.1016/j.metabol.2017.09.010

Iracheta-Vellve, A. et al. Endoplasmic Reticulum Stress-induced Hepatocellular Death Pathways Mediate Liver Injury and Fibrosis via Stimulator of Interferon Genes. J. Biol. Chem. 291, 26794–26805 (2016).

pubmed: 27810900 doi: 10.1074/jbc.M116.736991

He, J. et al. Hepatocyte nuclear factor 1A suppresses innate immune response by inducing degradation of TBK1 to inhibit steatohepatitis. Genes. Dis. 10, 1596–1612 (2023).

pubmed: 37397525 doi: 10.1016/j.gendis.2022.05.029

Tong, J. et al. Hepatic Interferon Regulatory Factor 6 Alleviates Liver Steatosis and Metabolic Disorder by Transcriptionally Suppressing Peroxisome Proliferator-Activated Receptor γ in Mice. Hepatology 69, 2471–2488 (2019).

pubmed: 30748020 doi: 10.1002/hep.30559

Li, H. et al. GRP/GRPR enhances alcohol-associated liver injury via the IRF1-mediated Caspase-1 inflammasome and NOX2-dependent ROS pathway. Hepatology 79, 392–408 (2023).

pubmed: 37409771

Liang, S. et al. Murine macrophage autophagy protects against alcohol-induced liver injury by degrading interferon regulatory factor 1 (IRF1) and removing damaged mitochondria. J. Biol. Chem. 294, 12359–12369 (2019).

pubmed: 31235522 doi: 10.1074/jbc.RA119.007409

Petrasek, J. et al. STING-IRF3 pathway links endoplasmic reticulum stress with hepatocyte apoptosis in early alcoholic liver disease. Proc. Natl Acad. Sci. USA 110, 16544–16549 (2013).

pubmed: 24052526 doi: 10.1073/pnas.1308331110

Luther, J. et al. Hepatic gap junctions amplify alcohol liver injury by propagating cGAS-mediated IRF3 activation. Proc. Natl Acad. Sci. USA 117, 11667–11673 (2020).

pubmed: 32393626 doi: 10.1073/pnas.1911870117

Correction for Luther et al., Hepatic gap junctions amplify alcohol liver injury by propagating cGAS-mediated IRF3 activation. Proc. Natl. Acad. Sci. USA. 117, 16704, (2020).

Du, M. et al. Absence of Interferon Regulatory Factor 1 Protects Against Atherosclerosis in Apolipoprotein E-Deficient Mice. Theranostics 9, 4688–4703 (2019).

pubmed: 31367250 pmcid: 6643443 doi: 10.7150/thno.36862

Shen, Y. et al. IRF-1 contributes to the pathological phenotype of VSMCs during atherogenesis by increasing CCL19 transcription. Aging (Albany NY) 13, 933–943 (2020).

pubmed: 33424012 doi: 10.18632/aging.202204

Fan, X. et al. Non-canonical NF-κB contributes to endothelial pyroptosis and atherogenesis dependent on IRF-1. Transl. Res. 255, 1–13 (2023).

pubmed: 36384204 doi: 10.1016/j.trsl.2022.11.001

Liu, H. et al. Ablation of Interferon Regulatory Factor 3 Protects Against Atherosclerosis in Apolipoprotein E-Deficient Mice. Hypertension 69, 510–520 (2017).

pubmed: 28115514 doi: 10.1161/HYPERTENSIONAHA.116.08395

Seneviratne, A. N. et al. Interferon Regulatory Factor 5 Controls Necrotic Core Formation in Atherosclerotic Lesions by Impairing Efferocytosis. Circulation 136, 1140–1154 (2017).

pubmed: 28698173 pmcid: 5598917 doi: 10.1161/CIRCULATIONAHA.117.027844

Edsfeldt, A., Swart, M., Singh, P. & Dib, L. Interferon regulatory factor-5-dependent CD11c+ macrophages contribute to the formation of rupture-prone atherosclerotic plaques. Eur. Heart J. 43, 1864–1877 (2022).

pubmed: 35567557 pmcid: 9113304 doi: 10.1093/eurheartj/ehab920

Leipner, J. et al. Myeloid cell-specific Irf5 deficiency stabilizes atherosclerotic plaques in Apoe(-/-) mice. Mol. Metab. 53, 101250 (2021).

pubmed: 33991749 pmcid: 8178123 doi: 10.1016/j.molmet.2021.101250

Tsiantoulas, D. et al. B Cell-Activating Factor Neutralization Aggravates Atherosclerosis. Circulation 138, 2263–2273 (2018).

pubmed: 29858401 pmcid: 6181204 doi: 10.1161/CIRCULATIONAHA.117.032790

Senatus, L. et al. RAGE impairs murine diabetic atherosclerosis regression and implicates IRF7 in macrophage inflammation and cholesterol metabolism. Jci. Insight 5, e137289 (2020).

pubmed: 32641587 pmcid: 7406264 doi: 10.1172/jci.insight.137289

Döring, Y. et al. Hematopoietic interferon regulatory factor 8-deficiency accelerates atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 32, 1613–1623 (2012).

pubmed: 22556330 doi: 10.1161/ATVBAHA.111.236539

Clément, M. et al. Deletion of IRF8 (Interferon Regulatory Factor 8)-Dependent Dendritic Cells Abrogates Proatherogenic Adaptive Immunity. Circ. Res. 122, 813–820 (2018).

pubmed: 29436389 doi: 10.1161/CIRCRESAHA.118.312713

Guo, M. et al. Inhibition of IFN regulatory factor-1 down-regulate Th1 cell function in patients with acute coronary syndrome. J. Clin. Immunol. 30, 241–252 (2010).

pubmed: 20177960 doi: 10.1007/s10875-010-9367-8

Guo, M. et al. IFN Regulatory Factor 1 Mediates Macrophage Pyroptosis Induced by Oxidized Low-Density Lipoprotein in Patients with Acute Coronary Syndrome. Mediators. Inflamm. 2019, 2917128 (2019).

pubmed: 31871426 doi: 10.1155/2019/2917128

Guo, M. et al. IFN regulatory Factor-1 induced macrophage pyroptosis by modulating m6A modification of circ_0029589 in patients with acute coronary syndrome. Int. Immunopharmacol. 86, 106800 (2020).

pubmed: 32674051 doi: 10.1016/j.intimp.2020.106800

Jiang, W., Chen, G. & Pu, J. The transcription factor interferon regulatory factor-1 is an endogenous mediator of myocardial ischemia reperfusion injury. Cell. Biol. Int. 46, 63–72 (2022).

pubmed: 34658101 doi: 10.1002/cbin.11713

Li, Y. et al. IRF2 contributes to myocardial infarction via regulation of GSDMD induced pyroptosis. Mol. Med. Rep. 25, 40 (2022).

King, K. R. et al. IRF3 and type I interferons fuel a fatal response to myocardial infarction. Nat. Med. 23, 1481–1487 (2017).

pubmed: 29106401 pmcid: 6477926 doi: 10.1038/nm.4428

Hu, S. et al. The selective STING inhibitor H-151 preserves myocardial function and ameliorates cardiac fibrosis in murine myocardial infarction. Int. Immunopharmacol. 107, 108658 (2022).

pubmed: 35278833 doi: 10.1016/j.intimp.2022.108658

Liu, Z. et al. Increased sympathetic outflow induced by emotional stress aggravates myocardial ischemia-reperfusion injury via activation of TLR7/MyD88/IRF5 signaling pathway. Inflamm. Res. 72, 901–913 (2023).

pubmed: 36933018 doi: 10.1007/s00011-023-01708-0

Cui, L. et al. Shexiang Tongxin Dropping Pill alleviates M1 macrophage polarization-induced inflammation and endothelial dysfunction to reduce coronary microvascular dysfunction via the Dectin-1/Syk/IRF5 pathway. J. Ethnopharmacol. 316, 116742 (2023).

pubmed: 37290736 doi: 10.1016/j.jep.2023.116742

Courties, G. et al. In vivo silencing of the transcription factor IRF5 reprograms the macrophage phenotype and improves infarct healing. J. Am. Coll. Cardiol. 63, 1556–1566 (2014).

pubmed: 24361318 doi: 10.1016/j.jacc.2013.11.023

Fan, J. H. et al. Association between IRF-5 polymorphisms and risk of acute coronary syndrome. Dna. Cell. Biol. 29, 19–23 (2010).

pubmed: 19778284 doi: 10.1089/dna.2009.0929

Zhang, Y. et al. Interferon regulatory factor 9 is an essential mediator of heart dysfunction and cell death following myocardial ischemia/reperfusion injury. Basic. Res. Cardiol. 109, 434 (2014).

pubmed: 25150882 doi: 10.1007/s00395-014-0434-9

Friesen, M. et al. Activation of IRF1 in Human Adipocytes Leads to Phenotypes Associated with Metabolic Disease. Stem. Cell. Rep. 8, 1164–1173 (2017).

doi: 10.1016/j.stemcr.2017.03.014

Kumari, M. et al. IRF3 promotes adipose inflammation and insulin resistance and represses browning. J. Clin. Invest. 126, 2839–2854 (2016).

pubmed: 27400129 pmcid: 4966307 doi: 10.1172/JCI86080

Yan, S. et al. IRF3 reduces adipose thermogenesis via ISG15-mediated reprogramming of glycolysis. J. Clin. Invest. 131, e144888 (2021).

pubmed: 33571167 pmcid: 8011904 doi: 10.1172/JCI144888

Mao, Y. et al. STING-IRF3 Triggers Endothelial Inflammation in Response to Free Fatty Acid-Induced Mitochondrial Damage in Diet-Induced Obesity. Arterioscler. Thromb. Vasc. Biol. 37, 920–929 (2017).

pubmed: 28302626 pmcid: 5408305 doi: 10.1161/ATVBAHA.117.309017

Correction to: STING-IRF3 Triggers Endothelial Inflammation in Response to Free Fatty Acid-Induced Mitochondrial Damage in Diet-Induced Obesity. Arterioscler. Thromb. Vasc. Biol. 38, e60 (2018).

Hu, H. Q. et al. The STING-IRF3 pathway is involved in lipotoxic injury of pancreatic β cells in type 2 diabetes. Mol. Cell. Endocrinol. 518, 110890 (2020).

pubmed: 32781250 doi: 10.1016/j.mce.2020.110890

Eguchi, J. et al. Interferon regulatory factor 4 regulates obesity-induced inflammation through regulation of adipose tissue macrophage polarization. Diabetes 62, 3394–3403 (2013).

pubmed: 23835343 pmcid: 3781469 doi: 10.2337/db12-1327

Cavallari, J. F. et al. Muramyl Dipeptide-Based Postbiotics Mitigate Obesity-Induced Insulin Resistance via IRF4. Cell. Metab. 25, 1063–1074.e1063 (2017).

pubmed: 28434881 doi: 10.1016/j.cmet.2017.03.021

Sindhu, S. et al. Increased Adipose Tissue Expression of Interferon Regulatory Factor (IRF)-5 in Obesity: Association with Metabolic Inflammation. Cells 8, 1418 (2019).

Sindhu, S. et al. Enhanced Adipose Expression of Interferon Regulatory Factor (IRF)-5 Associates with the Signatures of Metabolic Inflammation in Diabetic Obese Patients. Cells 9, 730 (2020).

Orliaguet, L., Ejlalmanesh, T. & Humbert, A. Early macrophage response to obesity encompasses Interferon Regulatory Factor 5 regulated mitochondrial architecture remodelling. Nat. Commun. 13, 5089 (2022).

pubmed: 36042203 pmcid: 9427774 doi: 10.1038/s41467-022-32813-z

Dalmas, E. et al. Irf5 deficiency in macrophages promotes beneficial adipose tissue expansion and insulin sensitivity during obesity. Nat. Med. 21, 610–618 (2015).

pubmed: 25939064 doi: 10.1038/nm.3829

Hoang, A. C., Sasi-Szabó, L. & Pál, T. Mitochondrial RNA stimulates beige adipocyte development in young mice. Nat. Metab. 4, 1684–1696 (2022).

pubmed: 36443525 pmcid: 9771821 doi: 10.1038/s42255-022-00683-w

Wang, X. A. et al. Interferon regulatory factor 7 deficiency prevents diet-induced obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 305, E485–E495 (2013).

pubmed: 23695216 doi: 10.1152/ajpendo.00505.2012

Liu, Z. et al. Melatonin alleviates inflammasome-induced pyroptosis through inhibiting NF-κB/GSDMD signal in mice adipose tissue. J. Pineal. Res. 63, e12414 (2017).

Jiang, H. et al. Interferon-α promotes MHC I antigen presentation of islet β cells through STAT1-IRF7 pathway in type 1 diabetes. Immunology 166, 210–221 (2022).

pubmed: 35298836 doi: 10.1111/imm.13468

Wang, X. A. et al. Interferon regulatory factor 9 protects against hepatic insulin resistance and steatosis in male mice. Hepatology 58, 603–616 (2013).

pubmed: 23471885 doi: 10.1002/hep.26368

Jiang, D. S. et al. Interferon regulatory factor 1 is required for cardiac remodeling in response to pressure overload. Hypertension 64, 77–86 (2014).

pubmed: 24732887 doi: 10.1161/HYPERTENSIONAHA.114.03229

Ma, X. M. et al. Lipotoxicity-induced mtDNA release promotes diabetic cardiomyopathy by activating the cGAS-STING pathway in obesity-related diabetes. Cell. Biol. Toxicol. 39, 277–299 (2023).

pubmed: 35235096 doi: 10.1007/s10565-021-09692-z

Yan, M. et al. Mitochondrial damage and activation of the cytosolic DNA sensor cGAS-STING pathway lead to cardiac pyroptosis and hypertrophy in diabetic cardiomyopathy mice. Cell. Death. Discov. 8, 258 (2022).

pubmed: 35538059 pmcid: 9091247 doi: 10.1038/s41420-022-01046-w

Xie, R. et al. LncRNA ZNF593-AS alleviates diabetic cardiomyopathy via suppressing IRF3 signaling pathway. Mol. Ther. Nucleic Acids 32, 689–703 (2023).

pubmed: 37215148 pmcid: 10199406 doi: 10.1016/j.omtn.2023.04.025

Li, N. et al. STING-IRF3 contributes to lipopolysaccharide-induced cardiac dysfunction, inflammation, apoptosis and pyroptosis by activating NLRP3. Redox Biol. 24, 101215 (2019).

pubmed: 31121492 pmcid: 6529775 doi: 10.1016/j.redox.2019.101215

Garcia-Gonzalez, C., Dieterich, C. & Maroli, G. ADAR1 Prevents Autoinflammatory Processes in the Heart Mediated by IRF7. Circ. Res. 131, 580–597 (2022).

pubmed: 36000401 doi: 10.1161/CIRCRESAHA.122.320839

Wu, D. et al. Interferon Regulatory Factor-1 Mediates Alveolar Macrophage Pyroptosis During LPS-Induced Acute Lung Injury in Mice. Shock 46, 329–338 (2016).

pubmed: 26939040 pmcid: 4978602 doi: 10.1097/SHK.0000000000000595

Liu, S. et al. IRF-1 Intervention in the Classical ROS-Dependent Release of NETs during LPS-Induced Acute Lung Injury in Mice. Inflammation 42, 387–403 (2019).

pubmed: 30315525 doi: 10.1007/s10753-018-0903-7

Chen, X. et al. Interferon regulatory factor 1 (IRF1) inhibits lung endothelial regeneration following inflammation-induced acute lung injury. Clin. Sci. (Lond.). 137, 367–383 (2023).

pubmed: 36857175 pmcid: 10011169 doi: 10.1042/CS20220876

Wang, N. et al. The STING-IRF3 pathway contributes to paraquat-induced acute lung injury. Toxicol. Mech. Methods 32, 145–157 (2022).

pubmed: 34455893 doi: 10.1080/15376516.2021.1974133

Messaoud-Nacer, Y. et al. STING agonist diABZI induces PANoptosis and DNA mediated acute respiratory distress syndrome (ARDS). Cell. Death. Dis. 13, 269 (2022).

pubmed: 35338116 pmcid: 8953969 doi: 10.1038/s41419-022-04664-5

Zhang, S. et al. IFIH1 Contributes to M1 Macrophage Polarization in ARDS. Front. Immunol. 11, 580838 (2020).

pubmed: 33519803 doi: 10.3389/fimmu.2020.580838

Zhang, Y. et al. Anisodamine Enhances Macrophage M2 Polarization through Suppressing G9a-Mediated Interferon Regulatory Factor 4 Silencing to Alleviate Lipopolysaccharide-Induced Acute Lung Injury. J. Pharmacol. Exp. Ther. 381, 247–256 (2022).

pubmed: 35383125 doi: 10.1124/jpet.121.001019

Xu, Q. et al. Interferon Regulatory Factor 5 siRNA-Loaded Folate-Modified Cationic Liposomes for Acute Lung Injury Therapy. J. Biomed. Nanotechnol. 17, 466–476 (2021).

pubmed: 33875081 doi: 10.1166/jbn.2021.3046

Gharib, S. A. et al. Computational identification of key biological modules and transcription factors in acute lung injury. Am. J. Respir. Crit. Care. Med. 173, 653–658 (2006).

pubmed: 16387799 doi: 10.1164/rccm.200509-1473OC

Yang, L. et al. Attenuation of interferon regulatory factor 7 activity in local infectious sites of trachea and lung for preventing the development of acute lung injury caused by influenza A virus. Immunology 157, 37–51 (2019).

pubmed: 30667045 pmcid: 6459777 doi: 10.1111/imm.13045

Winterberg, P. D. et al. Reactive oxygen species and IRF1 stimulate IFNα production by proximal tubules during ischemic AKI. Am. J. Physiol. Ren. Physiol. 305, F164–F172 (2013).

doi: 10.1152/ajprenal.00487.2012

Wang, Y. et al. IRF-1 promotes inflammation early after ischemic acute kidney injury. J. Am. Soc. Nephrol. 20, 1544–1555 (2009).

pubmed: 19443641 pmcid: 2709690 doi: 10.1681/ASN.2008080843

Yan, Q., Hu, Q. & Li, G. NEAT1 Regulates Calcium Oxalate Crystal-Induced Renal Tubular Oxidative Injury via miR-130/IRF1. Antioxid. Redox Signal. 38, 731–746 (2023).

pubmed: 36242511 doi: 10.1089/ars.2022.0008

Yang, X. et al. AhR activation attenuates calcium oxalate nephrocalcinosis by diminishing M1 macrophage polarization and promoting M2 macrophage polarization. Theranostics 10, 12011–12025 (2020).

pubmed: 33204326 pmcid: 7667681 doi: 10.7150/thno.51144

Liu, H. et al. Erratum: Sulforaphane elicts dual therapeutic effects on Renal Inflammatory Injury and crystal deposition in Calcium Oxalate Nephrocalcinosis: Erratum. Theranostics 12, 421 (2022).

pubmed: 34987656 pmcid: 8690918 doi: 10.7150/thno.68830

Liu, H. et al. Sulforaphane elicts dual therapeutic effects on Renal Inflammatory Injury and crystal deposition in Calcium Oxalate Nephrocalcinosis. Theranostics 10, 7319–7334 (2020).

pubmed: 32641994 pmcid: 7330860 doi: 10.7150/thno.44054

Li, Y. et al. IRF-1 promotes renal fibrosis by downregulation of Klotho. Faseb. j. 34, 4415–4429 (2020).

pubmed: 31965641 doi: 10.1096/fj.201902446R

Wu, H., Lai, C. F., Chang-Panesso, M. & Humphreys, B. D. Proximal Tubule Translational Profiling during Kidney Fibrosis Reveals Proinflammatory and Long Noncoding RNA Expression Patterns with Sexual Dimorphism. J. Am. Soc. Nephrol. 31, 23–38 (2020).

pubmed: 31537650 doi: 10.1681/ASN.2019040337

Zhao, B. et al. A Genome-Wide Association Study to Identify Single-Nucleotide Polymorphisms for Acute Kidney Injury. Am. J. Respir. Crit. Care. Med. 195, 482–490 (2017).

pubmed: 27576016 pmcid: 5378420 doi: 10.1164/rccm.201603-0518OC

Renken, I. J. E. et al. No Association between Genetic Loci near IRF2 and TBX1 and Acute Kidney Injury in the Critically Ill. Am. J. Respir. Crit. Care. Med. 201, 109–111 (2020).

pubmed: 31487200 doi: 10.1164/rccm.201903-0633LE

Zhang, Y., Zhang, Y., Yang, A. & Xia, F. Downregulation of IRF2 Alleviates Sepsis-Related Acute Kidney Injury in vitro and in vivo. Drug. Des. Devel. Ther. 15, 5123–5132 (2021).

pubmed: 34992348 pmcid: 8710674 doi: 10.2147/DDDT.S334518

He, T., Yang, L. & Wu, D. Effect of interferon regulatory factor 2 on inflammatory response and oxidative stress in lipopolysaccharide-induced acute kidney injury. Drug. Dev. Res. 83, 940–951 (2022).

pubmed: 35088417 doi: 10.1002/ddr.21919

Chen, X. et al. Targeting the mechanism of IRF3 in sepsis-associated acute kidney injury via the Hippo pathway. Int. Immunopharmacol. 122, 110625 (2023).

pubmed: 37441808 doi: 10.1016/j.intimp.2023.110625

Li, W., Tan, Y., Gao, F. & Xiang, M. Overexpression of TRIM3 protects against LPS-induced acute kidney injury via repressing IRF3 pathway and NLRP3 inflammasome. Int. Urol. Nephrol. 54, 1331–1342 (2022).

pubmed: 34643859 doi: 10.1007/s11255-021-03017-z

Baatarjav, C. & Komada, T. dsDNA-induced AIM2 pyroptosis halts aberrant inflammation during rhabdomyolysis-induced acute kidney injury. Cell. Death. Differ. 29, 2487–2502 (2022).

pubmed: 35739254 pmcid: 9750976 doi: 10.1038/s41418-022-01033-9

Xie, J. & Liu, L. The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. Nat. Commun. 11, 1600 (2020).

pubmed: 32231244 pmcid: 7105485 doi: 10.1038/s41467-020-15383-w

Li, M. et al. Genome-Wide Meta-Analysis Identifies Three Novel Susceptibility Loci and Reveals Ethnic Heterogeneity of Genetic Susceptibility for IgA Nephropathy. J. Am. Soc. Nephrol. 31, 2949–2963 (2020).

pubmed: 32912934 pmcid: 7790208 doi: 10.1681/ASN.2019080799

Deng, Y. X. et al. Identification and validation of hub genes in drug induced acute kidney injury basing on integrated transcriptomic analysis. Front. Immunol. 14, 1126348 (2023).

pubmed: 37063876 pmcid: 10090697 doi: 10.3389/fimmu.2023.1126348

Sasaki, K. et al. Deletion of Myeloid Interferon Regulatory Factor 4 (Irf4) in Mouse Model Protects against Kidney Fibrosis after Ischemic Injury by Decreased Macrophage Recruitment and Activation. J. Am. Soc. Nephrol. 32, 1037–1052 (2021).

pubmed: 33619052 pmcid: 8259665 doi: 10.1681/ASN.2020071010

Chen, M. et al. IRF-4 deficiency reduces inflammation and kidney fibrosis after folic acid-induced acute kidney injury. Int. Immunopharmacol. 100, 108142 (2021).

pubmed: 34555644 doi: 10.1016/j.intimp.2021.108142

Gao, Y. et al. Interferon regulatory factor 4 deletion protects against kidney inflammation and fibrosis in deoxycorticosterone acetate/salt hypertension. J. Hypertens. 41, 794–810 (2023).

pubmed: 36883469

Lorenz, G. et al. IFN Regulatory Factor 4 Controls Post-ischemic Inflammation and Prevents Chronic Kidney Disease. Front. Immunol. 10, 2162 (2019).

pubmed: 31632388 pmcid: 6781770 doi: 10.3389/fimmu.2019.02162

Liu, J., Li, X., Yang, J. & Zhang, D. LncRNA ENSMUST_147219 mediates the progression of ischemic acute kidney injury by targeting the miR-221-5p/IRF6 axis. Apoptosis 27, 531–544 (2022).

pubmed: 35618996 pmcid: 9308590 doi: 10.1007/s10495-022-01730-3

Kiryluk, K. & Sanchez-Rodriguez, E. Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy. Nat. Genet. 55, 1091–1105 (2023).

pubmed: 37337107 doi: 10.1038/s41588-023-01422-x

Guo, C. et al. DNA methylation protects against cisplatin-induced kidney injury by regulating specific genes, including interferon regulatory factor 8. Kidney Int. 92, 1194–1205 (2017).

pubmed: 28709638 pmcid: 5651199 doi: 10.1016/j.kint.2017.03.038

Li, N. et al. IRF8-Dependent Type I Conventional Dendritic Cells (cDC1s) Control Post-Ischemic Inflammation and Mildly Protect Against Post-Ischemic Acute Kidney Injury and Disease. Front. Immunol. 12, 685559 (2021).

pubmed: 34234783 pmcid: 8255684 doi: 10.3389/fimmu.2021.685559

Liu, Y. et al. Negative Regulation of SIRT1 by IRF9 Involved in Hyperlipidemia Acute Pancreatitis Associated with Kidney Injury. Dig. Dis. Sci. 66, 1063–1071 (2021).

pubmed: 32462510 doi: 10.1007/s10620-020-06331-1

Bialek, K. et al. Novel association between TGFA, TGFB1, IRF1, PTGS2 and IKBKB single-nucleotide polymorphisms and occurrence, severity and treatment response of major depressive disorder. PeerJ 8, e8676 (2020).

pubmed: 32140313 pmcid: 7047865 doi: 10.7717/peerj.8676

Li, J. et al. Lack of interferon regulatory factor 3 leads to anxiety/depression-like behaviors through disrupting the balance of neuronal excitation and inhibition in mice. Genes. Dis. 10, 1062–1074 (2023).

pubmed: 37396521 doi: 10.1016/j.gendis.2022.05.003

Li, X. et al. Common variants of IRF3 conferring risk of schizophrenia. J. Psychiatr. Res. 64, 67–73 (2015).

pubmed: 25843157 doi: 10.1016/j.jpsychires.2015.03.008

Lago, S. G. et al. Peripheral lymphocyte signaling pathway deficiencies predict treatment response in first-onset drug-naïve schizophrenia. Brain. Behav. Immun. 103, 37–49 (2022).

pubmed: 35381347 doi: 10.1016/j.bbi.2022.03.016

Xu, Q. et al. Efficacy and mechanism of cGAMP to suppress Alzheimer’s disease by elevating TREM2. Brain. Behav. Immun. 81, 495–508 (2019).

pubmed: 31283973 doi: 10.1016/j.bbi.2019.07.004

Guo, H. et al. ZBP1 mediates the progression of Alzheimer’s disease via pyroptosis by regulating IRF3. Mol. Cell. Biochem 478, 2849–2860 (2023).

pubmed: 36964897 doi: 10.1007/s11010-023-04702-6

Li, R. et al. Silencing of IRF3 alleviates chronic neuropathic pain following chronic constriction injury. Biomed. Pharmacother. 88, 403–408 (2017).

pubmed: 28122305 doi: 10.1016/j.biopha.2017.01.085

Zhou, Y., Song, W. M., Andhey, P. S. & Swain, A. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease. Nat. Med. 26, 131–142 (2020).

pubmed: 31932797 pmcid: 6980793 doi: 10.1038/s41591-019-0695-9

Zeng, Q. et al. IRF-8 is Involved in Amyloid-β(1-40) (Aβ(1-40))-induced Microglial Activation: a New Implication in Alzheimer’s Disease. J. Mol. Neurosci. 63, 159–164 (2017).

pubmed: 28856571 doi: 10.1007/s12031-017-0966-1

Huang, Y. et al. IRF1-mediated downregulation of PGC1α contributes to cardiorenal syndrome type 4. Nat. Commun. 11, 4664 (2020).

pubmed: 32938919 pmcid: 7494935 doi: 10.1038/s41467-020-18519-0

Wang, A., Kang, X., Wang, J. & Zhang, S. IFIH1/IRF1/STAT1 promotes sepsis associated inflammatory lung injury via activating macrophage M1 polarization. Int. Immunopharmacol. 114, 109478 (2023).

pubmed: 36462334 doi: 10.1016/j.intimp.2022.109478

Chen, X. Y. et al. Interferon-regulatory factor-1 boosts bevacizumab cardiotoxicity by the vascular endothelial growth factor A/14-3-3γ axis. Esc. Heart Fail. 11, 986–1000 (2024).

pubmed: 38234115 pmcid: 10966242 doi: 10.1002/ehf2.14640

Tanaka, N. et al. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 77, 829–839 (1994).

pubmed: 8004672 doi: 10.1016/0092-8674(94)90132-5

Testa, U. et al. Impaired myelopoiesis in mice devoid of interferon regulatory factor 1. Leukemia 18, 1864–1871 (2004).

pubmed: 15385939 doi: 10.1038/sj.leu.2403472

Penninger, J. M. et al. The interferon regulatory transcription factor IRF-1 controls positive and negative selection of CD8+ thymocytes. Immunity 7, 243–254 (1997).

pubmed: 9285409 doi: 10.1016/S1074-7613(00)80527-0

Lohoff, M. et al. Interferon regulatory factor-1 is required for a T helper 1 immune response in vivo. Immunity 6, 681–689 (1997).

pubmed: 9208841 doi: 10.1016/S1074-7613(00)80444-6

Hayashi, H. et al. Characterization of dsRNA-induced pancreatitis model reveals the regulatory role of IFN regulatory factor 2 (Irf2) in trypsinogen5 gene transcription. Proc. Natl Acad. Sci. USA 108, 18766–18771 (2011).

pubmed: 22042864 pmcid: 3219097 doi: 10.1073/pnas.1116273108

Li, M. M. et al. Interferon regulatory factor 2 protects mice from lethal viral neuroinvasion. J. Exp. Med. 213, 2931–2947 (2016).

pubmed: 27899441 pmcid: 5154937 doi: 10.1084/jem.20160303

Lohoff, M. et al. Deficiency in the transcription factor interferon regulatory factor (IRF)-2 leads to severely compromised development of natural killer and T helper type 1 cells. J. Exp. Med. 192, 325–336 (2000).

pubmed: 10934221 pmcid: 2193225 doi: 10.1084/jem.192.3.325

Tang, P. et al. Regulation of adipogenic differentiation and adipose tissue inflammation by interferon regulatory factor 3. Cell. Death. Differ. 28, 3022–3035 (2021).

pubmed: 34091599 pmcid: 8563729 doi: 10.1038/s41418-021-00798-9

Negishi, H. et al. Essential contribution of IRF3 to intestinal homeostasis and microbiota-mediated Tslp gene induction. Proc. Natl Acad. Sci. USA 109, 21016–21021 (2012).

pubmed: 23213237 pmcid: 3529020 doi: 10.1073/pnas.1219482110

Moore, T. C., Vogel, A. J., Petro, T. M. & Brown, D. M. IRF3 deficiency impacts granzyme B expression and maintenance of memory T cell function in response to viral infection. Microbes Infect. 17, 426–439 (2015).

pubmed: 25777301 pmcid: 4479197 doi: 10.1016/j.micinf.2015.03.001

Santosa, E. K. et al. Control of nutrient uptake by IRF4 orchestrates innate immune memory. Nat. Immunol. 24, 1685–1697 (2023).

pubmed: 37697097 pmcid: 11098052 doi: 10.1038/s41590-023-01620-z

Raczkowski, F. et al. The transcription factor Interferon Regulatory Factor 4 is required for the generation of protective effector CD8+ T cells. Proc. Natl Acad. Sci. USA 110, 15019–15024 (2013).

pubmed: 23980171 pmcid: 3773801 doi: 10.1073/pnas.1309378110

Lien, C. et al. Critical role of IRF-5 in regulation of B-cell differentiation. Proc. Natl Acad. Sci. USA 107, 4664–4668 (2010).

pubmed: 20176957 pmcid: 2842054 doi: 10.1073/pnas.0911193107

Thomason, H. A. et al. Cooperation between the transcription factors p63 and IRF6 is essential to prevent cleft palate in mice. J. Clin. Invest. 120, 1561–1569 (2010).

pubmed: 20424327 pmcid: 2860913 doi: 10.1172/JCI40266

Wu, M. et al. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis. Ann. Rheum. Dis. 78, 1583–1591 (2019).

pubmed: 31439591 doi: 10.1136/annrheumdis-2019-215208

Dror, N. et al. Interferon regulatory factor-8 is indispensable for the expression of promyelocytic leukemia and the formation of nuclear bodies in myeloid cells. J. Biol. Chem. 282, 5633–5640 (2007).

pubmed: 17189268 doi: 10.1074/jbc.M607825200

Das, A. et al. Murine IRF8 Mutation Offers New Insight into Osteoclast and Root Resorption. J. Dent. Res. 103, 318–328 (2024).

pubmed: 38343385 doi: 10.1177/00220345231222173

Wang, P. X. et al. Interferon regulatory factor 9 is a key mediator of hepatic ischemia/reperfusion injury. J. Hepatol. 62, 111–120 (2015).

pubmed: 25152205 doi: 10.1016/j.jhep.2014.08.022

Yang, K. et al. Hsp90 regulates activation of interferon regulatory factor 3 and TBK-1 stabilization in Sendai virus-infected cells. Mol. Biol. Cell. 17, 1461–1471 (2006).

pubmed: 16394098 pmcid: 1382332 doi: 10.1091/mbc.e05-09-0853

Probst, P. et al. A small-molecule IRF3 agonist functions as an influenza vaccine adjuvant by modulating the antiviral immune response. Vaccine 35, 1964–1971 (2017).

pubmed: 28279563 doi: 10.1016/j.vaccine.2017.01.053

Hemann, E. A. et al. A Small Molecule RIG-I Agonist Serves as an Adjuvant to Induce Broad Multifaceted Influenza Virus Vaccine Immunity. J. Immunol. 210, 1247–1256 (2023).

pubmed: 36939421 doi: 10.4049/jimmunol.2300026

Boeszoermenyi, A. et al. A conformation-locking inhibitor of SLC15A4 with TASL proteostatic anti-inflammatory activity. Nat. Commun. 14, 6626 (2023).

pubmed: 37863876 pmcid: 10589233 doi: 10.1038/s41467-023-42070-3

Ramírez-Carvajal, L. et al. Expression of porcine fusion protein IRF7/3(5D) efficiently controls foot-and-mouth disease virus replication. J. Virol. 88, 11140–11153 (2014).

pubmed: 25031341 pmcid: 4178809 doi: 10.1128/JVI.00372-14

The multiple roles of interferon regulatory factor family in health and disease.

Journal

Informations de publication

Résumé

Identifiants

Substances chimiques

Types de publication

Langues

Sous-ensembles de citation

Pagination

Subventions

Informations de copyright

Références

Auteurs

Lian Wang (L)

Yanghui Zhu (Y)

Nan Zhang (N)

Yali Xian (Y)

Yu Tang (Y)

Jing Ye (J)

Fekrazad Reza (F)

Gu He (G)

Xiang Wen (X)

Xian Jiang (X)

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Smoking Cessation and Incident Cardiovascular Disease.

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Classifications MeSH